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Abstract 
As a principal gatekeeper, p53 is inactivated mutationally in over 50% of human 
cancer (1). However, in approximately 7% of tumours, especially of the glia, bone, 
and soft tissues, loss of wild-type p53 function results from amplification and 
over-expression of the MDM2 gene, causing transformation and uncontrolled tumour 
growth (2-7). Several research reports have revealed that p53 and MDM2 proteins 
form an auto-regulatory feedback loop (8-10). Inhibition of the p53-MDM2 
interaction has been validated as an attractive target for anti-cancer therapy.  
Several different scaffold small-molecule inhibitors have been discovered by both 
structure-based design and compound library screening (11-16). 
The first chapter of this thesis contains a general overview of research carried out 
that lead to the discovery and optimization of published potent p53-MDM2 
interaction inhibitors, together with an overview of the p53-MDM2 antagonists 
development project carried out in our group, the progress obtained so far and future 
directions. 
After the presentation of general materials and methods of experiments applied in my 
thesis in chapter two, four chapters are formed for presenting the research results I 
obtained within more than three years laboratory work. 
Chapter three demonstrates the evaluation (ELISA) and optimization of the in vitro 
activity of isoindolin-1-one compounds, which is a group of potent lead 
small-molecule inhibitors of the MDM2-p53 interaction developed by our research 
group in Newcastle. The results indicate the impressive progress of this series of 
compounds, from NU8260 (IC50=2.4±0.2 µM) to the most recently developed lead 
compound, NCL-00016149 (IC50=15.8±2.6 nM), which is about 150-fold more 
potent. 
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The followed chapter (chapter 4) presents the evaluation (Western blot, SRB and 
Caspase-Glo 3/7 assay) of cellular activity of potent isoindolin-1-one compounds, 
especially the comparison of pure enantiomers, by using Nutlin-3 as the positive 
control. The result show that isoindolin-1-one compounds can induce p53 and its 
down stream target MDM2 and p21 accummulation and activation, corresponding to 
their in vitro potencies; both the in vitro and cellular activities presented are mainly 
for the potent enantiomer.    
Chapter five is aimed at obtaining a better understanding of MDM2/MDMX inhibitor 
design and screening procedures. As part of the FP6 DePPICT project, more than 
3800 compounds that were selected as possible MDM2 and/or MDMX inhibitors by 
in silico screening millions of commercially available compounds, together with 
some in-house pyrrole scaffold compounds and p53 peptides analogs were evaluated 
by ELISA. A number of lead compounds showed dose-dependent activity, and 7 
scaffold series were selected for further SAR exploration by using synthetic 
chemistry technology. 
With the progress of the isoindolin-1-ones and the development of Nutlin-3 and 
MI-63 series of MDM2 antagonists, several drug candidates may enter clinical trials 
soon. As a result, relapse caused by drug resistance may need to be considered as 
early as possible. Therefore, in chapter six, the research of MDM2 antagonists 
resistant cell clones is demonstrated. Several resistant cell clones were selected by 
treating SJSA-1 and NGP tumour cell lines with Nutlin-3 and MI-63. Resistance 
mechanisms were explored by using a range of bioassays, and one of the key 
mechanisms was confirmed to be p53 dysfunctional missense mutation. 
Finally, the achievements and future work of my research are discussed in chapter 
seven.  
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Chapter One 
Introduction 
1.1 Literature Review 
1.1.1 p53, a Vital Tumour Suppressor Gene 
Tumour-suppressor genes are important to prevent the abnormal poliferation of 
cells. The p53 gene, initially reported in 1979 (17-18), was originally thought to be a 
target of the simian virus 40 (SV40, a strain of virus that induced development of 
tumours) DNA large-T antigen. Because of the use of mutated p53 cDNA following 
purification of tumour cell mRNA, it was initially regarded as a cellular oncogene 
(19-21). Then p53 was identified to be a tumour-suppressor in 1989 (22-24). It is 
known as the ‘guardian of the genome’ owing to its ability to integrate many signals 
that control life or death (25-26).  
1.1.1.1 p53 Structure and Function 
In humans, p53 is encoded by the TP53 gene located on the short arm of 
chromosome 17 (17p13) (27) and the human p53 protein contains 393 amino acids. 
Although the amino acid composition of p53 protein varies from species to species 
(28), the primary structure of the protein, especially the five functional domains, is 
conserved during evolution.   
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Figure 1. 1 The schematic view of the functional domain structure of p53 together with 
relative mutation frequency in human cancer bar chart according to the table of ‘p53 
mutation distribution’ in The TP53 Web Site 
(http://p53.free.fr/Database/p53_database_distr.html). 
The 393-residue p53 protein comprises (Figure 1. 1):  
1. The N-terminal transcription-activation domain (TAD), contains 
transactivation domain 1 (TAD1, residues 1-42, light green) and 
transactivation domain 2 (TAD2, residues 43-62, green). The transactivation 
domain 1 is required for transcriptional transactivation activity and interacts 
with its downstream targets, such as its negative regulator MDM2 (murine 
double minute 2) (29-31), and various transcription factors, such as 
components of the transcription initiation complex including the TATA box 
binding protein (TBP) and TBP associated factors (TAFs), which are the 
components of TFIID (32-33), and the acetyltransferases p300 and CBP that 
act as co-activators and regulate p53 function by acetylating its C-terminus 
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(34-36). The transactivation domain 2 is also reported to be important in p53 
regulation (37-40). 
2. Src homology 3-like (SH3, residues 63-97, yellow) domain is a proline-rich 
domain required for interaction of p53 with SIN3, which prevents p53 from 
degradation. It contains SH3-domain binding motifs PXXP, where P 
designates proline and X for any amino acid, and is suggested to have a 
regulatory function (41-42). In addition, it has been suggested to have the 
function of mediating p53 transactivation by binding to p300 (43). 
3. A central sequence-specific DNA binding domain (DBD, residues 98-292, 
orange), which contains several arginine amino acids. It can bind specifically 
to double-stranded target DNA, which consists of two copies of 10 bp motifs 
5’-PuPuPuC(A/T)(T/A)GPyPyPy-3’ separated by 0-13 bps (Pu is a purine base, 
Py is a pyrimidine base) (44). Interestingly, p53 always binds with high 
affinity to the recognition elements of genes responsible for cell cycle arrest; 
whereas the lower binding affinity positions are found in genes responsible 
for apoptosis (45-49). This domain is also the most frequently mutated 
region that accounts for above 80% of all the p53 mutations found in human 
tumours (50-53).   
4. Nuclear localization signal (NLS, residues 300-323, light blue) (54). 
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5. Homo-oligomerisation domain (OD, residues 326-355, cyan), enables p53 
tetramerization, which makes the sequence-specific binding of p53 to DNA 
more efficient (55).  
6. Nuclear export signal (NLS, residues 340-351, light brown) (56). 
7. C-terminal negative regulatory domain (NRD, residues 363-393, blue) that is 
responsible for down regulation of specific DNA binding and the stability of 
the p53 protein (57). This region is the target of a number of 
post-translational modifications (58). 
The p53 protein initiates several programmes that arrest proliferation and prevent 
the generation of genetically-altered cells, and is activated by various types of 
cellular stress, such as DNA damage and oncogenic stress. Firstly, p53 can mediate 
cell cycle arrest. It is known that wild type p53 is required for the induction of G1 
arrest in response to ionising irradiation (IR) as cell lines that lack p53 activity 
display a reduced response (59-60). Also, embryonic fibroblasts from p53 null mice 
lose the ability to undergo G1 arrest in response to IR (61). Another function of p53 
is mediating apoptosis. In certain cell types, such as cells of hematopoietic origin, 
activation of the p53 pathway leads to apoptosis (62-63). Works of Yamamoto et al. 
showed that Huh6 cells underwent apoptotic cell death in response to oxidative 
stress, which was associated with the nuclear translocation of p53. When the 
endogenous p53 was knocked down by siRNA, Huh6 cells became resistant to 
oxidative stress (64). In addition, p53 also influences differentiation. Several studies 
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have shown that wild-type p53 expressed in undifferentiated cells can result in 
progression to a more differentiated state (65-66). 
In fact, p53 plays a central role in a large network of messengers and effectors that 
are associated with the G1 and G2 DNA-damage checkpoints, apoptosis and DNA 
repair (Figure 1. 2) (67). 
 
Figure 1. 2 p53 Tumour Suppression 
The figure is a combination of two figures (67-68).Various cellular stresses can induce p53 stabilization and 
accumulation by different pathways to promote anti-proliferative and/or pro-apoptotic cellular effects. For 
example, deregulated oncogenes induce p14
ARF
 activation, which sequesters one of the key regulator of p53, 
MDM2, into the nucleolus; DNA damage activates protein kinase ATM, which, through DNA-dependent protein 
kinase (DNA-PK) phosphorylate the N-terminal of p53 to interrupt the MDM2 binding, and another protein 
kinase ATR can be activated by chemotherapy, which through casein kinase II (CKII) to phosphorylate the 
C-terminal of p53 to enhance sequence-specific DNA binding. These factors increase p53 level, which  then 
activates its downstream targets. By activate the transcription of its target gene GADD45, stressed cells may be 
recovered via DNA repair procedure; 14-3-3σ and p21 activation can induce cell cycle arrest at the DNA-damage 
checkpoints G1 and G2 by suppressing the activity of cyclin-dependent protein kinases (CDK1, CDK2 and CDK4) 
respectively. By acting as a transcription factor, p53 can activate target genes (PUMA, NOXA, BAX, p53AIP) or 
direct translocation to mitochondria to induce cytochrome c release, and it can also bind to the inhibitors of 
apoptosis (such as BCL-2 that block the release of cytochrome c from mitochondria) or death receptor, to 
promote caspase activation and lead to programmed cell death if the DNA can not be repaired properly. 
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1.1.1.2 p53 Dysfunctional Alteration in Human Cancer  
That p53 was considered as a common denominator in human cancer has 
stimulated lots of investigations since 1989. In fact, p53 is one of the 
most-frequently altered proteins in human cancer.  
It is found that most human cancers contain either mutations in the p53 gene that 
generate a dysfunctional or absent protein, or have disrupted p53 function induced 
by altered expression of other gene products (69). In about a half of adult cancers, 
p53 is inactivated directly as a result of mutations in the p53 gene(69). 
In 1994, Cho et al. determined the crystal structure of the DNA binding site of p53 
core domain at 2.2 Angstroms resolution, based on a complex containing the core 
domain of human p53 binding with double-stranded cognate DNA (70). The result 
revealed that the p53 core domain structure consists of a beta sandwich that serves 
as a scaffold for two large loops and a loop-sheet-helix motif. An even better 
structure resolution result was presented in the work done by Kitayner et al. (71), 
which together with the 1994 data enabled us to understand how p53 recognizes 
target sequences specifically (Figure 1. 3).    
However, about half of all cancers retain the ability of expressing a normal p53 
protein and many are thought to have inadequate p53 function as a result of 
abnormal regulation of p53 or defective signalling in the p53 pathway (26, 72).  
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Figure 1. 3 Crystal structure of DNA bind with p53 core domain. 
A) The structure of p53 core domain (light blue, ribbon diagram) bound to double-stranded DNA (blue, thick 
line), with high relative mutation frequency amino acid residues high lighted (yellow, stick model) and labelled, 
the blue and red spheres indicate nitrogen and oxygen atoms, respectively (PDB ID code 2AHI) (71), this image is 
generated by using PyMOL (Delano, 2002); B) & C) Detailed view of the two most frequently mutated residues 
of p53, Arg273 and Arg282 (yellow) and residues surround them (≤7Å). The protein back bone atoms are in 
purple, amino acid side chains are in cyan, the DNA is in blue and the hydrogen bond and electrostatic 
interactions that the mutation hotspot residues make with DNA and other side chains are indicated by 
red-dotted lines (70). 
 
 
 
 
          
A 
B C 
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1.1.2  p53 Restoration as a Cancer Therapy 
The high frequency of inactivation of p53 in human cancers suggests that restoring 
p53 function might be an attractive and tumour cell-specific strategy for treating 
cancers.  
Recent papers have supported the hypothesis that restoration of p53 function in 
established tumours causes regression of tumours in vivo.  
By using a reversibly switchable p53 knockin (KI) mouse model that permits 
modulation of p53 status from wild-type to knockout at will, Martins et al. found 
that p53 was spontaneously activated when restored in established E-myc 
lymphomas in vivo, leading to rapid apoptosis and a significant increase in survival 
(73).  
Another study used regulatable RNA interference (RNAi) to demonstrate that p53 
loss is required for maintenance of aggressive hepatocarcinomas. They have 
observed that even brief reactivation of endogenous p53 in p53-deficient tumours 
can produce complete tumour regressions (74).  
Restoring endogenous p53 expression also leads to regression of lymphomas and 
sarcomas arising either spontaneously or induced in p53-null mice, without 
affecting normal tissues (75).  
These observations strongly support efforts to treat human cancers by the method 
of pharmacological reactivation of p53 (76-77). 
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1.1.3  MDM2 Plays a Pivotal Role in Restraining p53 
A number of ubiquitin ligases have been identified to target the p53 protein for 
degradation through the proteasome (78). These ubiquitin ligases include MDM2, 
Pirh2 (p53-induced RING-H2 protein), and Cop1 (constitutively photomorphogenic 1) 
(79). Although the exact role of some of the more recently described ubiquitin 
ligases in the regulation of p53 stability is unclear, numerous studies have shown 
that MDM2 plays a pivotal role in restraining p53. 
The murine double minute 2 (mdm2) gene was originally identified as one of three 
genes (mdm1, 2, and 3) which were over-expressed greater than 50-fold by 
amplification in a spontaneously transformed mouse BALB/c cell line (3T3-DM) (80). 
The amplified mdm genes in the 3T3-DM cells were found to be located on small, 
acentromeric extrachromosomal nuclear bodies, called double minutes, which are 
retained in cells only if they provide a growth advantage, and mdm2 is the most 
important one among them. 
The full-length transcript of the MDM2 gene encodes the human MDM2 protein, 
which consists of 491 amino acids. This protein contains several conserved 
functional domains and residues in its primary structure (Figure 1. 4): 
1. The N-terminal p53 binding domain(red), residues 18-101, contributes to its 
binding with the p53 transactivation domain to inhibit the transcription 
activation function of p53 (10);  
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2. Nuclear Localization Signal (NLS, light blue), residue 178 and Nuclear Export 
Signal (NES, brown), residue 192 (81-82); 
3. The acidic region(green), residues 237-288. This domain has been suggested 
to be involved in p53 ubiquitination (83-84); 
4. The zinc finger domain(cyan), residue 289-331, which based on missense 
mutation identified in follicular lymphomas and liposarcomas (85-86), was 
suggested to have a role in negatively regulating the level of MDM2 (87); 
5. The Really Interesting New Gene (RING) finger domain (yellow), residue 
436-482, which confers the E3 ubiquitin ligase function to MDM2 protein 
that is responsible for the proteasomal degradation of p53 and itself (88-91). 
Moreover, this domain was implicated to be required for p53 nuclear 
exclusion (92-93);  
6. A Nucleolar Location Signal (NoLS, purple), residue 466-473, which is located 
within the MDM2 RING finger domain (82, 94). Wang et al. (95) reported 
that MDM2 could be acetylated in vitro by CREB-binding protein (CBP) and 
also by p300 to a relatively lesser extent, although not by 
p300/CPB-associated factor, and only by CBP in vivo. Interestingly, they 
observed that an MDM2 mutant (K466/467Q) mimicking acetylation led to 
its decreased ability to promote ubiquitination of p53 and itself, as well as 
inactivating its function of promoting p53 degradation in living cells.  
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Figure 1. 4 The schematic view of the human MDM2 protein primary structure (96). 
MDM2 was shown to bind p53 and form a complex with p53, leading to inhibition of 
p53-mediated transactivation (10). MDM2 gene amplification was subsequently 
observed in many human sarcomas that retained wild-type p53 (3). In Momand’s 
database, information on MDM2 amplification frequency has been collected from 
previously published sources on 3889 samples from tumours or xenografts from 28 
tumour types. MDM2 gene amplification was reported to be observed in 19 tumour 
types, with the highest frequency observed in soft tissue sarcomas (20 %), 
osteosarcomas (16 %) and oesophageal carcinomas (13 %). In these studies, 29 out 
of a total of 33 MDM2 amplification-positive tumours retained wild-type p53 (2). 
These data were consistent with the previously published overall MDM2 
amplification frequency reported for human tumours (7 %) (2). A large body of 
research indicates that over-expression of MDM2 is an important factor that can 
inactivate p53.  
Further studies demonstrated that MDM2 is a prominent regulator of p53 stability 
and activity. The crucial role of MDM2 in p53 regulation is strongly supported by the 
fact that mdm2-null mouse embryos die early after implantation, but are fully 
rescued if they are co-deficient for p53 (97-98). This indicates the most important 
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role of MDM2 is in the regulation of p53 function, at least in early development. 
Meanwhile, MDM2 itself is the product of a p53-transcriptionally regulated gene 
(99). When nuclear p53 level is elevated, it activates the transcription of the MDM2 
gene, thus raising the level of MDM2 protein. On the other hand, MDM2 binds to 
p53, which blocks its N-terminal transactivation domain and targets p53 for 
degradation via the ubiquitin–proteasome system following ubiquitinylation of p53 
through the E3 ligase activity of MDM2 (100-101). Thus, p53 and MDM2 form an 
autoregulatory negative feedback loop so that p53 is maintained at a low level in 
the absence of stress (Figure 1. 5) (102).  
 
Figure 1. 5 Regulation of p53 by MDM2. (102) 
As one of the downstream targets of p53, MDM2 regulate the function of p53 via a autoregulatory 
feedbackloop mechanism. First, MDM2 can bind to p53 transactivation dormain to block its ability of activating 
transcription; sencond, MDM2 acts as an E3 ubiquitin ligase that promotes the proteasomal degradation of p53; 
last, MDM2 is involved in the nuclear export of p53. Moreover, growth/survival signals activate Akt and mediate 
nuclear import of MDM2 to suppress p53 function. Conversely, various cellular stresses such as DNA damage, 
oncogene activation can activate p53 via different mechanisms. DNA damage promote p53 and MDM2 
phosphorylation and p53 acetylation through the activation of protein kinase pathways, such as ATM, ATR, to 
interrupt the interaction of MDM2 and p53 and stablize p53. Activated oncogenes induce p14
ARF
 protein, which 
prevents p53 degradation by sequestering MDM2 into the nucleous. 
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However, this feedback loop is frequently dysregulated in cancer. There is 
inadequate p53 activation induced by stress in many tumours, leading to inefficient 
growth arrest and/or apoptosis, as a result of abnormal regulation (26, 72). 
Therefore, rescue of p53 function by disrupting the MDM2-p53 interaction is 
considered to be a potential approach for anti-cancer therapy in some 
circumstances (103). 
1.1.4  Rescue of p53 Function by Disrupting the p53–MDM2 Interaction 
The rescue of p53 function by disrupting the MDM2-p53 interaction has been 
explored by several studies using macromolecular tools. A synthetic MDM2-binding 
mini-protein was reported to bind to the p53-binding pocket on the MDM2 protein 
(104). When introduced into cells containing low levels of wild-type p53, this 
protein caused a striking accumulation of the endogenous p53 protein, activation of 
a p53-responsive reporter gene, and cell cycle arrest which was similar to the 
effects seen in these cells after exposure to UV or ionising radiation. An octamer 
synthetic peptide (AP-B) which has been developed by Chene et al. from the 
peptide sequence corresponding to the minimal p53 binding site for MDM2, was 
shown to be a potent inhibitor of the p53-MDM2 interaction in vitro. In cellular 
assays, this untagged peptide also showed an induction of the accumulation of p53 
in tumour cells. Furthermore, the AP-B peptide induced apoptosis in tumour cells 
over-expressing MDM2 protein (105). These studies suggest that, once released 
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from MDM2, p53 rapidly accumulates and then activates p53 target genes and the 
p53 pathway, resulting in cell-cycle arrest and/or apoptosis.  
Several strategies have been used to release p53 from MDM2 control, including 
blocking MDM2 expression, inhibition of MDM2 ubiquitin ligase activity and 
disruption of MDM2–p53 binding.  
1.1.4.1 Blocking MDM2 Expression 
Zhang et al. described antisense mixed-backbone oligonucleotides (MBO) which 
specifically inhibited MDM2 expression in a dose- and time-dependent manner, 
resulting in significant anti-tumour activity in vitro and in vivo (106). A study by 
Tortora et al. also showed that oligonucleotide anti-sense MDM2 treatment could 
induce a growth-inhibitory effect and apoptosis in human GEO colon cancer cells 
and anti-tumour activity in vivo (107). Moreover, anti-sense MDM2 was shown to 
have a co-operative growth-inhibitory and apoptosis-induction effect with different 
classes of cytotoxic drugs acting by different mechanisms (107). However, the 
drawback of this strategy is the inefficient delivery of antisense oligonucleotides 
into cells. 
1.1.4.2 Inhibiting MDM2 Ubiquitin Ligase Activity 
Inhibiting the ubiquitin ligase activity of MDM2 has also been investigated as a 
p53-activating strategy, as p53 ubiquitination and degradation is the major 
component of the negative control of p53 by MDM2 (88-89, 108). Ribosomal 
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proteins L5, L11, and L23 have been shown to activate p53 by inhibiting 
MDM2-mediated p53 ubiquitination and thus activate p53 (109-110); other small 
proteins such as p19ARF (a 19 kDa polypeptide in the mouse, but p14ARF in 
humans) inhibit p53 degradation and activate p53 by binding to a C-terminal 
domain of MDM2 and promoting MDM2 degradation, rather than by directly 
preventing the MDM2/p53 interaction (111-112). In 2004, Yang et al. reported the 
identification of a family of small molecules (HLI98) that inhibit the E3 ligase activity 
of human MDM2. The compounds were observed to stabilize both p53 and HDM2 
proteins and to active p53-dependent transcription and apoptosis in cells (Table 
1.1) (113). Three years later, the synthetic route and biological evaluation data for 
this series of inhibitors (with the 5-deazaflavin scaffold) were disclosed (114) with 
further optimization to increase their potency, specificity and to eliminate 
p53-independent off-target activities (68) based on a structure-activity relationship 
(SAR) analysis. Also in 2007, a series of compounds (PYR-41, Table 1.1) with a 
different core structure to 5-deazaflavin was identified by the same group, which 
specifically inhibits the ubiquitin E1 rather than E2 to block protein degradation. 
Moreover, the results showed that PYR-41 at 20 µM induced p53 accumulation and 
downstream target p21 activation (115). 
1.1.4.3 Disruption of the p53-MDM2 Interaction 
Many studies have concentrated on disrupting the MDM2 and p53 protein-protein 
interaction, especially after the publication of the co-crystal structure of the 
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complex between MDM2 protein and a peptide corresponding to p53 residues 
17-29, and the revelation of the molecular details of their interface (116). MDM2 
and p53 bind to each other via their N-terminal domains (Figure 1. 6). The MDM2 
binding site of p53 partially overlaps with its transactivation domain and this is why 
MDM2 effectively inhibits p53 transcriptional activity (10).  
 
Figure 1. 6 Structure aspect of p53-MDM2 Interaction 
The MDM2 protein can inhibit p53 transaction by binding to the N-terminal transactivation domain of p53 
through a well defined p53 binding pocket in its N-terminal binding domain. The co-crystal structure of this 
binding interaction published in 1996 revealed that three key amino acid residues of the α-helix p53 peptide 
(green), Phe19, Trp23 and Leu26 insert deeply into the hydrophorbic binding groove of the MDM2 protein (light 
brown).  The schematic view of the functional domain structures of p53 and MDM2 are presented above and 
below the p53-MDM2 binding image respectively (68). 
Early studies have shown that p53-derived peptides inhibit the p53-MDM2 
interaction, suggesting that they could be used as starting points in the design of 
inhibitors (105, 117-118). The introduction of non-natural amino acids can further 
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enhance binding and lead to even more potent peptides (105, 117-119). On the 
other hand, a retroinverso isomer of the natural N-terminal helical peptide was 
found to interact with MDM2 using the same hydrophobic residues, Phe19, Trp23, 
and Leu26, indicating that the retroinverso D-peptide adopts a right-handed helical 
conformation to mimic the p53 peptide, with key residues maintained in an 
appropriate conformation to interact with the binding pocket of MDM2, and the 
potency is enhanced at least two-fold (120).  
However, since these peptides were macromolecules with low bioavailability, 
researchers tried to find antagonists from natural products and compound libraries 
or via structure based design. 
Although approximately 60% of small molecule drugs on the market are derived 
from natural products (121), only three natural products including chalcone-based 
inhibitors (122), chlorofusin (123) and hexylitaconic acid (124) have been reported 
to inhibit p53-MDM2 binding (Table 1. 1). 
With the contribution of many researchers focused on the p53-MDM2 interaction, 
an increasing number of small molecules have been developed to disrupt 
p53-MDM2 binding interaction (Table 1. 1). 
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Table 1. 1 Inhibitors of the p53-MDM2 Interaction 
 
No. Structure 
Evaluation 
methods 
IC50 
(µM) 
Type of 
compounds 
Ref. 
1 Ac-Gln-Glu-Thr-Phe19-Ser-Asp-Leu-Trp23-Lys-Leu-Leu26-Pro-NH2 ELISA (GST) 8.7 
Wild-type p53 
derived 
peptide 
(125) 
2 Ac-Met-Pro-Arg-Phe19-Met-Asp-Tyr-Trp23-Glu-Gly-Leu26-Asn-NH2 ELISA (GST) 0.3 
Phage-derived 
peptide 
(125) 
3 Ac- Phe19-Met-Asp-Tyr-Trp23-Glu-Gly-Leu26-NH2 ELISA (GST) 8.9 
Truncated 
phage-derived 
peptide 
(125) 
4 Ac-Glu-Thr-Phe19-Aib-Asp-Aib-Trp23-Lys-Aib-Leu26-Aib-glu-NH2 ELISA (GST) 5.2 
Constrained 
wild-type p53 
(126) 
5 Ac-Phe19-Met-Aib-Tyr-Trp23-Glu-Ac3C-Leu26-NH2 ELISA (GST) 2.2 
Constrained 
peptide 3 
(125) 
6 Ac-Phe19-Met-Aib-Pmp-Trp23-Glu-Ac3C-Leu26-NH2 ELISA (GST) 0.3 
Peptide 5 with 
a PMP at 
position 22 
(125) 
7 Ac-Phe19-Met-Aib-Pmp-6ClTrp23-Glu-Ac3C-Leu26-NH2 ELISA (GST) 0.005 
Peptide 6 with 
a 6ClTrp at 
position 23 
(125) 
8 
 
Library 
Docking 
ND 
[1,4]benzodiaz-
epine-2-one 
(127) 
9 
 
ELISA 
(Streptavidin) 
117 
Chalcone 
derivative 
(B-1) 
(122) 
10 
 
ELISA 
(detection 
only) 
ND 
Polycyclic 
Compound 
(syc-7) 
(128) 
11 
 
DELFIA-modifi
ed ELISA 
4.6 Chlorofusin (123) 
12 
 
ELISA (GST) ND 
Hexylitaconic 
acid 
(124) 
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ELISA (GST) 31.8 
Sulfonamide 
(NSC279287) 
(129) 
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14 
 
Cell line 
Screening  
ND 
 
RITA 
(binding to 
p53) 
(130) 
15 
 
Biacore’s 
Surface 
Plasmon 
Resonance 
Competition 
Assay 
0.09 
cis-imidazoline 
compounds 
(Nutin) 
(77) 
16 
 
Fluorescence-
Polarization 
(FP)-based 
Binding Assay  
0.1 
Nα-(2-phenoxy
-benzoyl) 
tryptophan- 
based MDM2 
inhibitors 
(131) 
17 
 
Plate-based 
Assays 
20 
Deazaflavins 
HL198C 
(113) 
18 
 
Plate-based 
Assays 
ND PYR-41 (115) 
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ELISA (GST) 10 
Terphenyl 
scaffold 
compounds 
(132) 
20 
 
ThermoFluor 
Assay 
 
0.08 
Benzodiazepin
edione 
compounds 
(11) 
21 
 
FP-based 
Binding Assay 
0.003 Spiro-oxindoles (133) 
22 
 
FP-based 
Binding Assay 
12 
Proteomimetic 
library 
chemisets 
(14) 
23 
 
FP-based 
Binding Assay 
0.12 
Quilinols 
(NSC 66811) 
(134) 
24 
 
ELISA 
(b-IP3 & 
Streptavidin) 
5.3 
Isoindolinone 
compounds 
(15-16) 
Compounds 1 to 7 are peptides. Compounds 11, 12 and 14 are natural products. The remained compounds are 
synthetic molecules. Aib, -amino isobutyric acid; Ac3C, 1-amino-cyclopropanecarboxylic acid; PMP, 
phosphonomethylphenylalanine; 6ClTrp, 6-chloro-tryptophan; GST ELISA, Glutathione Transferase ELISA.    
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Targeting of protein–protein interactions by small molecules is challenging. The 
factors contributing to the challenge include 1) the general lack of small-molecule 
starting points for drug design, 2) the typical flatness of the interface, 3) the 
difficulty of identifying real binding, and 4) the limitation of the size and character 
of typical small-molecule libraries (135). However, protein–protein interfaces with a 
α-helix binding groove might be particularly valuable for small-molecule drug 
discovery (135).  
In the case of the MDM2-p53 interaction it involves the binding of a single α-helix 
(from p53) in a hydrophobic groove formed by three α-helices (from MDM2). 
 
Figure 1. 7 The crystal structure of p53 peptide binding with MDM2 protein (116).  
The crystal structure of p53 peptide forms an amphipathic helix (main chain structure in red and side chains in 
yellow) and binds with the MDM2 protein (main chain structure in blue and side chains in cyan) by inserting its 
key hydrophorbic amino acid residues into the p53 binding groove on MDM2 protein surface. The binding 
groove is formed by an α2 helix on one side, and a β-sheet on the other side, and is lined with hydrophobic and 
aromatic amino acids (or both)., the blue and red spheres indicate nitrogen and oxygen atoms, respectively, the 
key hydrogen bond interactions are shown as red dotted lines. (A) The helical backbond of p53 peptide is shown 
as a circle-like structure, by presenting the structure view as looking down the helix axis, with all amino acid side 
chains labelled to emphasize its amphipathic nature. The  α2 helix and β-sheet backbone structure of MDM2 is 
located below the p53 peptide structure with amino acid sidechains at the interface presented but without label. 
The two hydrogen bonds at the interface are also emphasized as red dotted lines. (B) View of the interface in an 
orientation clockwisely rotated 90°  about the vertical axis of (A), so that the MDM2 α2 helix is behind the 
plane of the figure, and its β-sheet is in front of the plane of the figure, with the p53 structure between them 
two. All the interacting amino acids of both p53 and MDM2 at the interface are shown and labelled.   
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In fact, as displayed in Figure 1. 7 only a limited number of amino acid residues, just 
three p53 amino acids – Phe19, Trp23 and Leu26, are crucial for the binding of 
these two proteins (116). These three amino acid residues are inserted into a deep 
hydrophobic pocket on the surface of the MDM2 molecule which made designing 
small molecules to inhibit this interaction possible (68).  
Using a cell-proliferation assay to screen the National Cancer Institute (NCI) library 
of compounds, Issaeva et al. identified RITA (reactivation of p53 and induction of 
tumour cell apoptosis), 2,5-bis(5-hydroxymethyl-2-thienyl)furan, which suppressed 
the growth of HCT116 cells in a dose-dependent manner as a result of binding with 
p53 and inducing its accumulation in cells (130). It was observed that RITA binds to 
the MDM2-p53 transactivation domain-binding cleft (136). However, a recent study 
report from Krajewski et al. argues that RITA does not block the formation of the 
complex in vitro between p53(residues1-312) and the N-terminal p53-binding 
domain of MDM2(residues 1-118) (137). Although Grinkevich et al. attempted to 
defend their hypothesis by suggesting that the native conformation of p53 may be 
required for enabling RITA to bind with it, they also admitted that elucidation of the 
structure-activity relationship of RITA-p53 binding could be important for future 
research (137).         
By using a high-throughput fluorescence polarization binding assay (138-139), 
Zhang et al. have rank ordered a series of small-molecule inhibitors (Table 1. 2 &  
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Table 1. 3) that block the binding of MDM2 to a p53-derived fluorescent peptide 
(131). In their research results, all the octapeptide-based MDM2 inhibitors in Table 
1. 2 had Ki values in the nanomolar range of potency, however, most of the tested 
Nα-(2-phenoxybenzoyl) tryptophan-based MDM2 inhibitors in  
Table 1. 3 exhibited micromolar range potencies. No binding mode analysis or 
cellular activity evaluation data have been published to date following this report. 
 
Table 1. 2 Trp indole C5/C6 substitution SAR of octapeptide-based MDM2 inhibitors. 
  Octapeptide Ki (nM)
a
 
1 AC- Phe- Lys- Lys- Ac6C- Trp- Glu- Glu- Leu- NH2 240 
2 AC- Phe- Lys- Lys- Ac6C- (5-CN)Trp- Glu- Glu- Leu- NH2 530 
3 AC- Phe- Lys- Lys- Ac6C- (5-Me)Trp- Glu- Glu- Leu- NH2 76 
4 AC- Phe- Lys- Lys- Ac6C- (5-F)Trp- Glu- Glu- Leu- NH2 45 
5 AC- Phe- Lys- Lys- Ac6C- (6-Me)Trp- Glu- Glu- Leu- NH2 120 
6 AC- Phe- Lys- Lys- Ac6C- (6-F)Trp- Glu- Glu- Leu- NH2 44 
7 AC- Phe- Lys- Lys- Ac6C- (6-Cl)Trp- Glu- Glu- Leu- NH2 1 
8 AC- Phe- Lys- Lys- Ac6C- (6-Br)Trp- Glu- Glu- Leu- NH2 0.7 
9 AC- Phe- Arg- Dpr- Ac6C- (6-Br)Trp- Glu- Glu- Leu- NH2 2 
a
 Ac6C-, α-aminocyclohexyl carboxylic acid and its residue; Dpr-, α,β-diaminopropionic acid and its resibue; 
Reported are FP Ki values to Trx-MDM2. The FP assay was performed at room temperature in PBS containing 
2.5% DMSO (131). 
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Table 1. 3 C5/C6/N1 SAR of Nα-(2-phenoxybenzoyl) tryptophan-based MDM2 inhibitors. 
 
FP Ki Values are reported in µM. The compounds are identified by column and row numbers. 
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Nutlins were identified as the first potent and selective small-molecule antagonists 
of MDM2 by Vassilev et al.(77). X-ray crystallography was used to confirm the 
specific binding of Nutlins in the p53-binding pocket of MDM2 (Figure 1. 8). 
 
Figure 1. 8 MDM2-Nutlin-2 binding image. 
The MDM2-Nutlin-2 co-crystal structure in this figure indicated that one Nutlin-2 (in red) blocked the 
p53-binding pocket of MDM2 (in blue) and the other Nutlin-2 (in yellow) bound to another position of the 
MDM2 protein surface (PDB ID code 1RV1 molecule group A) (77). The figure was generated using PyMOL 
(DeLano, 2002). 
With the blocking of the p53-MDM2 binding interaction by Nutlins, the p53 
pathway was activated, leading to cell cycle arrest, apoptosis, and growth inhibition 
of human tumour xenografts in nude mice (77, 140-141). The specificity of Nutlin-3 
activation of the p53 pathway was shown by the induction of apoptosis in cells with 
wild-type p53, but not mutant p53 (141-142). Supportive evidence for Nutlin-3 
being a highly selective MDM2 antagonist and p53 inducer has been provided by 
gene array analysis of Nutlin-induced expression patterns, and also by SJSA-1 and 
MHM osteosarcoma xenografts in vivo (143). Van Maerken et al. came to the same 
conclusion when investigating neuroblastoma cells with wild-type p53 (144). The 
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discovery of the Nutlinsmall molecule inhibitors of the p53-MDM2 interaction was 
suggested to represent the end of the ‘peptide era’ and beginning of the ‘low 
molecular weight era’ of protein-protein interaction antagonists (145). 
 
Figure 1. 9 Structure-based design produced small molecule antagonists of MDM2-p53 
binding interaction by mimicking Phe19, Trp23, Leu26 and Leu22 residues in p53 (133).   
(A) The analysis of X-ray structure of the p53−MDM2 complex indicates  that except Phe19, Trp23, and Leu26, 
Leu22 in p53 has also contributed to the interaction between p53 and MDM2. The MDM2 binding site is 
colour-coded according to the cavity depth (the binding groove is  coded in light green, and solvent-exposed 
regions are coded in blue). The four key amino acid side-chain residues in p53 are shown as stick model and 
colour-coded in purple. (B, C) Predicted binding models of two spiro-oxindole complexed with MDM2 binding 
groove using the GOLD programme. For both of the two compounds (1 and 4 as labelled), carbons are in white, 
nitrogens in blue, chloride in green, and oxygens in red. Hydrogen bonds interaction between each compound 
with  MDM2 are shown with a dashed yellow line. (D) View of superposition of compound 4 (is colour-coded as 
illustrated in C) to the p53 peptide (α-helix backbone is shown in light green) conformation in the crystal 
structure of p53 peptide in complex with MDM2. Four amino acid side-chains, Phe19, Leu22, Trp23, and Leu26, 
in p53 are labelled and colour-coded in purple. 
Using a structure-based design strategy to mimic the Phe19, Trp23, Leu26, and 
Leu22 residues in p53, Ding et al. have designed a class of small-molecule inhibitors 
(spirooxindoles) of the MDM2-p53 interaction(Figure 1. 9).  
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 The most potent inhibitor, which was named MI-63 (MDM2 inhibitor 63), has a Ki 
value of 3 nM for binding to MDM2, and is over 2000-times more potent than the 
natural p53 peptide (residues 13-29). The study also showed that MI-63 is a highly 
effective activator of p53 function and inhibitor of LNCaP prostate cancer cell 
growth, and reported to have minimal toxicity to normal cells (133).  
 
Figure 1. 10 Chemical structures of potent spirooxindole MDM2 inhibitors (146). 
With several years of continuous optimization (147-151), a batch of potent and 
orally active small-molecule inhibitors of the MDM2-p53 interaction were obtained 
based on the spirooxindole core scaffold (Figure 1. 10). Noticeably, compound 5 
binds to MDM2 with a Ki value of 0.6 nM and activates p53 at the concentration as 
low as 40 nM with a good oral bioavaliability (146). These successful 
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structure-based MDM2 inhibitor design strategies have provided solid evidence that 
reactivation of p53 using small-molecule inhibitors is a promising new cancer 
therapeutic strategy (146). 
A series of isoindolin-1-ones has been identified as inhibitors of the MDM2-p53 
interaction in previous studies by our group, using in silico screening and small 
library synthesis (15-16). As this research was carried out without structural data on 
the isoindolinone-MDM2 interaction, docking was applied using the published 
MDM2 crystal structure 1YCR and the easyDock computer programme as a virtual 
screening method, but a unique binding mode could not be defined with the limited 
information available. As a result, a combinatorial approach was employed to 
optimize the activity of a series of compounds, and three side chains were chosen 
for the first attempt. With a series of SAR analyses, two of the most potent 
compounds, 2-benzyl-3-(4-chlorophenyl)-3-(3-hydroxypropoxy)-2, 
3-dihydroisoindol- 1-one (IC50 = 15.9 µM) and 3-(4-chlorophenyl)-3-(4-hydroxy-3, 
5-dimethoxybenzyloxy)-2-propyl- 2, 3-dihydroisoindol-1-one (IC50 = 5.3 µM) (Table 
1. 1), were identified. Bioassay evaluation showed that these two compounds 
induced p53-dependent gene transcription, in a dose-dependent manner, in the 
MDM2 amplified SJSA human sarcoma cell line(15-16). Further investigations to 
increase the potency, bioavailability and selectivity, and to evaluate biological 
effects in vivo of these lead compounds has been the priority of this project. 
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1.1.5  MDMX as a druggable target for p53 reactivation 
A cDNA clone encoding MDMX (MDM4) was isolated and identified from a whole 
mouse cDNA expression library in 1996 and showed the function of inhibiting 
p53-activated transcription (152). One year later, the human homologue of MDMX 
was isolated and identified, which contains 490 amino acids and is 90% similar to 
mouse MDMX (153). The comparison between MDM2 and MDMX proteins (Figure 
1. 11) showed marked structural similarity (96).  
 
Figure 1. 11 Primary strucutre comparison of human MDM2 and human MDMX proteins. 
In the schematic primary structures of both MDM2 and MDMX proteins, the p53 binding domain (red), Zinc 
finger domain (cyan) and RING finger domain (yellow) are well conserved, with marked conserved percentage 
(53.6%, 41.9% and 53.2% correspondingly). It also shows that although both of the two proteins contain high 
content of acidic amino acids, but no significant similarity between these two domains, which in MDM2 is from 
237 to 288, and in MDMX is from 215 to 255. In addition, although a consensus nucleolar location signal (NoLS, 
purple) is present within the RING domain of both MDM2 and MDMX protein structures, nuclear localization 
signal (NLS, light blue) and nuclear export signal (NES, brown) present only in MDM2 but not MDMX (96).     
The highest similarity of MDM2 and MDMX protein structure is found at the 
N-terminal region that overlaps the p53-binding domain, which is consistent with 
the observation that both MDM2 and MDMX can interact with p53, and the amino 
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acids required for the interaction of p53 with human MDM2 are precisely conserved 
in human MDMX. Moreover, these amino acids are strictly conserved in all known 
orthologs of human MDM2 and human MDMX (154).  
Using cells deficient in either MDM2 or MDMX, Gu et al. (155) demonstrated that 
MDM2 and MDMX are actually functionally dependent on each other. On the one 
hand, in the absence of MDMX, MDM2 is quite ineffective in suppressing p53 
activity because of the handicap of its very short half-life, i.e. MDMX enhances 
MDM2 protein stability sufficiently to enable its p53 degradation function 
thoroughly. On the other hand, as a cytoplasmic protein, MDMX presents no NLS 
and NES regions, and hence has to rely on MDM2 (155-156) or other shuttles such 
as p53 (157) to get into the nucleus to inhibit p53 function. When excessively 
overexpressed, MDMX can inhibit MDM2-mediated p53 degradation by competing 
with MDM2 for binding to p53 (157).  
To study MDMX function in vivo, Parant et al. generated MDM4-null mice by using a 
homologous recombination method to delete exon 3-5 of MDM4 that encodes most 
of the p53 binding domain (amino acids 27-96). This mutation caused the death of 
MDM4-/- embryos at 7.5-8.5 dpc (days postcoitum) due to loss of cell proliferation 
but not induction of apoptosis. In addition, by crossing in the Trp53-null allele, they 
observed complete rescue of MDM4-/- embryonic lethality. Based on these 
observations, they suggested that MDM4 and MDM2 may regulate p53 function via 
different pathways in vivo (158). By random insertion mutagenesis upstream of the 
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ATG start codon with a viral insertion mapped in intron 1, Finch et al. generated a 
2nd MDMX null (mutant) mouse line, which results in midgestational embryo 
lethality (died between 9.5-10.5 dpc) because of overall growth defects and massive 
apoptosis in the neuroepithelium (159). Furthermore, this mouse line can be 
completely rescued by the absence of p53, and mice homozygous for both MDMX 
and p53 null mutations are viable and appear developmentally normal (159). 
Migliorini et al. characterized a mutant mouse line with a specific gene trap event in 
the MDM4 locus. Without the MDM4 expression, the mice embryos died at 
between 10 and 12 dpc because of overall growth deficiency, anaemia, improper 
neural tube closure and dilation of lateral ventricles, and this could be rescued by 
transferring the MDM4 mutation into a Trp53-null background. In situ analysis of 
RNA showed p21 level increasing and decreased levels of Cyclin E, as well as 
proliferating cell nuclear antigen expression, which suggest a G1 phase cell cycle 
arrest of the MDM4 mutant embryo cells. It also demonstrated that 
MDM4-deficient mouse embryonic fibroblasts showed a marked reduction of 
prolifrative capacity in culture, and p53-dependent cell death was generally 
detected in the developing central nervous system of MDM4 mutant embryos (160). 
In a further mouse model study, Francoz et al. generated sophisticated mouse 
models to demonstrate that both MDM2 and MDM4 are essential for preventing 
p53 activity in the same type of cells, at either proliferation or differentiation status 
(30). The data suggest that MDM2 is responsible for preventing p53 protein 
accumulation, while MDM4 contributes to the overall inhibition of p53 activity 
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independent of MDM2 (30). They seem to cooperate like ‘brothers in arms’ (96) to 
keep p53 in check. 
These observations confirmed that MDMX function is critical and synergistic for 
negative regulation of p53 activity in vivo (at least during embryogenesis).  
After the confirmation of MDMX as a key down-regulator of p53 function in vivo, it 
was necessary to figure out if MDMX can contribute to tumour formation directly or 
not. Using retrovirus-mediated MDMX over-expression in primary mouse 
embryonic fibroblasts, Danovi et al. (161) demonstrated that increased and 
constitutive MDMX expression led to immortalization and neoplastic 
transformation of the cells, which suggested that the abnormal expression of 
MDMX could contribute to tumourgenesis. Following this observation, human 
MDMX mRNA expression levels of hundreds of primary human tumour samples 
were checked using in situ hybridization (ISH) and tissue microarray (TMA) methods, 
and observed 3-5 fold higher levels of human MDMX expression in 19 % of breast 
(41 of 218), 19 % of colon (5 of 27) and 18 % of lung (16 of 88) cancers than those in 
matched controls. In addition, MDMX amplification was observed(defined as more 
than 6 to 8 copies per cell) in 5 % (8 of 162) of primary breast tumour samples 
analyzed and all of the tested tumour samples retained wild type p53. Actually, 
human MDMX over-expression has been reported in around 40 % (13 of 31) of 
cancer cell lines tested (162). It is amplified in 4 % of glioblastomas (163), and about 
60% of retinoblastomas have been reported to have MDMX over-expression or 
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gene amplification (164). All these data indicated MDMX as a new putative drug 
target for cancer therapy.     
By using an ELISA method and cellular assays, Hu et al. (165) demonstrated that 
Nutlin-3 could inhibit the binding of p53 to MDM2 but not to MDMX. In the 
experiment, Nutlin-3 inhibited the p53-MDM2 binding interaction with an IC50 of 
about 800 nM, but showed little or no inhibitory activity against p53-MDMX binding 
at concentrations up to 30 µM. Following that, JEG3 and MCF7 cell lines that 
express a high level of endogenous MDMX had been used for confirming the 
observation. The data suggested a correlation between MDMX level in cell lines 
with p53 activation and p21 protein induction, as well as with cell cycle and growth 
arrest effects. In the report of Patton et al. (166), isogenic populations of normal 
human fibroblasts transformed in vitro by human MDM2, human MDMX or shRNA 
to p53 had been applied to determine the effects of Nutlin-3 in cells with wild type 
p53. The result indicated that Nutlin-3 efficiently induced apoptosis in cells 
expressing human MDM2, whereas human MDMX-expressing cells and cells with 
low level of p53 have no significant response. Moreover, for the Nutlin-3 resistance 
cells overexpressing human MDMX, elimination of MDMX expression by shRNA 
sensitized them to Nutlin-3 mediated cell cycle arrest or cell death. These findings 
highlighted the requirement of developing MDMX-specific small molecule inhibitors 
for research into MDMX function and as therapeutic agents. 
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Most recently, Bo et al. (167) have validated a subgroup of chronic lymphocytic 
leukaemia (CLL) cells containing wild type p53, which show a lack of cytotoxic 
response to in vitro treatment with Nutlin-3. Interestingly, by utilizing a qRT-PCR 
method, they compared the MDM4 transcript level of a different series of 43 CLL 
samples to the normal B cells purified from peripheral blood samples of 15 healthy 
donors and observed that MDM4 was not only remarkablely over-expressed in a 
subset of CLL cells that contain wild type p53 and lack of cytotoxic response to 
Nutlin-3 treatment, but also universally over-expressed by CLL cells compared to 
normal B cells. These observations suggest that MDM4 could be a potential 
therapeutic target for CLL.  
In 2008, Popowicz et al. (168) determined the first co-crystal structure of a peptide 
derived from human p53 transactivation domain binding with a humanized 
zebra-fish MDMX and compared the p53 binding pocket of the MDMX crystal 
structure together with that of two MDM2 (PDB Code: 1YCR & 1T4F) crystal 
structures (Figure 1. 12). The comparison of these structures indicate that although 
the principal features of the MDM2-p53 binding interaction are preserved in the 
MDMX-p53 binding interaction, and the three key residues of p53 (Phe19, Trp23 
and Leu26) still contribute to the binding, the central hydrophobic groove of MDMX 
that the p53 peptide binds is smaller and differently shaped than those of MDM2 
proteins. The key amino acid residues that contribute to this difference (Leu53 and 
Tyr99 in MDMX, and Leu54 and Tyr100 in MDM2) are highlighted in Figure 1. 12.  
34 
 
 
Figure 1. 12 Surface representations of human MDMX (the left side) and two human 
MDM2 structures (the right side) (168). 
Significant differences in the shape of p53 binding pocket are clearly visible. Amino acid residues mainly 
responsible for the differences in the binding groove are labelled. 
Following these observations, several p53 analogue peptide inhibitors were 
generated (169-173) to explore the p53-MDMX binding interaction and to refine the 
differences of MDMX-p53 binding with MDM2-p53 binding, which together with the 
assays developed for evaluating the binding affinity should contribute to speeding 
up the development of a simple pharmacophore model of cross-selective 
MDM2-MDMX/p53 inhibitors.     
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1.2 Research Project 
My research project is based on the theories and hypotheses about MDM2/p53 
small molecule antagonists design and mentioned above, and the progress our 
research group has made. 
Aims: 
1. Continue to optimize the structure of the isoindolin-1-one scaffold compounds, 
based on the X-ray crystal structure model of the MDM2-p53 binding 
interaction, and structure/activity analysis to design more potent compounds 
with good water solubility and bioavailability. 
2. Evaluate the activity of newly synthesised isoindolin-1-one scaffold compounds 
with a sequence of cell-free and intact cell bioassay methods combined with 
information from NMR and X-ray crystal structure analysis to establish the 
binding modes of inhibitors with MDM2, so that we can obtain SAR information 
to inform the continued optimization process.  
3. Test the most potent isoindoline-1-one compounds for differential growth 
inhibition and/or cytotoxicity with a panel of cell lines of defined p53 and 
MDM2 status, to validate the specificity of the compounds for inhibition of the 
MDM2-p53 interaction. 
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4. Establish whether or not the new inhibitors can also bind MDMX, a closely 
related structural homologue of MDM2, which can also potentially prevent p53 
activation after MDM2 has been inhibited. 
5. Screen compounds with different core scaffolds in an attempt to obtain 
alternative scaffold compounds as MDM2/p53 and/or MDMX/p53 small 
molecule antagonists. 
6. Generate MDM2/p53 antagonist-resistant cancer cell lines and explore the 
possible mechanisms of their resistance.  
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Chapter Two 
General Materials and Methods 
 
During this PhD project, a broad range of techniques have been employed, including 
synthetic chemistry, biochemistry (ELISA, western blotting, SRB assay, Caspase-Glo 
3/7 assay, DNA sequencing, FISH assay) and computational quantitative structure 
activity relationship (QSAR, for binding mode prediction) analysis for the purpose of 
developing a better understanding of the p53 pathway and its activation with 
MDM2/p53 antagonists. 
This chapter focuses on the general methods and materials applied during my 
study, and further specific information for each method will be explained where 
appropriate in the Results chapters. 
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2.1 ELISA Assay 
Enzyme-Linked Immuno-Sorbent Assay (ELISA) is a technique often employed due 
to its extreme sensitivity and scale, which enables a rapid detection system suitable 
for high throughput screens of protein expression and protein interactions with 
other macromolecules, including protein-protein binding. The original ELISA 
description was published by Dr Peter Perlmann and Dr Eva Engvall in 1971 (174). 
After about four decades development, a vast number of applications based on the 
initial ELISA principal have been published worldwide and all of them typically 
contain the procedure that an unknown amount of antigen or antibody is tightly 
affixed to a surface (in a tube or microtiter plate), and then a specific antibody or 
antigen is applied over the surface so that it can bind to the antigen/antibody, 
respectively. Then a detection antibody labelled with an enzyme is added, and in 
the final step a substance is added that the enzyme can convert to some detectable 
signal, most commonly a colour change or light emission in a chemical substrate. 
2.1.1 Experiment Design 
2.1.1.1 Mechanisms of ELISA for MDM2/MDMX Antagonist Screening 
An ELISA method, as previously described (16) was used to screen compounds using 
a 96 well Streptavidin Covalent ScintiPlate (Perkin Elmer), as schematically 
illustrated in Figure 2. 1.  
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The plate was coated with streptavidin which formed a complex with the 
biotinylated IP3 (118) peptide that based on the wild type p53 sequence (b-IP3: 
Biotin-Met-Pro-Arg-Phe[19]-Met-Asp-Tyr-Trp[23]-Glu-Gly-Leu[26]-Asn-NH2) when it 
was added. Samples from a parallel clear plate consisting of in vitro translated 
MDM2/MDMX lysate (IV-MDM2/IV-MDMX) incubated with various concentrations 
of antagonists was then directly transferred to the IP3 peptide coated binding plate. 
Since the antagonists and IP3 bind to the same N-terminal region of MDM2/MDMX, 
the potency of the compound is determined by the amount of 
IP3-MDM2/IP3-MDMX complex formation; the less complex formation detected by 
the subsequent procedure, the greater the potency of the compound. 
The amount of IP3-MDM2 or IP3-MDMX complex formation was determined by 
using a primary mouse anti-MDM2 antibody (MDM2-Ab5 from Calbiochem)/rabbit 
anti-MDMX antibody (BL1258 from Bethyl), as appropriate, followed by a goat 
anti-mouse secondary horseradish peroxidase (HRP) conjugated antibody for 
MDM2 primary antibody detection or a goat anti-rabbit secondary horseradish 
peroxidase (HRP) conjugated antibody for MDMX primary antibody detection. An 
Enhanced Chemiluminescence (ECL) system was used to detect the amount of HRP 
bound and hence to quantify the complex formation. By detecting the amount of 
light produced using a luminometer, the amount of secondary antibody bound to 
the primary MDM2/MDMX antibody can be inferred. 
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Figure 2. 1 Procedure of ELISA for MDM2/MDMX antagonists screening in A) single well 
and B) a 96-well plate 
A 
B 
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2.1.1.2 Plate Arrangement for MDM2/MDMX Antagonists IC50 Determination 
For evaluation of dose-dependent-activity, the ELISA assays were carried out with 
the plate arrangement method shown in Figure 2. 2; 7 compounds could be 
evaluated within one plate. The first three vertical lines of wells were solvent 
controls and three different concentrations of positive controls (Nutlin-3 at 50, 100, 
200 nM for MDM2 inhibitor screening, IP3 peptide at 0.5, 2, 10 µM for MDMX 
inhibitor screening) were placed in the top row 9 wells. Each concentration of every 
compound was plated out in triplicate at three different concentrations. 
The 63 wells colour coded as grey can also be individual compounds with the same 
concentration for high throughput screening. 
 
Figure 2. 2 Plate arrangements for IC50 value determination 
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2.1.2 Plasmid DNA Preparation 
For the preparation of MDM2/MDMX plasmid DNA, we have produced detailed 
protocol of ‘Plasmid preparation by using QIAGEN tip 2500’ based on the QIAGEN 
tip 2500 supplier’s protocol in the QIAGEN Plasmid Purification Handbook. 
Day 1 
Prepare bacterial culture 
For high yields of pure DNA (~2.5mg), 500ml of LB culture are needed for high 
copy-number plasmids. 
LB broth (per Liter): 10 g bacto-tryptone, 5 g Bacto-yeast extract and 10 g NaCl. The 
mixture of the materials in the list needs to be autoclaved immediately after adding 
the right amount of water. 
Day 2 
1. Prepare a starter culture by inoculating 10µl from a bacterial frozen stock 
stored in 10% DMSO at -70°C (prepared by Dr. Xiaohong Lu) into 2–10 ml LB 
medium containing the appropriate antibiotic (Ampilcillin 50µg/ml). Grow at 
37°C for approxmately 5 hours with vigorous shaking (~300 rpm). 
2. Dilute the starter culture 1/500 to 1/1000 into a larger volume of selective LB 
medium. 
A flask that is at least 5 times the volume of culture will be needed to ensure 
sufficient aeration. 
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A larger culture volume than recommended in the protocol should not be used, 
as it will produce too many cells that will result in inefficient lysis and reduce the 
quality of the preparation. 
3. Grow the culture at 37°C with vigorous shaking (~300 rpm) for 12–16 h. 
Growth for 12–16 h corresponds to the transition from logarithmic into 
stationary growth phase, when cell density is high (3–4 x 109 cells per ml) and 
RNA content of cells is low. 
The growth of cultures is dependent on factors such as host strain, plasmid 
insert and copy number, and culture medium. 
Day 3 
1. Harvest the bacterial culture by centrifugation at 6000 x g for 15 min at 4°C.  
Remove all traces of the supernatant. The cells will then be ready for the lysis 
procedure. 
The procedure may be stopped at this point and continued later by freezing the 
cell pellets obtained by centrifugation. The frozen cell pellets can be stored at 
–20°C for several weeks. 
2. Re-suspend the bacterial pellet in 50 ml of Buffer P1. 
For efficient lysis it is important to use a vessel that is large enough to allow 
complete mixing of the lysis buffers.  
A 500 ml bottle is recommended for large scale (Mega) preparations.  
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Ensure that the RNase A has been added to Buffer P1 to give a final 
concentration of 100 µg/ml. The bacteria should be resuspended completely by 
vortexing or pipetting up and down until no cell clumps remain. 
3. Add 50 ml of Buffer P2, mix thoroughly by vigorously inverting 4–6 times, and 
incubate at room temperature for 5 min. 
Vortexing should be avoid at this stage, as this may result in excessive shearing 
of bacterial genomic DNA, which may cause difficulties in later separation from 
plasmid DNA. The lysate should appear viscous. The lysis reaction should not be 
continued for more than 5 min. After use, the bottle containing Buffer P2 should 
be closed immediately to avoid acidification of Buffer P2 from CO2 in the air. 
4. Add 50 ml of chilled Buffer P3, mix immediately and thoroughly by vigorously 
inverting 4–6 times, and incubating on ice for 30 min.  
Precipitation is enhanced by using chilled Buffer P3 and incubating on ice. After 
addition of Buffer P3, a fluffy white material forms and the lysate becomes less 
viscous. The precipitated material contains genomic DNA, proteins, cell debris, 
etc. The lysate should be mixed thoroughly to avoid localized potassium dodecyl 
sulfate precipitation. 
5. Centrifuge at ≥20,00 × g for 30 min at 4°C. Collect supernatant containing 
plasmid DNA promptly. 
Before loading the centrifuge, the sample should be mixed again. Centrifugation 
should be performed in 250 ml or 500 ml non-glass tubes (e.g., polypropylene). 
Note: Instead of centrifugation, steps 7 and 8 can be applied.  
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6. The lysate can then be efficiently cleared by filtration using a paper filter (e.g. 
Whatman Grade 2V 8µm, Cat. 1202-240). 
7. Equilibrate a QIAGEN-tip 2500 by applying 35 ml Buffer QBT, and allow the 
column to empty by gravity flow. 
Flow of buffer will begin automatically by reduction in surface tension due to 
the presence of detergent in the equilibration buffer. Allow the QIAGEN-tip to 
drain completely. QIAGEN-tips can be left unattended, since the flow of buffer 
will stop when the meniscus of the solution reaches the upper frit in the 
column. 
8. Apply the supernatant from step 8 to the QIAGEN-tip and allow it to enter the 
resin by gravity flow. 
The supernatant should be loaded onto the QIAGEN-tip promptly. If it is left too 
long and becomes cloudy due to further precipitation of protein, it must be 
centrifuged again or filtered before loading to prevent clogging of the 
QIAGEN-tip. 
9. Wash the QIAGEN-tip with a total of 200 ml Buffer QC. 
Allow Buffer QC to move through the QIAGEN-tip by gravity flow. The first half 
of the volume of wash buffer is sufficient to remove all contaminants in the 
majority of plasmid DNA preparations. The second half is particularly necessary 
when large culture volumes or bacterial strains producing large amounts of 
carbohydrates are used. 
10.  Elute DNA with 35 ml Buffer QF. 
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Use of polycarbonate centrifuge tubes for collection is not recommended as 
polycarbonate is not resistant to the alcohol used in subsequent steps. 
11.  Precipitate DNA by adding 24.5 ml (0.7 volumes) room-temperature 
isopropanol to precipitate the eluted DNA. Mix and centrifuge immediately at 
≥15,000 x g for 30 min at 4°C. Carefully decant the supernatant. 
All solutions should be at room temperature in order to minimize salt 
precipitation, although centrifugation is carried out at 4°C to prevent 
overheating of the sample. 
Alternatively, disposable conical bottom centrifuge tubes can be used for 
centrifugation at 5000 x g for 60 min at 4°C. Isopropanol pellets have a glassy 
appearance and may be more difficult to see than the fluffy, salt-containing 
pellets that result from ethanol precipitation. Marking the outside of the tube 
before centrifugation allows the pellet to be more easily located. Isopropanol 
pellets are also more loosely attached to the side of the tube, as a result, care 
should be taken when removing the supernatant. 
12.  Wash DNA pellet twice with 1 ml of room-temperature 70% ethanol, and 
transfer into an eppendorf tube. Centrifuge at ≥15,000 × g for 10 min, then 
carefully decant the supernatant without disturbing the pellet. 
Alternatively, disposable conical-bottom centrifuge tubes (not supplied) can be 
used for centrifugation at 5000 x g for 60 min at 4°C. The 70% ethanol removes 
precipitated salt and replaces isopropanol with the more volatile ethanol, 
making the DNA easier to be re-dissolved. 
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13.  Air-dry the pellet for 10–20 min, and re-dissolve the DNA in a suitable volume 
of basic buffer (e.g. 1×Tris-EDTA buffer, pH 7.4 or 10 mM Tris∙Cl, pH 8.5). 
Re-dissolve the DNA pellet by rinsing the walls to recover the entire DNA, 
especially if glass tubes have been used. Pipetting the DNA up and down to 
promote re-suspension may cause shearing and should be avoided. Over drying 
the pellet will make the DNA difficult to re-dissolve. DNA dissolves better under 
slightly alkaline conditions; it does not easily dissolve in acidic buffers. 
14.  Determination of yield. 
To determine the yield, DNA concentration should be determined by a 
nanodrop spectrophotometry at 260 nm. For reliable spectrophotometric DNA 
quantification, Absorbance reading at 260nM (A260) readings should lie between 
0.1 and 1.0; and a ratio of A260/A280 should ideally be reach approximately 1.8. 
15.  Dilute plasmid DNA to 1 µg/ml with deionized water and stored at -20°C for 
ELISA assay. 
             Reproduced based on QIAGEN Plasmid Purification Handbook. 
 
2.1.3 Compound Sample Preparation 
Due to the limitation of low aqueous solubility of the compounds, they were 
dissolved in 100 % DMSO to make up an initial stock concentration of 10 mM, and 
then diluted in DMSO to 2 mM and 400 M. The compounds were screened at final 
concentrations of 20 M, 100 M and 500 M, respectively. After calculating the 
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approximate IC50 range of the antagonists based on the initial three concentrations, 
three lower concentrations may be determined, which should be around the IC50 
value, and the detailed IC50 results can be obtained thereafter. 
To make 10 mM concentration compound solution: 
Volume (µl) = Weight (mg) x 100 / Molecular Weight of the compound 
Then dilute it into the required lower concentration solutions before the 
experiment and the sample’s final concentration is 1/20 of the working stock in 
each well of the plate.                                                                                                                                             
To make -IP3 peptide solution: 
Dissolve -IP3 peptide powder in DMSO to make 20 mg/ml Stock. 
Add the same volume of phosphate buffered saline (PBS) in above stock and make 
10 mg/ml. Store in -80 C. 
To make working solution 0.1µg/µl: 
Add 10µl of 10 mg/ml stock into 990µl PBS. 
2.1.4 ELISA Protocol 
For the convenience of describing the ELISA method, the flow chart (Figure 2. 3) was 
designed to illustrate the procedure of ELISA for MDM2 antagonists screening, and 
the procedure for MDMX antagonists screening was almost the same. 
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2.1.4.1 In Vitro Transcription/Translation Reaction 
The coupled transcription/translation system using the TNT® Rabbit Reticulocyte 
Lysate system (Promega) was used for the in vitro production of the full length 
MDM2/MDMX protein. 
2.1.4.2 Components of TNT® Rabbit Reticulocyte Lysate System 
The reaction components (Table 2. 1) were put together in a 5 ml universal (Bijou, 
Sterilin); mixed gently using a vortex and incubated in 100 l aliquots in microfuge 
tubes for 2 hours at 30 ˚C. The human MDM2/MDMX sequence was cloned in a 
pCR3 plasmid (Invitrogen) by Iakovos Sigalas (175) and was used at the 
concentration of 1 g/l. Following incubation the microfuge tubes were removed 
and stored at -20 ˚C for the ELISA procedure illustrated in the followed flow charts. 
 
Table 2. 1 Coupled Transcription/Translation Components 
 
 
Components MDM2 protein preparation MDMX protein preparation 
Volume per 
reaction (l) 
Volume per 
Promega pack (l) 
Volume per 
reaction (l) 
Volume per 
Promega pack (l) 
T7 Buffer 1.0 80 1.0 80 
T7 RNA polymerase 0.5 40 0.5 40 
Amino acid mixture 1.0 80 0.5 40 
RNasin 0.5 40 0.5 40 
Plasmid DNA (1 g/l) 2.0 160 0.5 40 
Nuclease free water 9.5 750 9.5 760 
Reticulocyte Lysate 125 1000 125 1000 
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(A) Add 200 µl 1 µg/ml b-IP3 in each wells in a streptavidin coated 96-well plate 
(Dilute 200µl 0.1mg/ml b-IP3 stock in 20 ml PBS)                                                                                               
                              4°C, at least 1hr with shaking     
(B) Meanwhile, making up compounds or p53 peptide in DMSO to working stock 
(20x final conc.)   
 
 
 
 
 
 
 
 Add 3x10 µl to triplicate wells in a clear 96-well plate including –ve 
(MDM2 alone), +ve (2 µM AP peptide) and DMSO (Changed to be 
Nutlin-3 50, 100 200 nM positive controls only later). 
 Dilute 800 µl MDM2-IV to 20ml PBS and then add 190µl of this solution 
to each well. Mix well. 
            RT, 20min without shaking 
(C) From step(A), wash three times with PBS (200 µl/well) and transfer the 
contents of the clear plate from step(B) to the Streptavidine plate 
         4°C, 1.5 hours with shaking 
(D) Discard the contents of the plate and wash 3x with 1x TBS/Tween (200µl/well). 
Add 200 µl diluted MDM2 antibody (Ab-5) to each well  
(Dilute 100 µl Ab-5 MDM2 in 20ml PBS) 
          RT, 1 hour with shaking 
(E) Discard the contents of the plate and wash 3x with 1x TBS/Tween (200µl/well). 
Add 200 µl diluted secondary antibody (Ab-5) to each well  
                            (Dilute 10 µl goat anti-mouse Ab in 20 ml PBS) 
          RT, 45 minutes with shaking 
(F) Discard the contents of the plate and wash 4x with 1x TBS/Tween (200µl/well) 
as follows:  
  1st time: shake briefly and discard. 
  2nd time: shake vigorously on a plateform shaker for 5 min and discard. 
  3rd time: shake vigorously on a plateform shaker for 10 min and discard. 
  4th time: shake vigorously on a plateform shaker for 15 min and discard. 
 
(G) The plate is now ready to be placed on the luminometer for data collection. 
Figure 2. 3 The ELISA Flow Chart for MDM2 Inhibitors Screening 
Working stock Final conc. 
10 mM   500 µM  
2 mM   100 µM  
400 µM  20 µM  
100 µM   5 µM  
20 µM   1 µM  
10 µM   0.5 µM  
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2.1.4.3 Data Analysis 
Using Microsoft Office EXCEL software: 
The plate layout should already be saved in an Excel file. 
1. Cut and paste the RLU results from the luminometer onto the same page as the 
plate layout. 
2. On the same page set out a table with the well contents down the side, as 
below: 
         Mean RLU SE % complex formation  % inhibition 
5% DMSO 
Positive Control  
NU8354 
NU8355 
 ……    
Greater % inhibition = greater compound activity 
3. Tools – Data analysis – Descriptive statistics – Highlight cells containing data to 
be averaged (eg. 4 results for control wells, or 3 results for a specific compound) 
– Summary Statistics – Click box for Output range – Press OK twice – Move the 
Mean RLU and SE results to the correct place in the above table 
4. Calculate % complex formation for DMSO using the following equation: 
   = DMSO RLU/ MDM2 RLU * 100 
   eg. = B2/A2*100 
5. Calculate % complex formation for the compounds as follows: 
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 % complex formation = Compound RLU/type in number for DMSO RLU * 100 
 Drag this down to calculate all the compound results 
6. Calculate % inhibition as follows: 
  % inhibition = 100 - % complex formation 
 Drag this down to calculate all the compound results 
7. Highlight the columns of results – Format – Cells – Number – 1 decimal place 
8. Go to Chart Wizard – Bar chart by rows - Highlight the Mean RLU’s & Headings – 
Click on each bar in turn – right click – Format data series – Y error bars – 
Custom – Highlight SE box in table 
 This will give a bar chart including error bars 
Using GraphPad PRISM v 4.0 statistical software (San Diego, CA, USA): 
Point to Point Analysis (for compounds’ general IC50 validation based on 3 
concentrations evaluation) 
1. In the ‘X’ column enter 0, 20, 100 & 500 (the compound concentrations) 
2. In the ‘Y’ column enter the % inhibition values for the compound at each 
concentration, as calculated by Excel.  Put 50 in the box below this list of 
values as this is to be calculated 
3. Select Analyse – Curves & Regression – Fitspline/LOWESS - OK 
4. Select Point to point – Show the table XY co-ordinates – Standard X from Y - OK 
5. Select View – Standard curve X from Y.  This will show the IC50 value for the 
compound 
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Non-linear Regression (for compounds’ refined IC50 validation and dose-dependent 
curve formation based on 8 or 9 concentrations evaluation) 
1. In the ‘X’ column enter the log of the concentrations 
2. In the ‘Y’ column enter the % inhibition values for the compound, but do not 
include the 50 at the bottom of this column 
3. Select Analyse – Non-linear regression – Sigmoidal dose response – Constants, 
top = 100, bottom = 0 – Unknowns from standard curve - OK 
4. This will give a slightly different IC50 from the Point to point analysis. 
In brief, the MDM2 inhibition at a given concentration was calculated by taking into 
account the effect of the DMSO control on the percentage of IP3-MDM2 complex 
formation, and evaluated using the following formula: (RLU detected in the 
compound treated sample / RLU of DMSO controls) x 100 and hence the percentage 
of MDM2 inhibition is 100 minus the value from previous formula.  
The IC50 for each isoindolin-1-one compound was calculated from 3 concentrations 
where each concentration was tested in a triplicate. The quoted IC50 for each 
compound was calculated by using Prism Graph-pad (point-point analysis). The final 
IC50 value is the average of three independent experiments, and hence a standard 
error (SE) was also generated. 
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2.2 Tissue Culture 
2.2.1 Cell Lines 
The cell lines used in experiments included the osteosarcoma cell line SJSA-1 with 
MDM2 amplification and wt-p53, the neuroblastoma cell line NGP with MDM2 
amplification, wt-p53 and MDMX expression, and the isogenic matched colourectal 
cancer cell line pair HCT116p53+/+ and HCT116p53-/-. 
All cell lines used in this study were previously confirmed as being mycoplasma 
negative using the Mycoalert Elisa Method (carried out by Mrs Elizabeth Matheson). 
All tissue culture was carried out using aseptic technique in class II containment 
hoods (Biomat, Medair Technologies). The growth media was made in a sterile 
environment and PBS was made up using sterile filtered H2O and autoclaved prior 
to use. All surfaces and equipment were swabbed with 70 % Ethanol. The MDM2, 
p53 status and doubling times of all the cell lines used in the current study are 
summarized in Table 2. 2. 
Table 2. 2 Original Cell lines applied for the experiments 
Cell line MDM2 status P53 status Doubling 
time (hours) 
Reference Extra 
information 
SJSA-1 Amplified WT 24 (3)  
NGP Amplified WT 53 (176) Express 
MDMX 
HCT116+/+ None-amplified WT 24 (177-178)  
HCT116-/- None-amplified Knock 
out 
24 (179)  
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2.2.2 Cell Culturing 
The NGP, HCT116+/+ and HCT116-/- cell lines were grown in RPMI 1640 medium 
(Sigma) supplemented with 10 % foetal bovine serum (FBS, Sigma) and the SJSA-1 
cell line was also supplemented with a further 1 % (v/v) HEPES buffer (Sigma), 1 % 
(v/v) sodium pyruvate (Sigma) and 1.25 g/500 ml glucose (Sigma), then all of them 
were kept in a humid atmosphere at 37 ˚C containing 5 % carbon dioxide in the 
incubator (Incu Safe, Sanyo). 
Cell lines were maintained in flat-sided flasks (Corning) of various sizes (growth 
surface areas of 25 cm2, 75 cm2 and 175 cm2) with appropriate amounts of medium. 
Cells were sub-cultured once a week into fresh medium. 
2.2.3 Sub-culturing 
To sub-culture adherent cells, the medium was aspirated and cells washed in PBS to 
remove any remaining medium. Cells were then treated with a Trypsin-PBS-EDTA 
solution (see Appendix II) for between 2-5 minutes in 37 ˚C incubator in order to 
detach cells from the growth surface. In the case of the HCT116 cell lines, the 
detached cells were passed through a plastic syringe (Sterilin) with a 23 G needle in 
order to separate the cells. Then 8 ml fresh growth media was added into the flask 
to neutralize the trypsin and the cells were counted using a haemocytometer. Cells 
were then re-cultured, frozen down or used in experiments, keeping a note of the 
passage number every time. 
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2.2.4 Counting Cells 
A 20 μl solution containing equal amounts of harvested cell suspension and 
Carnoy’s fixative (see Appendix II) was pipetted from the top edge of the chamber 
of the haemocytometer (Neubauer assistant, BDH), under the coverslip and the 
cells were counted. The haemocytometer had 2 grids for scoring cells and each grid 
was 1mm2 (area) x 0.1 mm (depth), with a total volume of 0.1 mm3. Cells within 
each grid were counted under a light microscope (Teitz). The average number of 
cells scored from the two grids was calculated (n). The concentration of the cells in 
the solution was equal to 2 (n x 104). This takes into account the 1:2 dilution of the 
cell suspension with Carnoy’s solution.  
2.2.5 Cell Storage and Cryopreservation 
The cells were trypsinised and counted as described in the previous section. The 
cells were initially made into pellets by centrifugation at 1,000 rpm in a 
Beckman-Coulter Allegra X-12R benchtop centrifuge at 23 ˚C for 5 minutes, followed 
by aspirated of the medium and then re-suspended in freezing medium composed 
of 8 ml of full culture medium (10 % FBS), 1 ml of cryoprotective agent DMSO 
(Sigma, Tissue culture grade,10 % final concentration), and 1 ml FBS (20 % final 
concentration). Approximately about 5 x 105 cells were aliquoted into a cryo-vial 
(1-1.5 ml). The vials were initially stored at -20 ˚C and then transferred into a -80 ˚C 
freezer or even liquid nitrogen for long-period storage. 
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2.2.6 Thawing Cells 
Freezing vials were removed from liquid nitrogen and thawed in a 37 ˚C water bath 
for less than 30 seconds. The thawed cell suspension was then transferred into a 
sterile universal tube (Sterilin) containing 5 ml of pre-warmed medium. The cells 
were then collected into a pellet by centrifugation for 3-5 minutes at 1,500-2,000 
rpm and the supernatant was removed by aspirating. Finally, the cells were then 
re-suspended in 5 ml of fresh medium, transferred to a 25 cm2 culture flask 
(Corning) and kept in humid atmosphere at 37 ˚C containing 5 % carbon dioxide in 
the incubator (Incu Safe, Sanyo). 
2.2.7 Plating out cells 
Adherent cells were trypsinised and counted as described above. For irradiation 
experiments, 28 cm2 tissue culture dishes were used (Corning). 5x 105 cells were 
plated per dish with 5 ml of growth media. Cell plates were then incubated for 
48-72 hours until 70% confluent before irradiation experiments. 
 
2.3 Western Blotting 
Western blotting is a technique by which a sample of proteins is separated by gel 
electrophoresis and then transferred to a binding membrane (immobilizing matrix) 
enabling characterization, identification and quantification of the proteins of 
interest.  
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2.3.1 Basic Principles of Western Blotting Assay 
Western blotting determines the level of protein expression in a sample and 
comprises 3 main steps: 1) electrophoresis using sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) to separate proteins according to 
size; 2) transfer to a nitrocellulose membrane; and 3) antibody detection of the 
immobillised proteins. 
The electrophoresis step separates proteins depending on molecular weight. 
Proteins are completely denatured during this process through boiling the protein 
lysate with detergent (SDS) and the reducing agent β-mercaptoethanol. The 
reducing agent is used to break disulphide bonds within the protein. The use of 
reducing conditions means that proteins are separated only on size but not on the 
size/charge ratio that occurs under non-denaturing conditions. On the SDS gel, 
when an electric field is applied, smaller proteins move faster than bigger ones. In 
these experiments, protein sizes ranged from 14 KDa to 110 KDa and 4-20 % 
acrylamide tris-glycine gradient gels were used to give good separation and 
resolution across the range of protein sizes.  
The separated proteins were then transferred onto a nitrocellulose membrane 
electrophoretically.  
Proteins were detected using primary antibodies that recognize specific proteins. 
Secondary antibodies were conjugated to horseradish peroxidise (HRP) for use with 
59 
 
the enhanced chemiluminescence (ECL TM) detection kit (Amersham) and then 
visualized by using an X-ray film. 
2.3.2 Cell Seeding into Culture Plates and Drug/IR Treatment 
2.4.2.1 Plating out Cells 
To seed plates for drug treatment or irradiation, cells were taken from a 3 day old 
flask, which were exponentially growing, and adherent cells were trypsinised and 
counted as described in Section 2.3. Then the cells were plated into 28 cm2 tissue 
culture dishes (Corning) with a final volume of 5 ml in growth media with the 
concentration displayed in Table 2. 3.  
Table 2. 3 Cell lines seeding densities applied for the experiments 
Cell line Seeding density 
HCT116 & HCT116-/- 5 x 105 
NGP & NGP MDM2 Antagonists Resistant Clones 5 x 105 
SJSA-1 & SJSA-1 MDM2 Antagonists Resistant Clones 2 x 105 
Cell plates were then incubated for 48-72 hours until 70 % confluent before 
experiments. 
2.4.2.2 Drug Treatment 
Compounds were taken forward for intact cell studies if the IC50 in the cell-free 
ELISA was <1µM. For evidence of intact cell activity by Western blot analysis of p53, 
MDM2 and p21, the initial dose range tested was 5, 10 and 20µM.  
Lower doses were tried subsequently depending on the observed initial effect.  
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For example, Nutlin-3 was used at final concentrations in dishes of 0.2, 1 and 5 µM 
in 1 % DMSO, from stock concentrations made up in 100 % DMSO: 
0.5 mM 100 % DMSO         30 µl in 3 ml dish = 5 µM final Concentration at 1 % DMSO. 
0.1 mM 100 % DMSO         30 µl in 3 ml dish = 1 µM final Concentration at 1 % DMSO. 
20 µM 100 % DMSO         30 µl in 3 ml dish = 0.2 µM final Concentration at 1 % DMSO. 
2.4.2.3 X-ray Irradiation 
After seeding cells into plates and incubating for 48 hours, the sample plates were 
put into a D3300 X-ray System cabinet and just below the X-ray tube (within the 
shaded area in Figure 2. 4) and exposed to 6.3 Gy X-ray irradiation treatment, then 
put back into an incubator until each time point of testing. 
 
 
 
 
 
Figure 2. 4 Sample plate placing area for X-ray irradiation treatment 
NB: In order to irradiate samples within the cabinet they must be placed below the X-ray tube on the metal 
shelf. The shelf must be positioned as far to the back and to the right of the cabinet as it will go in. In this 
position, the cross on the shelf identifies the centre of the cabinet. With the shelf in the lowest position a 
square area measuring 18 cm x 18 cm receives uniform amounts (±5 %) of radiation at all points within this 
square. The square is positioned to the centre (back to front) and left (as viewed from the front of the cabinet). 
This area is marked as a hashed square on the shelf (The fact that it is not central is because the X-ray beam is 
not truly perpendicular). 
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2.3.3 Collecting Cell Lysate 
At each time point, the medium was removed from the dish and the attached cells 
rinsed with ice cold PBS before adding 50 l of a Laemmli lysis buffer (see Appendix 
II) to the 2 ml plate with approximately 7.5 x 105 cells.  
Whole cell extracts were prepared by scraping adherent cells from the bottom of 
the dishes using cell scrapers (Sterilin) and lysis buffer, then pipette into 0.5 ml 
eppendorf tubes. The samples were then boiled for 10 minutes at 100 ˚C before 
sonicating for 3 x 15 seconds at maximum power. The protein lysate samples were 
then stored at -20 ˚C. 
2.3.4 Protein Estimation 
The protein estimation assay was carried out on the lysates to calculate and decide 
the amount of protein to load on the gel. Generally, for SJSA-1 cells 20-30 g was 
loaded per sample track, and for other cell lines 35-50 g was loaded. 
The protein concentrations of the cell lysates were estimated using a protein 
concentration estimation assay with a BCA kit (Pierce) in a 96-well plate format 
(Figure 2. 5). 
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Figure 2. 5 Plate arrangements for BCA assay 
Bovine Serum Albumin (BSA) was used as a reference standard at 0.2, 0.4, 0.6, 0.8, 
1.0, 1.2 and 2.0 mg/ml were used. Samples were diluted from 2 mg/ml using double 
distilled H2O (ddH2O) and plated out in 10 l volumes in quadruplets along with a 
dH2O blank into a 96 well plate to produce a standard curve that the concentration 
of the lysates samples would fall on. The cell lysates were diluted 1:10 with ddH2O 
and plated out in quadruplicate. 
BCA Reagent A and B were combined in a ratio of 50:1 and 190 l of the mixture 
added to each well and mixed on a plate shaker for 1 minute at room temperature.  
The plate was then covered in cling film and incubated at 37 ˚C for 30 minutes 
followed by absorbance reading at 562 nm on a Spectra Max Pro 400 plate 
spectrophotometer (Molecular Devices). The protein concentration of each sample 
was calculated from the standard curve using Genesis life software. 
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2.3.5 Gel Electrophoresis of Protein (SDS-PAGE) 
Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) is a 
technique used for the analysis of proteins which enables both an estimation of 
polypeptide molecular mass as well as high-resolution analysis of a complex mixture 
of proteins. 
Following protein estimation, 20-50 g of protein was diluted in SDS loading buffer 
(if non-ionic detergent was used to lyse cells, see Appendix) or a 1:1 ratio of 
bromophenol blue and beta-mercaptoethanol (if SDS buffer was used) and made up 
to a maximum volume of 25 l, which was suitable for 1.5 mm, 15 wells, pre-cast 
4-20 % gradient tris-glycine Polyacrylamide gel (Invitrogen). This mixture was then 
heated at 100 ˚C for 10 minutes, followed by brief centrifugation before loading 
onto the gel. 10 l of SeeBlueTM (Invitrogen) pre-stained protein molecular weight 
standards were run on each gel in parallel to the test cell lysate samples. Gel 
electrophoretic separation was carried out in a Novex XL tank (Invitrogen) 
containing 1 x electrophoresis buffer containing SDS at 180 V for 90 min.   
2.3.6  Protein Transfer 
Western-blotting was performed by filling a BioRad mini-blot electrophoresis tank 
(Novex) with transfer buffer (see Appendix II).  
Two pieces of glass fibre pads, two pieces of filter papers (the same size as the gel, 
Whatman 3MM Chr) and a piece of Hybond-C nitrocellulose membrane 
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(Amersham) was soaked in the transfer buffer. The following items were then 
assembled in order starting from the black side of the cassette as was illustrated in 
Figure 2. 6: fibre pad, filter paper, gel, Hybond membrane, filter paper and fibre 
pad.  
Then the entire apparatus will be placed into the chamber of the transfer tank that 
filled with transfer buffer by making the black side of the cassette face the black 
anode side. The transfer step was carried out at 30 V overnight or at 65 V for 1-1.5 
hours.  
One key thing needs to remember is to make sure there are no air bubbles between 
the gel and membrane when setting up the transfer cassette, as a result, this 
procedure can be carried out in a glass pan filled with transfer buffer or add some 
transfer buffer onto the surface of the gel then put the membrane onto it and push 
gently to remove air bubbles with excessive transfer buffer. 
 
 
Figure 2. 6 Western blot cassette order illustration in transfer procedure 
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2.3.7 Immunodetection 
The levels of various proteins including p53, MDM2 and p21 WAF 1, etc. were 
measured using western blot analysis. 
After the transfer procedure, the Hybond-C membrane was removed from the 
blotting cassette and incubated in 5 % non-fat milk TBS-Tween (PBST-M) solution 
(Appendix II) on a platform shaker for one hour at room temperature, followed by 
washing the membrane three times with 1 x TBS-Tween (15 minutes per wash). 
Then it was cut into three strips at 64 and 36 KDa based on the position to which 
protein molecular weight standards had migrated.  
Then the primary antibodies (Table 2. 4) were diluted in 3 ml 5 % skimmed 
milk-TBS-Tween in a 50 ml Falcon tube. The membrane strips then been transferred 
into the tubes containing the appropriate primary antibodies. After that, these 
tubes were left on a roller for 1 hour at room temperature or overnight at 4˚C. 
Every western blot membrane was probed with α-tubulin or β-actin as a control of 
sample loading and transfer. 
The membrane was then washed three times with 1 x TBS-Tween (5 minutes per 
wash), at the same time, the secondary antibodies: HRP conjugated goat anti mouse 
IgG (Dako) or HRP conjugated goat anti rabbit IgG (Dako) were diluted 1:1000 in 3 
ml 5 % skimmed milk-TBS-Tween solution. Then these membrane strips were 
incubated in 50 ml Falcon tubes containing the appropriate secondary antibody 
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solution on a roller for 45-60 minutes at room temperature. The final washing 
procedure of the membrane involves 6 washes with TBST (5 minutes per wash) 
before Enhanced Chemiluminescence (ECL) detection. 
Table 2. 4 Details of Primary Antibodies Used for Western Blot 
Protein 1st Antibody 
(Clone No. ) 
Type Dilution Band size in 
Western blot 
Manufacturer 
P53 P53 (DO7) Mouse 1:1000 53 KDa Novocastra 
MDM2 MDM2 (IF2) Mouse 1:100 90 KDa Calbiochem 
P21WAF1 P21WAF1 (DF10) Mouse 1:100 21 KDa Calbiochem 
MDMX MDMX/MDM4 Rabbit 1:1000 70 KDa Bethyl 
PARP PARP-1/2 
(H-250) 
Rabbit 1:1000 116, 85 KDa Santa Cruz 
α-Tubulin α-Tubulin  
(DM1A) 
Mouse 1:3000 55 KDa Sigma-Aldrich 
β-Actin β-Actin (AC-40) Rabbit 1:1000 42 KDa Sigma-Aldrich 
Cleaved 
Caspase-3 
Cleaved 
Caspase-3 
(Asp175) 
Rabbit 1:1000 19, 17 KDa Cell Signaling 
PUMA PUMA Rabbit 1:1000 23 KDa Cell Signaling 
2.3.8 Enhanced chemiluminescence (ECL) detection 
The ECL kit (Amersham) was used for indirectly detecting the amount of proteins by 
actually detecting secondary antibodies with the conjugated HRP (mechanism is 
illustrated in Figure 2. 7). The ECL kit contains solution A and B. They were mixed in 
a 1:1 ratio just before adding onto the washed membrane strips. The washed 
membrane strips were dabbed by using blue paper tissue to remove excess 
TBS-Tween, placed on cling film and then fully covered with the mixed ECL solution. 
After ~1 minute room temperature incubation, the excessive ECL solutions were 
removed and the membrane strips were covered with cling film and placed into an 
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X-ray cassette. Then X-ray film (Kodak or Super RX, Fuji) was used in the dark room 
by exposing it on the top of the membrane strips for various lengths of time, 
ranging from seconds to several minutes depending on the strength of the signal. 
Finally, the X-ray films were developed using a Mediphot 937 film developer 
(Colenta). 
 
Figure 2. 7 Chemiluminescent Peroxidase Substrates for protein band detection 
2.3.9 Densitometry analysis 
In order to quantify the protein bands from western blotting, densitometry analysis 
was performed using Fuji-Las Pro (Fuji) to obtain images of western blot bands from 
the film. The AIDA image analyser programme software (Raytest) was then applied 
to estimate the size and densities of each band. The emission value of each protein 
band was recorded by considering its integrality, area and the background 
lighteness. Obtained data were then normalized to the loading control of 
corresponding sample. The fold induction of proteins after various treatments were 
calculated based on untreated sample control for each experiment.  
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2.4 Sulphorhodamine B (SRB) Assay 
The SRB assay was developed by Skehan et al. (180) as a simple method to assess 
the growth rate of cells with various treatments. It is based on the total amount of 
protein accumulating in the wells of a culture dish over a period of time. 
2.4.1 Basic Principles of SRB Assay 
Cells growing in a 96-well plate were fixed using trichloroacetic acid (TCA) and then 
were stained using SRB dye solution. The SRB dye binds to the basic amino acid 
residues of the fixed cells’ proteins. Then the excessive SRB dye was washed away 
using 1 % acetic acid and air dried samples in the wells of the plates were 
re-suspended using 10 mM Tris base solution (pH 10.5) and the optical density of 
SRB bound proteins was evaluated at 564 nm, which gives a measure of the number 
of cells in each well. 
2.4.2 96-well Plate Preparation for Growth Curve Evaluation 
To prepare the 96-well cell sample plates for growth curve evaluation purpose, the 
70 % confluent adherent cells were trypsinised and cell concentration were 
determined by cell counts using a haemocytometer (Section 2.2.4).  
100 μl of a range of concentrations from 24,000 to 12 cells/well (with half cell 
density than the previous row for 12 rows) cell suspensions for each SJSA-1 series 
cell line was added into each well with the lay out shown in Figure 2. 8. 100 μl 
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medium/well were added into all outskirt wells surrounding the sample wells to 
prevent the evaporation effect that may affect the edge well samples.  
Then the sample plates were incubated in a humidified incubator at 37 °C, 5 % CO2 
until each time point at which the plates were fixed. Plates were fixed at 24 hour 
intervals for 9 days in the relevant experiments. 
 
Figure 2. 8 SRB structure and SRB assay plate for growth curve determination 
2.4.3 96-well Plate Sample Preparation for GI50 Value Evaluation 
To prepare the 96-well cell sample plates for growth curve evaluation, the 70 % 
confluent adherent cells were trypsinised and cell concentration were determined 
using a haemocytometer (Section 2.2.4). A 7 ml volume of 2×104 cells/ml cell 
suspension of SJSA-1 cells or 5×104 cells/ml cell suspension of NGP cells were 
prepared in ‘Universal’ tubes. Then 100 μl of cell suspension was added into each 
well and 100 μl media was added into each well surrounding the sample wells to 
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prevent the evaporation effect that can affect the edge well samples. For the Day 0 
plate, seed one row of cell suspension and also add medium to the empty wells to 
avoid edge effects due to evaporation. 
Then the sample plates were incubated in a humidified incubator at 37 °C, 5 % CO2 
for 24 hours to allow attachment and start growth, at which point plates would be 
ready for drug treatment. 
After 24 hours incubation, Day 0 plates were fixed. For other plate samples that 
need 72 hours drug treatment, the medium was removed by vacuum aspiration, 
using a fine tipped glass pipette to minimize the possibility of losing cells, from the 
plates. Then 100 μl qliquots of fresh medium containing compound with a range of 
concentrations were added into each well (Figure 2. 9).  
 
Figure 2. 9 SRB structure and SRB assay plate arrangement for GI50 evaluation 
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The plates were then put back in the humidified incubator at 37 °C, 5 % CO2 and 
incubated for 72 hours, then fixed. 
2.4.4 Plate Fixation, SRB Staining and Data Collection 
At the time point, plates were fixed in situ by adding 25 μl ice cold 50 % 
trichloroacetic acid (TCA) solution into each well and were stored at 4 °C for at least 
1 hour.  
Then the plates were put on the bench for 30 minutes to equilibrate to room 
temperature and the TCA solution was washed away using distilled water (dH2O) for 
5 times.  
After air drying the plates, 100 μl SRB dye at 0.4 % (w/v) in 1 % acetic acid solution 
was added into each well of the plates and incubated at room temperature for 30 
minutes.  
After staining, unbound dye was removed by washing 5 times with 1% acetic acid 
and plates were air dried overnight.  
Bound stain was solubilized with 10mM Tris base solution (pH 10.5) and absorbance 
was measured on a Spectra Max Pro 400 plate reader (96-well microtiter) at 570 
nm. Data were then exported into an Excel file and analysed using Prism v 4.0 
statistical software for GI50 calculation. For growth curve generating, the optical 
densities were plotted using Microsoft Excel software. 
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2.5 Caspase-Glo® 3/7 Assay 
Caspase-3 and caspase-7 are the members of the cysteine aspartic acid-specific 
protease (caspase) family that play key effector roles in mammalian cells apoptosis. 
2.5.1 Basic Principles of Caspase-Glo® 3/7 Assay 
The Caspase-Glo® 3/7 Assay is a luminescent assay that is designed to measure 
caspase-3 and -7 activities. The assay provides a luminogenic caspase-3/7 substrate, 
which contains the tetrapeptide sequence DEVD, in a reagent optimized for cell 
lysis, caspase activation and luciferase activation. By adding a single Caspase-Glo® 
3/7 Reagent into an “add-mix-measure” format results in cell lysis, followed by the 
caspase cleavage of the substrate and the generation of a “glow-type” luminescent 
signal that produced by luciferase. Luminescence is proportional to the amount of 
caspase activity (Figure 2. 10).  
 
Figure 2. 10 The reactions and mechanisms of Caspase-Glo® 3/7 Assay 
(From Technical Bulletin, Promega Part# TB323) 
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2.5.2 Cell Seeding 
To seed plates for drug treatment, cells were taken from 3 day old flasks that were 
exponentially growing, and adherent cells were trypsinised and counted as 
described in Section 2.2.  
SJSA-1 cells were seeded at 2×103/100 µl/well and NGP cells at 5×103/100 µl/well 
into four 96-well black/white plates (Wallac, PerkinElmer), to allow cells to reach at 
25-50 % confluence on the day of drug treatment. To set up blank wells, medium 
alone was added into the first row of wells (Figure 2. 11). 
    
 
Figure 2. 11 The plate arrangements for Caspase-Glo® 3/7 Assay 
(A. is for the comparison of different drugs using one cell line; and B. is for comparison of different cell lines 
treated with one drug). 
A. 
B. 
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2.5.3 Drug Treatment 
Working concentrations (100×) were prepared for each compound (eg. Nutlin3, 
using 0.1 mM, 0.2 mM, 0.5 mM and 1 mM in DMSO): 
Working 
concentration 
(100×) 
Final concentration (1×) volume 
1 mM 40 µl 2 mM+40 µl DMSO 1 0 µM 20 µl in 2 ml medium 
0.5 mM 40 µl 1mM+40 µl DMSO  5 µM 20 µl in 2 ml medium 
0.2 mM 20 µl 0.5 mM +40 µl DMSO  2 µM 20 µl in 2 ml medium 
0.1 mM 10 µl 0.5 mM+40 µl DMSO  1 µM 20 µl in 2 ml medium 
For isoindolinone compounds, 100x concentrations of 0.1 mM, 0.5 mM, 1 mM and 2 
mM in DMSO were used: 
Working 
concentration 
(100×) 
Final concentration (1×) volume 
2 mM 20 µl10 mM+80 µl DMSO  20 µM 20 µl in 2ml medium 
1 mM 40 µl 2 mM+40 µl DMSO   10 µM 20 µl in 2 ml medium 
0.5 mM 20 µl 2 mM+40 µl DMSO    5 µM 20 µl in 2 ml medium 
0.1 mM 10 µl 0.5 mM+40 µl DMSO  1 µM 20 µl in 2 ml medium 
Medium was aspirated from the 96-well plate and drug-containing medium added 
into the appropriate wells, including 1 % DMSO controls.   
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2.5.4 Caspase-Glo® 3/7 Assay 
The plates were incubated at 37 °C for 48 hours. 
At the time point, Caspase-Glo®3/7 Assay was performed by adding equal volumes 
of buffered Caspase-Glo®3/7 substrate (100 µl), followed by mixing and incubation 
at room temperature for 30 minutes to 3 hours. Then the luminescence value in 
each well were collected by using microplate luminometer (MicroLumatPlus LB96V, 
EG&G Berthold). 
2.5.5 Data Analysis 
The original data were generated by using Winglow (Berthold technologies) 
software and transformed into Excel version. Triplicate repeat assays were 
performed for each compound concentration, which allowed the calculation of an 
average and standard deviation of the result using Excel.  
The average luminometer reading in relative light units (RLU) and standard 
deviations were used to calculate fold changes by dividing the RLU from drug 
treatment by the RLU from DMSO control. 
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2.6 Cell Cycle Analysis Using FACscan 
Flow cytometers analyse the fluorescence and light scatter from cells in a flowing 
fluid stream passed through a fixed laser beam. Several measurements can be made 
based on the physical characteristics and labelling of the sample cells, which is 
represented by how the cells scatter light and emit fluorescence. This provides 
information about the cell size, internal complexity and relative fluorescence 
intensity. The distribution of cells with respect to their position in the cell growth 
cycle can be measured by using propidium iodide (PI) as fluorescent DNA stain. 
2.6.1 Basic principles of fluorescence activated flow cytometry 
The flow cytometer used in this project was a FACscan (Beckton Dickinson).  
When samples of cells are analysed on the machine, they are forced into a single 
stream to pass through the flow chamber. This is achieved by passing a sample in 
the form of a single cell suspension through the flow chamber, where an argon laser 
beam excites the fluorescent PI dye that is bound to the DNA. The scattered 
fluorescent light generated by cells passing through the laser beam is collected by 
photo-detectors. Dichromic mirrors at right angles of the laser beam reflect specific 
wavelength of light onto the detector (Figure 2. 12). Then this light signal is 
converted into an electronic signal that can be recorded (181). The FACscan can 
measure five parameters including: forward light scatter (FSC), side light scatter 
(SSC) and three fluorescence wavelengths (FL1, FL2 and FL3). For the cell cycle 
analysis using the PI staining method, the FSC, SSC and FL2 were used. 
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Figure 2. 12 FACscan optical configuration with the common fluorochromes list for each 
detector.  
This figure is from igc-wiki.igc.gulbenkian.pt/doku.php?id=uic:fl....   
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2.6.2 Apply Flow Cytometry for Cell Cycle Analysis 
The phases of cell cycle are described in Figure 2. 13, cells undergoing mitosis or in 
G2 phase have doubled the DNA content of cells in G1 phase. Because the DNA is 
synthesized in the S phase, these cells have DNA content between G1 and G2.  
 
Figure 2. 13 A schematic of the cell cycle and cytometric components of each phase. 
The cell cycle cartoon is from teachline.ls.huji.ac.il/.../substance_x/q2a.html. Within the cytometric components 
images, the component portion corresponding to each phase are highlighted in dark blue.  
The DNA of cells undergoing apoptosis becomes fragmented and separates into 
apoptotic nuclei, which produce signal intensities below those corresponding to G1 
phase cell DNA content. This is often referred to as the “sub-G1” peak. The 
differences in DNA contents can be detected by flow cytometry after PI staining 
because PI binds to the chromatin of cells by intercalating between the bases in 
DNA. Since double stranded regions of ribonucleic acid (RNA) can also bind PI, cell 
samples are treated with RNase to degrade all the RNA before or at the same time 
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of the PI staining procedure. It is also important to pass cell samples through a fine 
needle syringe several times to prevent cell clumping. Otherwise, the clumped cells 
will disturb the signal recording procedure and produce misleading results. 
2.6.3 Protocol of cell cycle analysis assay 
2.6.3.1 Sample Preparation 
Cells were plated into 28 cm2 tissue culture dishes and incubated for 48-72 hours 
until 70% confluent. Then they were treated by DMSO, drugs or X-ray irradiation. 
After 24 hours drug treatment or post irradiation, all cells in each dish were 
harvested and transferred into a Sterilin tube, spun down at 1,000 × g for 5 minutes, 
then washed by using ice cold PBS once. Then after spinning down at 1,000 × g for 5 
minutes again, the supernatant was removed and cells were resuspended and fixed 
in 2 ml of ice cold 70 % ETOH/PBS solution and stored at 4˚ C for at least 2 hours. 
2.6.3.2 PI Staining 
In preparation for running cell samples on the Facscan, the fixed samples were spun 
at 1,000 × g for 5 minutes to remove the solution, then suspended in 800 μl PBS and 
passed through a 23 gauge syringe before adding 100 μl of 40 μg/ml PI and 100 μl 
0.1 mg/ml RNase A and incubating at 37˚C for ~0.5 hour, using aluminium foil to 
protect the samples from light.  
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2.6.3.3 Running Samples on FACscan 
The measurements were carried out on a FACscan (Beckton Dickinson). To set up 
the template for a cell line, the control sample was run on the machine firstly. The 
SSC versus FSC, FL2-A versus FL2-W scatter plots and FL2-A histogram were used to 
evaluate the data collected. Ideally, the G1 peak was at 200 FL2-A and G2 peak at 
400 FL2-A fluorescence intensity channels. The optimized setting for each cell line 
on the FACscan was saved as the specific named template for each cell line. For 
each sample, fluorescence data for 10,000 cells in total were collected. Each sample 
was run at least three times. 
2.6.3.4 Data Analysis 
FACscan data were analysed using WinMDI 2.8 software (TSRI). G1, S, G2/M and sub 
G1 populations defined and quantified by the gate method. The gated data were 
plotted as an FL2-A histogram and the proportion of cells in each phase was 
determined by defining them as section M1, M2, M3 and M4. Then the statistics 
function of the software calculated the percentage of cells in each phase. 
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2.7 PCR 
2.7.1 Principle of Polymerase Chain Reaction (PCR) 
PCR is a molecular biology technique, invented by Kary Mullis, for enzymatically 
replicating DNA without using a living organism, such as E. coli or yeast. Just like 
amplification using living organisms, the technique allows a small amount of DNA to 
be amplified exponentially in a sequence specific manner for a wide range of 
genetic applications including DNA mutation detection. 
The purpose of a PCR is to make a huge number of copies of a gene, as illustrated in 
Figure 2. 14. As Mullis has written in the Scientific American: "Beginning with a 
single molecule of the genetic material DNA, the PCR can generate 100 billion 
similar molecules in an afternoon. The reaction is easy to execute. It requires no 
more than a test tube, a few simple reagents, and a source of heat." 
 
Figure 2. 14 The exponential amplification of the gene in PCR.  
This figure is obtained from http://users.ugent.be/~avierstr/principles/pcr.html. 
The reaction involves target DNA, properly designed sense and antisense primers, 
the four deoxyribonucleoside triphosphates (dNTPs) and a thermostable DNA 
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polymerase. There are three major steps in a standard PCR including denaturation, 
annealing and extension Figure 2. 15, which are repeated for 30 to 40 cycles. This is 
carried out on an automated cycler that can heat and cool the tubes with the 
reaction mixture in a very short time. 
 
 
Figure 2. 15 Three steps of a Polymerase Chain Reaction.  
This figure is adapted from information on http://users.ugent.be/~avierstr/pdf/PCR.pdf. 
In the denaturation step, the sample is heated to ~94 °C to denature the double 
strand DNA into single stranded DNA for replication purpose, all enzymatic 
1 minute 94 °C 
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reactions stop. With the temperature rapidly cooled down to ~54 °C, the primers 
are then annealed to the target DNA single stranded templates by forming ionic 
bonds with them. Then the polymerase can attach and starts copying the 
template.Then with the reaction temperature jumps up to ~72 °C, which is the ideal 
working temperature for the polymerase, the DNA polymerase then elongates the 
primers on right position of the templates and produces a complementary strand of 
DNA that is conjugated to the template it attached. On the other hand, primers that 
are on the positions without exact match, are released again because of the higher 
temperature and do not give an elongation of the fragment. This process is 
repeated for 30 to 40 cycles to amplify large amount of target DNA (182). 
2.7.2 DNA extraction and purification for PCR 
DNeasy Blood & Tissue Mini Kit (QIAGEN) and protocol was applied for cancer cells 
DNA extraction and purification. The detailed procedure was illustrated as a flow 
chart in Figure 2. 16.  
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Figure 2. 16 Purification of total DNA from cells by using DNeasy Blood & Tissue Kit  
                       (This flow chart is generatd by combine the flow chat with the 
protocol in the QIAGEN DNeasy Blood & Tissue Kit Handbook) 
 
 
 
 
1. Cultured cells: Centrifuge the appropriate number of 
cells (maximum 5 x 106) for 5 min at 300 x g. Resuspend 
the pellet in 200 μl PBS. Add 20 μl proteinase K. 
Continue with step 2. 
2. Add 200 μl Buffer AL (without added ethanol). Mix 
thoroughly by vortexing, and incubate at 56°C for 10 
min. 
3. Add 200 μl ethanol (96–100%) to the sample, and mix 
thoroughly by vortexing. 
4. Transfer the mixture from step 3 into the DNeasy Mini 
spin column placed in a 2 ml collection tube (provided). 
Centrifuge at _6000 x g (8000 rpm) for 1 min. Discard 
flow-through and collection tube. 
 
5. Place the DNeasy Mini spin column in a new 2 ml 
collection tube (provided), add 500 μl Buffer AW1, and 
centrifuge for 1 min at _6000 x g (8000 rpm). Discard 
flow-through and collection tube. 
 
6. Place the DNeasy Mini spin column in a new 2 ml 
collection tube (provided), add 500 μl Buffer AW2, and 
centrifuge for 3 min at 20,000 x g (14,000 rpm) to dry the 
DNeasy membrane. Discard flow-through and collection 
tube. 
 
7. Place the DNeasy Mini spin column in a clean 1.5 ml 
or 2 ml microcentrifuge tube (not provided), and pipet 
200 μl Buffer AE directly onto the DNeasy membrane. 
Incubate at room temperature for 1 min, and then 
centrifuge for 1 min at _6000 x g (8000 rpm) to elute. 
 
8. Recommended: for maximum DNA yield, repeat 
elution once as described in step 7. 
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2.7.3 PCR method 
Reagents Equipment 
DNA samples  Gilson pipettes  
Distilled water sterile filter tips 
10 x Buffer 0.2ml PCR tubes or PCR plate, and lids 
MgCl2 1.5ml tube (for making master mix) 
dNTP mix (2.5 mM) Bucket of ice 
Sense Primer (10 µM) Thermal Cycler 
Antisense Primer (10 µM)  
Amplitaq Gold  
 
1. Use the Stratalinker to UV irradiate the tips, Gilsons, PCR tubes, etc to be 
used in the protocol before proceeding. UV at 200-500 nm. To set: Type in 
200, Press Energy, then Start. 
(Remember to close tip boxes, tube lids before removing from the 
stratalinker). 
2. Working in the flow hood make up a ‘Master Mix’ of reagents, enough for all 
the samples, leaving the enzyme until last. 
3. Remove the Amplitaq Gold from –20 °C and keep on ice. Add the enzyme to 
the ‘Master Mix’ and vortex to mix thoroughly. 
4. Add the appropriate amount of ‘Master Mix’ to the tubes (23 µl for a 
standard reaction). 
5. No DNA is allowed in the flow hood, so when ready to add the DNA, do this 
outside of the hood. Add the appropriate amount of DNA to each tube, 
vortex briefly, and pulse spin. Keep the samples on ice until they are put 
onto the thermal cycler. 
6. For p53 PCRs there are programmes set up on the thermal cyclers.  
Touchdown 55 is used for Exons 4, 5, 6 and 9. Touchdown 60 is used for 
Exons 7 and 8. Touchdown 63 is used for codon 285 point mutation 
detection specific PCR reaction (the detailed information for Touchdown 
programmes is in appendix II).  
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Standard PCR Reaction Mix (for one 25ul reaction) 
 
Reagents Volume µL 
DNA samples  2 
10 x Buffer 2.5 
MgCl2 2.5 
dNTP mix (2.5mM) 2.5 
Sense Primer (10µM) 1 
Antisense Primer (10µM) 1 
Amplitaq Gold 0.25 
Distilled water 13.25 
                 (Amounts of DNA and dH2O can be varied) 
 
 
2.7.4 Agarose Gel Method 
Reagents Equipment 
Agarose Gilson pipettes  
0.5 x TBE sterile filter tips 
Loading buffer 0.2ml PCR tubes or PCR plate, and lids 
EtBr (10 mg/ml) Measuring cylinder 
 Microwave 
 Gel mould and combs 
 Electrophoresis tank and power pack 
 Gel doc image capture equipment 
 Balance 
 Conical flask 
 Image analysis system 
 
1. When the PCR run has finished, remove PCR product samples and either 
store at 4 °C, or prepare to load them onto an agarose gel. For loading onto 
a gel take 5 µl of the PCR product into a clean tube and add 2 µl loading 
buffer (Recipe see Appendix II).  
2. Make a 2 % agarose gel by weighing out 2 g agarose into a conical flask, and 
add 100 ml 0.5 x TBE, then heat in a microwave until the agarose has 
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melted. Cool this solution and add 1 drop (1 µl) EtBr, swirl to mix. Pour the 
cooled solution into a gel mould with the combs in place and leave to set. 
3. When the gel is set place it into an electrophoresis tank, submerge in 
electrophoresis buffer (0.5 x TBE) and gently remove the combs. Carefully 
load a DNA marker (8 µl) and your prepared samples. Connect the leads and 
apply a votage (100-150 V) for approx 1 hr. 
4. When the gel has finished the electrophoretic seperation procedure, remove 
it from the tank and place the gel onto the platform of the gel doc 
equipment. Using ‘Quantity One’ software position and focus the gel, then 
close the door and switch on the UV light to visualize the bands your PCR has 
generated. Save the image and print it to a local printer. 
2.7.5 PCR product purification for Sequencing 
After the PCR products were confirmed to be the desired products according to size 
and specificity by agarose gel image, the remaining PCR products were then purified 
by using PurelinkTM PCR Purification Kit K3100-02 (Invitrogen) following the 
protocol supplied by the manufacturer. 
The purified samples were sent together with their corresponding primers to our 
colleagues in Durham University (DBS Genomics) for sequencing.  
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2.8 FISH Assay 
2.8.1 Principle of Fluorescent in situ Hybridization (FISH) Assay 
FISH (fluorescence in situ hybridization) is a cytogenetic technique developed by 
Christoph Lengauer that is used to detect and localize the presence or absence of 
specific DNA sequences on condensed chromosomes in mitotic cells or in 
interphase muclei.  
 
Figure 2. 17 The process of the fluorescence in situ hybridization technique. 
This diagram is obtained from the National Human Genome Research Institute website 
http://www.genome.gov/10000206. The FISH technique is dependent upon hybridizing a probe with a 
fluorescently tagged cloned DNA fragment, complementary in sequence, to a short section of DNA on a target 
genomic region. The tag and probe are applied to a sample of interest under conditions that allow for the probe 
to hybridised to the complementary sequence in the specimen if it is present. After the specimen has been 
treated, excess fluorophore is washed away and the sample can be visualized under a fluorescent microscope. 
By quantifying the amount of fluorescence with the microscope it can be determined if sequence the probe was 
designed for is present, and if so, how much of it is present in a sample and its cellular location. 
As illustrated in Figure 2. 17, FISH uses fluorescent probes that bind to only those 
parts of the chromosome with which show a high degree of sequence similarity. 
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Fluorescence microscopy can be used to visualise the location of the fluorescent 
probe bound to the chromosomes.  
FISH is often used for finding specific features in DNA for use in genetic counselling, 
medicine, and species identification. FISH can also be used to detect and localize 
specific mRNAs within tissue samples. In our research project, this technique has 
been applied for identifying the status of p53 DNA sequences on chromosome 17p 
in stage I and II resistant cell clones, i.e. to detect p53 locus deletions and their 
distribution in the cell population. 
2.8.2 FISH Protocol 
2.8.2.1 Harvesting Cell Lines for FISH 
 
1. Transfer the media from a 25 cm2 flask contain > 70 % confluent cells into 
labelled 15 ml centrifuge tube, rinse with sterile PBS to remove remaining 
media by using sterilized PBS, then add 1 x trypsin to the cell culture, incubate 
in 37 °C incubator to release most of the cells from the bottom of the flask. 
2.  Suspend the detached cells using the original media, then transfer the cell 
suspension into the original labelled centrifuge tube. 
3. Add ~7 ml 0.075 M KCl , mix thoroughly by inverting. 
Reagents Equipment 
1 x Trypsin Centrifuge (1,000 × g for 5 minutes) 
75 mM KCl 15 ml Centrifuge Tubes 
Fixative (Freshly made) Nitrile Gloves 
3:1 Methanol : Acetic Acid Pasteur pipette 
Sterilized PBS Pipette aid 
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4. Incubate for 15 min at 37 °C if possible but room temperature is okay. 
5. Centrifuge at 1,000 × g for 5 min.  
6. Discard the supernatant and re-suspend the pellet thoroughly by vigorous 
flicking.  
7. Add 1ml of fresh 3:1 Methanol:Acetic Acid fixative a few drops at a time with 
constant flicking to avoid clumping.  Add further fixative to a total of 7ml. 
8.  Centrifuge at 1,000 × g for 5 min. 
9.  Discard the supernatant 
10. Add 7ml of fresh 3:1 Methanol:Acetic Acid fixative 
11. Repeat steps 8-10. 
12. Store at -20 °C. 
 
2.8.2.2 Slide Preparation 
Reagents Equipment 
Fixative (Freshly made) Centrifuge (1,000 × g for 2 minutes) 
3:1 Methanol : Acetic Acid Phase contrast microscope 
 Microscope slides (Cleaned) 
 Pasteur pipette 
 
Procedures 
 
1. Prepare fresh fixative by Mixing methanol and acetic acid 3:1 in a fume hood. 
2. Centrifuge the cell samples 5 mins at 1,000 × g. 
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3. Remove fixative from the sample using a pipette, being careful not to remove 
the cell pellet at the bottom of the tube. 
4. Re-suspend the cell pellet in a small amount of fresh fixative.  
5. One slide is required per FISH study. Delineate the FISH area with a glass 
marker on the reverse of the slide. Label the slides with sample number, 
storage box position, and the probe to be used.  
6. Drop 2-3µl of sample on to a slide and allow it to air dry. 
7. Check the slide under a microscope to make sure that there is a good spread 
of cells. 
 
2.8.2.3 Probe preparation 
Reagents Equipment 
FISH Probes Micro-centrifuge 
Hybridisation Solution 10 mm Cover slip 
Rubber Solution Micro pipette 
 Nitrile Gloves 
 Forceps 
Procedures 
1. Defrost the FISH probe and hybridisation buffer at room temperature for 5 
minutes.  
2. Mix the probe by flicking the tube. 
3. Spin in a micro-centrifuge if required for a maximum of 5 seconds. 
4. For commercial probes prepare a 1:10 Probe:Hybridisation buffer dilution.  
For home-grown probes dilution will be different for each probe. 
5. Mix well by flicking. 
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6. Spin in micro-centrifuge if required for a maximum of 5 seconds. 
7. Apply 2 l of probe mixture to the slide. 
8. Apply 10 mm diameter coverslip and once the solution has spread, seal with 
rubber solution. Allow to stand for 5 minutes at room temperature. 
 
2.8.2.4 Denaturation and Hybridisation 
Reagents Equipment 
Distilled Water Hybridisation heated block (Hybrite [Temp. 
set for probe]) 
 
 
Procedures 
 
1. Place the slide, with the coverslip uppermost, onto the pre-warmed Hybrite 
for the time allocated for that probe. Most commercial probes use 75 °C for 
2 minutes and 72 °C for 5 minutes for home-grown probes. 
2. Incubate on the Hybrite at 37 °C overnight. 
 
2.8.2.5 Post Hybridisation Wash 
Reagents Equipment 
0.4 × Standard saline citrate (SSC) / 0.3% 
Nonidet P-40 (NP-40) 
Water Bath at 72 °C 
2 × SSC / 0.1 % NP-40 Micro pipetter 
2 × SSC Nitrile Gloves 
4’,6-diamidino-2-phenylindole 
(DAPI)/Antifade Mountant 
Olympus BX51 microscope 
Forceps 
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Procedures 
1. Remove the slides from the hybrite and carefully remove the rubber solution 
from the coverslips using forceps. 
2. Soak  in 2 × SSC to remove coverslips. 
3. Soak slides in 0.4 × SSC / 0.3 % NP-40 at 72°C for 2 minutes exactly. 
4. Transfer immediately to 2 × SSC / 0.1 % NP-40 at RT. 
5. Tap the slide dry on absorbent paper and wipe dry the underside. 
6. Mount with 7 µl of DAPI/Antifade Mountant. A 50 × 25 rectangular cover slip 
should then be placed on to the slide. 
7. Store at 4 °C until required. 
8. Check the slides and score them using the Olympus BX51 fluorescence 
microscope (Olympus) equipped with appropriate filters. Images were 
captured with CytoVision image capture software (Applied Imaging). 
2.9 Computational QSAR 
2.9.1 Principle of Quantitative Structure-Activity Relationship (QSAR) 
Analysis 
 QSAR (quantitative structure-activity relationship) analysis is the process by which 
molecules with similar chemical structures are quantitatively correlated with a well 
defined process, such as biological activity, chemical reactivity or docking score 
(descriptors) produced by using virtual docking software. The last one is also be 
defined as computational QSAR. The purpose of using QSAR analysis is mainly to 
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allow the prediction of biological activities or mechanisms (in here, binding mode 
prediction) of untested or novel compounds to provide insight into relevant and 
consistent chemical properties or descriptors which defines the biological activity. 
After a series of predicted models is collected, they can be used for database mining 
for the identification of novel chemical compounds, particularly, for those having 
drug-like properties (following Lipinski’s Rule of Five) (183) along with suitable 
pharmacokinetic properties. 
2.9.2 Online Resources and Softwares Applied for Computational QSAR 
Analysis 
PDB files of structures of MDM2 protein in complex with either p53 related 
peptides or small molecule inhibitors were downloaded from ‘RCSB Protein Data 
Bank’ website http://www.pdb.org, which were then used for docking software 
training. 
ChemBioOffice 2008 software ChemBioDraw Ultra 11.0 and ChemBio3D Ultra 11.0 
from http://www.cambridgesoft.com were used for generating isoindolin-1-one 
compound structures and predicting their lowest energy configurations. 
PyMOL v0.99 software from Delano Scientific LLC http://www.PyMOL.org was 
applied for re-building isoindolin-1-one compounds structures. 
Molegro Virtual Docker software (Free Trial Version) from Bioinformatics Research 
Center, University of Asrhus (molegro bioinformatics solutions) 
http://www.molegro.com was used for virtual docking, to predict and rank the 
lowest energy binding modes and to generate final binding mode images. 
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After binding mode generation, PyMOL v0.99 software was used for detailed 
visualisation of binding mode structure, including side-chain interactions between 
the ligand and MDM2 protein. Furthermore, PyMOL v0.99 software was also used 
to generate docking movies for presentation purposes. 
All the methods for using these software packages were based on the manuals 
and protocols provided by the corresponding companies and programme authors. 
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Chapter Three 
Isoindolin-1-one Compounds: Structure-Activity 
Relationship Analysis 
 
3.1 Introduction 
After reviewing reports of the X-ray crystal structure of the MDM2-p53 complex 
(116), several structure design research reports based on it (11-12, 14, 133-134), 
and the SAR (structure-activity relationship) for the isoindoin-1-one scaffold 
compounds we had already synthesized and tested, a new hypothesis was 
proposed; that there should be taken into consideration an additional residue of the 
p53 transactivation domain that binds to the hydrophobic cleft of MDM2, namely 
residue Leu22, which we had not previously considered in our structure 
optimization studies before. This may also contribute substantially to the binding 
activity, and additional interaction should be incorporated in furtherstudies of 
structure-based design for lead optimisation. 
If this hypothesis is correct, it should be possible to design compound structures 
with improved binding affinity to the target protein MDM2, based on mimicking the 
four key binding residues of p53 rather than just the three previously assumed. It 
also argues for an adjustment of the drug design and in silico compound library 
screening methods used to search for potential inhibitors of the MDM2/p53 
interaction.   
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My research aims and analysis presented in this chapter are based on the theories 
and hypothesis mentioned above, and the progress our research group has made, 
as explained in detail below: 
1. Based on the X-ray crystal structure of the MDM2-p53 binding interaction and 
the hypothesis mentioned above, to use drug design software to optimize the 
structure of the isoindolin-1-one scaffold compound. 
2. Evaluate the activity of new compounds with a cell-free bioassay method (ELISA) 
to obtain structure-activity-relationship (SAR) information to inform the 
continued optimization process. 
3. Establish whether or not the new inhibitors can also bind MDMX, a closely 
related structural homologue of MDM2, which can also potentially prevent p53 
activation after MDM2 has been inhibited. 
 
3.2 ELISA for Isoindolin-1-one Compound in vitro Activity 
Evaluation 
3.2.1 Isoindolin-1-one Compound Potency Evaluation as MDM2/p53 
Inhibitors 
The compounds evaluated with the Enzyme-Linked Immuno-Sorbent Assay (ELISA) 
by me with the collaboration and guidance of Dr. Claire Hutton and Dr. Xiaohong Lu 
are listed in Table 3. 1 in NU number order, which essentially reflects the order of 
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successful synthesis. If the compound IC50 value could not be obtained, its 
percentage inhibition at the highest concentration tested was presented in the 
table.The isoindolin-1-one core structure shared by most of the compounds listed in 
Table 3. 1 is displayed in Figure 3.1, with the side-chain position labeled 
corresponding to the side-chain modification in Table 3. 1. The structures of four 
compounds (NU8433-NU8436) in the table are shown seperately because they do 
not share the core structure. 
Each compound was plated out in triplicate at three different concentrations and 
the experiments were repeated at least three times for confirmation. 
IC50 results of all compounds were calculated using Prism Graphpad
TM software by 
point-to point analysis. 
All the compounds with IC50 values lower than 1 µM are highlighted with light green 
background (grey background in black & white print version). The most potent 
compound (NCL-00016149) was labelled with a asterisk (Table 3. 1).  
 
Figure 3. 1 Isoindolin1-one core structure shared by compounds in Table 3.1. 
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Table 3. 1 IC50 of Isoindolin-1-ones with Side Chains Variation 
 
Compound
Code 
-R1 -X -R2 -R3 -R4 -R5 -R6 
IC50 
μM 
SE 
μM 
NU8260 
 
-Cl -OH -H -H -H -H 2.4 0.2 
NU8296 
 
-Cl 
 
-H -H -H -H 0.4 0.04 
NU8297 
 
-Cl 
 
-H -H -H -H 1.9 0.3 
NU8332 
 
-Cl 
 
-H -H -H -H 78.4 5.1 
NU8346 
 
-Cl -OH -H -H -H -H 10.8 3.8 
NU8348 
 
-Cl 
 
-H -H -H -H 0.5 0.01 
NU8349 
 
-Cl 
 
-H -H -H -H 0.4 0.044 
NU8350 
 
-Cl 
 
-H -H -H -H 0.4 0.01 
NU8351 
 
-Cl 
 
-H -H -H -H 0.4 0.01 
NU8352 
 
-Cl 
 
-H -H -H -H 0.4 0.04 
NU8353 
 
-Cl 
 
-H -H -H -H 0.4 0.08 
NU8354 
 
-Cl 
 
-H -H -H -H 0.27 0.01 
NU8354
A  
-Cl 
 
-H -H -H -H 0.16 0.02 
NO2
NO2
NO2
NO2
NO2
NO2
NO2
NO2
NO2
NO2
NO2
100 
 
NU8354
B  
-Cl 
 
-H -H -H -H 1.33 0.12 
NU8355 
 
-Cl 
 
-H -H -H -H 79.8 2.5 
NU8357 
 
-Cl 
 
-H -H -H -H 0.66 0.11 
NU8358 
 
-Cl 
 
-H -H -H -H 0.58 0.08 
NU8359 
 
-Cl 
 
-H -H -H -H 0.57 0.07 
NU8360 
 
-Cl 
 
-H -H -H -H 0.39 0.11 
NU8361 
 
-Cl 
 
-H -H -H -H 0.31 0.09 
NU8362 
 
-Cl 
 
-H -H -H -H 3.2 1.0 
NU8363 (n-pr) -Cl 
 
-H -H -H -H > 10  
NU8364 
 
-Cl 
 
-H -H -H -H > 10  
NU8365 
 
-Cl 
 
-H -H -H -H 0.87 0.06 
NU8366 
 
-Cl 
 
-H -H -H -H 0.98 0.20 
NU8367 
 
-Cl 
 
-H -H -H -H 0.73 0.13 
NU8368 
 
-Cl 
 
-H -H -H -H 2.5 0.8 
NO2
NO2
NO2
NO2
NO2
NO2
NO2
NO2
NO2
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NU8369 
 
-Cl 
 
-H -H -H -H > 10  
NU8370 
 
-Cl 
 
-H -H -H -H 3.5 1.5 
NU8371 
 
-Cl 
 
-H -H -H -H > 10  
NU8378 
 
-Cl 
 
-H -H -H -H > 20  
NU8380 
 
-Cl 
 
-H -H -H -H 1.9 0.17 
NU8383 
 
-Cl  -H -H -H -H 15.5 2.5 
NU8386 
 
-Cl  -H -H -H -H > 100 
NU8387 
 
-Cl  -H -H -H -H 83.8 2.4 
NU8388 
 
-Cl  -H -H -H -H > 10 
NU8389 
 
-Br  -H -H -H -H 3.1 0.2 
NU8390 
 
-Br  -H -H -H -H 0.57 0.06 
NU8391 
 
-Br  -H -H -H -H 0.37 
0.05 
NU8392 
 
-Br  -H -H -H -H 1.4 0.2 
NU8393 
 
-Cl  -Me -H -H -H 2.2 0.3 
NO2
NO2
NH2
OH
C HO2
OH
C HO2
OH
O
C HO2
O OH
NO2
OH
NO2
OH
O
NO2
O OH
NO2
OHO
NO2
OH
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NU8394 
 
-Cl  -H -H -H -Me 6.9 2.7 
NU8395 
 
-Cl  -H -Me -H -H 5.1 0.7 
NU8396 
 
-Cl  -H -t-Bu -H -H 12.7 1.4 
NU8397 
 
-Cl  -H -H -t-Bu -H 0.84 0.05 
NU8398 
 
-Cl  -Cl -H -H -H 0.50 0.03 
NU8399 
 
-Cl  -H -H -t-Bu -H 0.15 
0.03 
NU8400 
 
-Cl  -H -t-Bu -H -H 0.73 
0.03 
NU8401 
 
-Cl  -H -Me -H -H 0.49 
0.04 
NU8402 
 
-Cl  -H -H -H -H > 20 
NU8403 
 
-Cl  -H -H -H -H > 20 
NU8404 n-pr -Cl  -H -H -H -H > 20 
NU8405 
 
-Cl  -Me -H -H -H 0.27 
0.04 
NU8406 
 
-Cl  -Cl -H -H -H 0.14 
0.03 
NU8407 
 
-Cl  -H -H -H -H 433 
NU8408 
 
-Cl  -H -H -H -H 214 
NO2
OH
NO2
OH
NO2
OH
NO2
OH
NO2
OH
NO2
O OH
NO2
O OH
NO2
O OH
N
OH
S
OH
O OH
NO2
O OH
NO2
O OH
CF3
OH
CF3
O OH
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NU8409 
 
-Cl  -H -H -H -H > 500 
NU8410 
 
-Cl  -H -H -H -H 175 
NU8411 
 
-Cl  -H -H -H -H 252 
NU8412 
 
-Cl  -H -H -Me -H 1.5 0.4 
NU8413 
 
-Cl  -H -H -Br -H 5.4 0.5 
NU8414 
 
-Cl  -H -Br -H -H 5.7 0.2 
NU8415 
 
-Cl  -H -H -H -H 0.63 
0.02 
NU8416 
 
-Cl  -H -H -H -H 0.89 
0.06 
NU8417 
 
-Cl  -H -H -H -H 0.39 
0.06 
NU8418 
 
-Cl  -H -H -H -H 6.7 0.4 
NU8419 
 
-Cl  -H -H -H -H 7.2 1.0 
NU8420 
 
-Cl  -H -H -H -H > 200 
NU8421 
 
-Cl  -H -H -H -H > 200 
NU8422 
 
-Cl  -H -H -H -H > 200 
NU8423 
 
-Cl  -H -H -H -H > 200 
NU8424 
 
-Cl  -H -Br -H -H 0.9 
0.1 
NU8425 
 
-Cl  -H -H -Br -H 1.0 0.04 
S
O
OH
S
O OH
N
O OH
NO2
OH
NO2
OH
NO2
OH
CN
O OH
Cl
O OH
Br
O OH
Cl
O OH
Cl
O OH
N O
OH
N O O OH
N
OH
N
OH
NO2
O OH
NO2
O OH
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NU8426 
 
-Cl  -H -H -H -H > 200 
NU8427 
 
-Cl  -H -H -H -H > 200 
NU8428 
 
-Cl  -H -H -H -H 28.5 6 
NU8429 
 
-Cl  -H -H -H -H 10.6 0.8 
NU8430 
 
-Cl  -H -H -H -H > 200 
NU8431 
 
-Cl  -H -H -H -H 32.9 2.9 
NU8432 
 
-Cl  -H -Cl -Cl -H 35.1 6.8 
NU8433 
Me
N
O
Cl
HO
Me
 
>200  
NU8434 
Me
N
O
Cl
HO
Me
 
>200   
NU8435 
Me
N
O
Cl
O
Me
HO
 
8.9  
NU8436 
Me
N
O
Cl
O
Me
HO
 
3.7  
NCL-000
10485  
-Cl  -H -F -H -H 3.8 0.5 
N O
OH
N
O
OH
N
O OH
N
O OH
N O
O OH
N
O
O OH
NO2
OH
NO2
OH
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NCL-000
10486  
-Cl  -H -H -F -H 5.2 1.5 
NCL-000
10487  
-Cl  -H -Cl -Cl -H 3.7 1.2 
NCL-000
10488  
-Cl  -Cl -H -H -H 1.6 1.0 
NCL-000
10489  
-Cl  -H -H -H -Cl 9.0 2.2 
NCL-000
10490  
-Cl  -Cl -H -H -H 8.5 0.1 
NCL-000
10491  
-Cl -Me -H -H -H -H 85.3 12.5 
NCL-000
10492  
-Cl  -Cl -H -H -H 0.19 
0.02 
NCL-000
10493  
-Cl  -Cl -H -H -H 0.17 
0.00 
NCL-000
10494  
-Cl  -H2 -H2 -H2 -H2 2.8 
0.1 
NCL-000
10495  
-Cl  -H -F -H -H 0.3 
0.1 
NCL-000
10496  
-Cl  -H -H -F -H 0.9 
0.1 
NCL-000
10497  
-Cl 
 
-H -H -H -H 4.2 0.2 
NCL-000
13767  
-Cl  -H2 -H2 -H2 -H2 3.5 0.01 
NCL-000
13768  
-Cl 
 
-H -H -H -H 10.5 0.2 
NCL-000
13769  
-Cl 
 
-H -H -H -H 16.0 1.6 
NCL-000
13770  
-Cl 
 
-H -H -H -H 13.4 0.5 
NO2
OH
NO2
O OH
CN
OH
CN
OH
Br
OH
Br
CN
O OH
Br
O OH
NO2
O OH
NO2
O OH
NO2
O OH
NO2
NO2
O OH
NO2
NO2
NO2
106 
 
NCL-000
13774  
-Cl 
 
-Cl -H -H -H 0.04 0.01 
NCL-000
13775  
-Cl 
 
-Cl -H -H -H 1.30 0.01 
NCL-000
14527  
-Cl -OH -H -H -H -H >20  
NCL-000
14528  
-Cl -OH -H -H -H -H >20  
NCL-000
14529  
-Cl  -H -H -H -H 0.82 
0.01 
NCL-000
14530  
-Cl  -H -H -H -H 1.7 
0.4 
NCL-000
14531 
 
-Cl  -H -H -H -H 14.6 1.3 
NCL-000
14532  
-Cl -OH -H -H -H -H >20  
NCL-000
14533 
 
-Cl  -H -H -H -H >20  
NCL-000
16045 
 
-Cl -OH -H -H -H -H 85.4  
NCL-000
16046  
-Cl -OH -H -H -H -H 90.1  
NCL-000
16047  
-Cl -OH -H -H -H -H > 100  
NCL-000
16106  
-Cl  -H -H -H -H 57.8  
NCL-000
16107  
-Cl  -H -H -H -H 71.2  
NO2
NO2
O OH
O OH
O OH
O OH
O OH
O OH
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NCL-000
16147  
-Cl  -H -H -H -H 4.4 0.04 
NCL-000
16148  
-Cl -CN -H -H -H -H 48.2 3.7 
*NCL-00
016149   
-Cl 
 
-Cl -H -H -H 0.016 0.003 
NCL-000
16653  
-Cl 
 
-Cl -H -H -H 0.12 0.02 
NCL-000
16654  
-Cl -OH -H -H -H -Cl 4.5  
NCL-000
16655  
-H -OH -H -H -H -H 87.0  
NCL-000
16656  
-H  -H -H -H -H 8.3  
NCL-000
16657  
-F -OH -H -H -H -H 9.5  
NCL-000
16658  
-Cl -CH2OH -H -H -H -H 6.8  
NCL-000
16659  
-Cl 
 
-Cl -H -H -H 0.10 0.03 
NCL-000
16865  
-Cl  -H -H -H -H 2.3 0.1 
NCL-000
16866  
-Cl  -H -H -H -H 1.9 1.0 
NCL-000
16867 
 
-Cl  -H -H -H -H > 50  
NCL-000
16895  
-Cl 
 
-H -H -H -H 0.6 0.1 
NCL-000
16896  
-F  -H -H -H -H 2.3 0.5 
NO2
NO2
NO2
NO2
NO2
NO2
NO2
O OH
NO2
NO2
CN
O OH
O OH
O OH
NO2
NO2
O OH
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NCL-000
16897  
-Cl -OH -Cl -F -H -H 40 6 
NCL-000
16957  
-Me  -H -H -H -H 1.2  
NCL-000
16958 
 
-Cl  -H -H -H -H > 20  
NCL-000
16985  
-Cl -CO2H -H -H -H -H 7.7 1.9 
NCL-000
16986  
-Cl  -Cl -F -H -H 0.2 
0.05 
NCL-000
17305  
-Cl 
 
-Cl -H -H -H 0.12 0.02 
NCL-000
17306  
-Cl 
 
-Cl -H -H -H 0.12 0.03 
NCL-000
17310  
-Cl 
 
-Cl -H -H -H 4.1 0.2 
NCL-000
17311  
-Cl 
 
-Cl -H -H -H 4.3 
0
.
3 
NCL-000
17325 
 
-Cl -OH -H -H -H -H 168.3 3.4 
NCL-000
17326 
 
-Cl -OH -H -H -H -H > 200  
NCL-000
17327 
 
-Cl -OH -H -H -H -H > 200  
NCL-000
17328  
-Cl -OH -H -H -H -H 9.8 1.2 
NCL-000
17365  
-Cl  -H -H -H -H 0.46 
0.03 
  
NO2
NO2
O OH
O OH
NO2
NO2
O OH
CN
Br
Br
CN
O OH
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The IC50 values for isoindolin-1-one compounds with similar structure were 
compared as a group within the same ELISA plate to obtain further accurate SAR 
information, and the results are shown in Figure 3. 2. 
 
               
 
                
 
 
 
 
 
Figure 3. 2 Comparison of IC50 Values for Inhibition of the MDM2-p53 Binding Interaction 
by Isoindolin-1-ones with Side-chain Variation in the R2 position. 
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O
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HO
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O
Cl
NO2
NH
Fmoc
NU8354  269±12 nM NU8296  395±35 nM NU8348  453±4.8 nM 
NU8380  1.9±0.17 M NU8297  1.9±0.3 M NU8260  2.4±0.2 M 
NU8355  79.8±2.5 M 
110 
 
3.2.2 IC50 Comparison of MI-63, Nutlin-3, (-)-Nutlin-3 and potent 
isoindolin-1-ones as MDM2/p53 Inhibitors 
After obtained the MI-63 and potent Nutlin-3 enantiomer (-)-Nutlin-3, I evaluated 
and compared their IC50 values together with our potent isoindolin-1-one 
compounds as single enantiomers NU8354A, NU8406A, NCL-00017305 and 
NCL-00017306; together with the compound NCL-00016149 (Figure 3. 3) which was 
designed as a prodrug with the adding of the oxobutanoic acid side-chain at the end 
of –R2 position to improve water solubility. The compound is stable under acidic 
condition (e.g. in stomach) and can be hydrolyzed in mild basic condition (e.g. in 
intestines). 
Three independent ELISA assays were carried out on these compounds with specific 
ranges of concentrations for each individual compound. Mean and SD values of 
percentage inhibition for each concentration were calculated and non-linear 
regression curves fitted to the data to generate accurate IC50 values using PRISM 
software embedded programme ‘log (inhibitor) vs. response -- Variable slope’ 
(Figure 3. 4). 
MI-63 was the most potent MDM2/p53 inhibitor in this comparison set, with a 9 nM 
IC50 value, followed by NCL-00016149, (-)-Nutlin-3 and NU8406A; all the remaining 
compounds had IC50 values above 100 nM. 
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Figure 3. 3 Strucutres of MI-63, Nutlin-3, (-)-Nutlin-3 and potent isoindolin-1-ones 
NU8354A, NU8406A, NCL-00017305 and NCL-00017306 and NCL-00016149 
 
  
MI-63 Nutlin-3 (-)-Nutlin-3 
NU8354A NU8406A NCL-00017305 
NCL-00017306 NCL-00016149 
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Figure 3. 4 IC50 comparison of MI-63, Nutlin-3, (-)-Nutlin-3 and potent isoindolin-1-ones as 
MDM2/p53 inhibitors 
  
Compounds MI-63 Nutlin-3 (-)-Nutlin-3 NU8354A NU8406A NCL-00017305 NCL-00017306 NCL-00016149 
IC50 (nM) 9.0±1.3 103.3±10.6 22.75±5.3 173.4±20.1 42.8±2.6 107.9±15.3 109.1±25.8 18.90±4.1 
113 
 
3.2.3 Screening of isoindolin-1-ones as MDMX/p53 Inhibitors 
Based on the protein sequence similarity and the hydrophobic binding pocket 
structural similarity between MDM2/p53 and MDMX/p53 X-ray co-crystal 
structures, we also selected and screened some isoindolin-1-one scaffold 
compounds together with Nutlin-3 and MI-63 for activity as MDMX/p53 inhibitors, 
as listed in Table 3. 2. If the compound IC50 value could not be obtained, the 
percentage inhibition at the highest concentration was presented in the table.  
Table 3. 2 Compounds evaluated as MDMX/p53 interaction inhibitors 
Compound Code Structure Highest 
Concentration 
(µM) 
% Inhibition 
MI-63 
                        
25 -10.4 
Nutlin-3 
 
25 23.8 
NU8354A 
 
25 -14.1 
NU8354B 25 -23.8 
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NU8406 
 
100 20.5 
NU8406A 50 34.7 
NU8406B 50 -8.3 
NCL-00016149 
 
100 87.9 
NU8110 
 
100 -7.8 
NU8117 
 
100 32.5 
NU8136 
 
100 -16.5 
NU8210 
 
100 7.8 
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NU8211 
 
100 -5.1 
NU8214 
 
100 -31.9 
NU8219 
 
100 -18.9 
NU8275 
 
100 -29.2 
NU8285 
 
100 11.4 
NU8435 
 
100 23.0 
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NU8436 
 
100 -1.3 
NCL-00014530 
 
100 -10.7 
NCL-00016653 
 
50 52.3 
NCL-00016654 
 
100 37.3 
NCL-00016655 
 
100 -13.6 
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NCL-00016656 
 
100 -4.4 
NCL-00016657 
 
100 -5.7 
NCL-00016658 
 
100 1.5 
NCL-00016659 
 
50 41.1 
NCL-00016865 
 
50 -8.8 
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NCL-00016866 
 
50 -62.9 
NCL-00016867 
 
50 3.2 
NCL-00016895 
 
50 -5.9 
NCL-00016896 
 
50 37.5 
NCL-00016897 
 
50 24.1 
119 
 
NCL-00016957 
 
20 7.1 
NCL-00016958 
 
20 11.3 
NCL-00017305 
  
50 28.7 
NCL-00017311 50 22.3 
NCL-00017306 
 
50 34.1 
NCL-00017310 50 29.1 
NCL-00016985 
 
50 6.6 
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NCL-00016986 
 
50 2.0 
NCL-00017325 
 
200 70.0 
NCL-00017326 
 
200 24.8 
NCL-00017327 
 
200 31.6 
NCL-00017328 
 
200 33.2 
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3.3 Structure-activity Relationships for the analysis of ELISA 
IC50 data 
3.3.1 Isoindolin-1-one compounds side-chain comparison 
Selected isoindolin-1-ones were grouped based on the side-chain difference 
highlighted in blue in Figure 3. 5 and in the following tables put alongside with 
compound codes and their IC50 values so that the relationship between potency 
differences, and these side-chain variations can be compared. 
 
Figure 3. 5 Three side chains of isoindolin-1-one compounds with the modification to be 
discussed highlighted in blue 
3.3.1.1 Isoindolin-1-one compounds side-chain –R1 modification  
Grouped isoindolin-1-one IC50 values in Table 3. 3 illustrated the effect of modifying 
side-chain position –R1.  
The ELISA results comparison showed that using –C≡CH, –Br or –CN to replace 
–NO2 leads to a modest decrease of the compound potency, but using –F, –Cl, –I or 
–Me residues resulted in a marked loss of inhibitiory activity, which may contribute 
to further refinement of the binding mode model and structure optimization.  
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Although the IC50 values showed that the nitrobenzyl side-chain was still the most 
suitable one for its binding position, this makes the compounds likely to be unstable 
in vivo due to reductive metabolism of the nitrobenzyl group (184-185), the 
bromobenzyl, ethynylbenzyl or methyl-benzonitrile groups may be alternative 
candidates for maintaining MDM2/p53 inhibitoion activity in vivo.  
The modification results of side-chain –R1 indicated not only space occupying 
effects between the isoindolin-1-one compounds within the p53/MDM2 binding 
pocket, but also electronic effects and hydrogen bonding of the nitrobenzyl group 
with MDM2 residues, which might contribute to the higher binding potency of the 
–NO2 group compared to all other side-chain candidates we have tested.  
On changing the bromobenzyl group at the –R1 position into either chlorobenzyl, 
iodobenzyl or fluorobenzyl, the binding potency was decreased markedly, which 
may contribute to further refinement of the binding mode model and structure 
optimization, for example, considering the relationship between the size of this 
side-chain with the potencies of compounds.  
Moreover, the observation that the methoxybenzyl group was more potent than 
the methylbenzyl group and the (furan-2-yl) benzyl group was more potent than 
(thiophen-2-yl) benzyl, indicated a relationship between the hydrogen bond effects 
of this side-chain and the compound’s potency.  
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Other modifications in this side-chain position displayed in Table 3. 3 also indicated 
the influence of the side-chain size and H-bonding capacity effects on compound 
potency. 
Table 3. 3 Side-chain –R1 modification comparison 
   
NU8260 
IC50 2.4 ± 0.2 µM 
NCL-00012328 
IC50 9.8 ± 1.2 µM 
NU8346 
IC50 10.8 ± 3.8 µM 
   
NCL-00014527 
IC50 > 20 µM 
NCL-00014528 
IC50 > 20 µM 
NCL-00016656 
IC50 > 20 µM 
   
NCL-00014532 
IC50 > 20 µM 
NU8402 
IC50 > 20 µM 
NCL-00016045 
IC50 85.4 µM 
   
NCL-00016046 
IC50 90.1 µM 
NCL-00016047 
IC50 > 100 µM 
NU8386 
IC50 > 100 µM 
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NCL-00017325 
IC50 168.3 ± 3.4 µM 
NU8420 
IC50 > 200 µM 
NU8422 
IC50 > 200 µM 
   
NCL-00017326 
IC50 > 200 µM 
NU8426 
IC50 > 200 µM 
NU8423 
IC50 > 200 µM 
   
NCL-00017327 
IC50 > 200 µM 
NU8427 
IC50 > 200 µM 
NU8407 
IC50 433 µM 
  
 
NU8409 
IC50 > 500 µM 
  
   
NU8354 
IC50 0.27 ± 0.01 µM 
NU8417 
IC50 0.39 ± 0.06 µM 
NCL-00017365 
IC50 0.46 ± 0.03 µM 
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NU8415 
IC50 0.63 ± 0.02 µM 
NCL-00014529 
IC50 0.82 ± 0.01 µM 
NU8416 
IC50 0.89 ± 0.06 µM 
   
NCL-00014530 
IC50 1.71 ± 0.44 µM 
NCL-00016866 
IC50 1.88±0.96 µM 
NCL-00016896 
IC50 2.25±0.46 µM 
   
NCL-00016865 
IC50 2.29±0.05 µM 
NCL-00016656 
IC50 8.29 µM 
NU8429 
IC50 10.6±0.8 µM 
   
NU8388 
IC50 > 10 µM 
NCL-00014531 
IC50 14.58 ± 1.31µM 
NU8378 
IC50 > 20 µM 
   
NCL-00014533 
IC50 > 20 µM 
NCL-00016958 
IC50 > 20 µM 
NU8428 
IC50 28.5 ± 6 µM 
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NU8431 
IC50 32.9 ± 2.9 µM 
NCL-00016867 
IC50 > 50 µM 
NCL-00016106 
IC50 57.8 µM 
   
NCL-00016896 
IC50 71.2 µM 
NU8410 
IC50 175 µM 
NU8408 
IC50 214 µM 
   
NU8421 
IC50 >200 µM 
NU8430 
IC50 >200 µM 
NU8411 
IC50 252 µM 
 
3.3.1.2 Isoindolin-1-one compounds side-chain –R2 modification  
Grouped isoindolin-1-one scaffold compounds information in Table 3. 4 illustrated 
the modification of position –R2.  
Based on the binding mode prediction results using virtual docking software and 
SAR analysis, it appears that this side-chain is quite special, because the predicted 
binding mode can be quite different based on whether one considers the aqueous 
solvent environment effect or not (Appendix I), and one example is demonstrated in 
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Figure 3. 6, by using Molegro Virtual Docking software (Free Trial Version) from 
Bioinformatics Research Center, University of Aarhus (molegro bioinformatics 
solutions) to predict the mode of NU8354 binding with the p53 binding pockets of 
MDM2. The MDM2 protein surface images in Figure 3. 6 are produced based on 
volume electric charge density distribution. The colour ‘blue’ corresponds to the 
electropositive surface, ‘white’ corresponds to neutral surface and ‘red’ to 
electronegative surface. The compound NU8354 is presented as a 3D stick structure 
and colour coded as ‘green’ for carbon, ‘white’ for hydrogen, ‘blue’ for nitrogen and 
‘red’ for oxygen. The H-bonds are shown as green dashes. In the left hand side 
image, it shows the binding mode taking into consideration the effect of the water 
molecules from the aqueous enviroment (presented as red dots). The –R2 position 
side-chain of NU8354, (1-(methoxymethyl)cyclopropyl)methanol group, interacts 
with a H2O molecule, the oxygen atom on the isoindolin-1-one ring interacts with 
another two H2O molecules, and one oxygen atom on the 4-nitrobenzyl side-chain 
interacts with a nearby H2O molecule as well. These interactions enabled the three 
functional groups of NU8354 to seal the surface of the p53 binding pocket and leave 
the chlorophenyl side-chain of NU8354 to project into the p53 tryptophan 
side-chain binding pocket of MDM2. The importance of this binding mode is 
discussed in detail in the following section. In the right hand side image, the binding 
mode is quite different, although the MoleDock Score and Docking Score values are 
very similar to the one we have mentioned before. Without the water solvation 
effect, the (1-(methoxymethyl)cyclopropyl)methanol group points towards the p53 
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peptide Phe19 side-chain binding pocket of MDM2, the oxygen atom on the 
isoindolin-1-one ring interacts with an amino acid residue of MDM2 protein, and 
one oxygen atom on the nitrobenzyl side-chain interacts with another amino acid 
residue of the MDM2 protein. These interactions force the chlorophenyl side-chain 
of NU8354 into the remaining p53 binding pocket on MDM2, i.e. the Leu26 binding 
pocket. 
 
 
 
 
 
 
Figure 3. 6 NU8354-MDM2 Docking Results Generated by Using Molegro Virtual Docking 
Software Indicated Different Binding Modes with whether Considering Water Solvation 
Effects or Not. 
The most appropriate model is one which considers the aqueous environment, 
since this is the condition present in both the ELISA binding method,which is carried 
out in PBS solution, and in the cytoplasm and nucleoplasm environment of intact 
mammalian cells which is predominantly aqueous. 
NU8354-MDM2 binding mode Comparison 
   
 NU8354 docking into MDM2 cave 
with the water solvation effect. 
MolDock Score: -131.121 
Docking Score: -132.325 
NU8354 docking into MDM2 cave 
without the H2O solvation effect. 
MolDock Score: -129.339 
Docking Score: -131.047 
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The results in Table 3. 4 indicated that the length, shape and water solubility of the 
side-chain affected the compound’s potency markedly.  
NCL-00016149, and NU8354 were the most potent among the batch of compounds 
grouped in Table 3. 4, and different –R2 side-chain structures lead to different 
potency.  
Changing the terminal oxygen on the –R2 side-chain into nitrogen led to a 4-fold 
decrease of compound potency (compare NU8348 with NU8380), and the 
difference between NU8348 with NU8380 was only changing the terminal –OH 
group od the –R2 side-chain into an –NH2 group, which indicated the H-bond 
acceptor effect plus the H-bond donor effect of the –OH group is perhaps bigger 
than the combined effects of the –NH2 group.  
Comparison of NU8260 with NU8348 shows the extension of the –OH group with an 
n-propyl carbon chain increases the potency by a factor of 4 to 5 fold, which 
supports the hypothesis that a hydrophilic group of appropriate extension direction, 
shape and length of the carbon chain at the –R2 position contributes to enhancing 
the potency of isoindolin-1-one compounds.  
This hypothesis is also supported by the fact that with the influence of a large 
hydrophobic side-chain e.g. an –Fmoc group at the end of the –R2 side chain, the 
potency of the compound decreased markedly (NU8355).  
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Although compound NCL-00016149 contained a chlorine atom on the 
idoindolin-1-one ring, which contributed to the increase of the compound’s 
potency, another important factor was the adding of the oxobutanoic acid at the 
end of –R2 side chain, which markedly enhanced the compound’s potency by 8-fold.  
Changing the oxygen into carbon to link the isoindolin-1-one ring with the –R2 
side-chain should enhance the stability of the compounds (with the removal of the 
oxygen linkage), but their potencies were markedly sacrificed at the same time 
(compare NU8260 with NCL-00010497, NCL-00016147, NCL-00016658), which 
indicated some positive effect of this oxygen. However, comparing NCL-00016147 
with NCL-00016658 and NCL-00010497 with NCL-00016985, an interesting 
phenomenon with the extension of the side-chain is observed, i.e. increasing the 
distance between the hydrophilic groups from the main scaffold result in slightly 
better potencies, which needs further side-chain variation to explore the possible 
reason.  
The relationship between the –R2 side-chain variation and the compound potency 
from NU8354 to NU8297, especially the comparison of the IC50 results between 
NU8296 and NU8297, which also showed a 5 fold difference of potency, suggested 
another attractive hypothesis (which may need further experiments to examine). 
The residues on the –R2 side-chain may also contribute to the binding between 
isoindolin-1-ones with MDM2, possibly interacting with the same MDM2 binding 
position as the Leu22 of the p53 peptide. Also informing this potential binding 
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mode is the observation that the double bond in the five-carbon ring of NU8297 
which would have decreased flexibility of the –R2 side chain, resulting in a marked 
decrease of potency compared with NU8296.  
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Table 3. 4 Side-chain –R2 modification comparison 
Compound Code NCL-00016149 NU8354 NU8361 NU8349 NU8352 NU8360 NU8353 NU8296 NU8350 
 
 
   
  
 
 
 
IC50 (µM) 0.0158+Cl 0.269 0.306 0.357 0.375 0.388 0.395 0.395 0.402 
Compound Code NU8351 NU8348 NU8359 NU8358 NCL-00016695 NU8357 NU8367 NU8366 NU8297 
   
 
 
    
 
IC50 (µM) 0.405 0.453 0.569 0.582 0.617 0.656 0.732 0.983 1.90 
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Compound Code NU8380 NU8260 NCL-00010497 NCL-00016147 NCL-00016658 NCL-00016985 NCL-00013768 
  
 
  
  
 
IC50 (µM) 1.90 2.40 4.16 4.41 6.83 7.67 10.46 
Compound Code NCL-00013770 NCL-00013769 NCL-00016148 NU8355 NU8371   
   
 
  
  
IC50 (µM) 13.36 15.99 48.16 79.8 > 100   
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3.3.1.3 Isoindolin-1-one compounds side-chain –X modification 
Table 3. 5 compares isoindolin-1-one scaffold compounds with variation of the –X 
position, including the corresponding space filling view reproduced by using PyMOL 
software (the side-chain –X was colour coded as: green to –Cl, brown to –Br, cyan to –F 
and light orange to the carbon atom of –CH3 group, with the white coding all the 
hydrogen and light green to the carbon atoms on benzene ring).  
When the chlorine atom was replaced by other halogen atoms, hydrogen or a methyl 
group the change in the IC50 results indicated that it might be the size of this side-chain 
and the van der Waals interaction between the side-chain and the MDM2 protein side 
chains around the tryptophan binding pocket, rather than a halogen ‘salt-bridge effect’, 
that determined the binding potency.  
The binding model poses with the –X group docking into the tryptophan binding 
pocket of MDM2 indicated that the sizes of bromo and methyl were too large for the 
binding pocket, and the sizes of fluoro and hydrogen were too small to occupy the 
binding pocket fully. Chloro was the most suitable group for this position, which is 
quite similar to the comparison of the peptide side-chain binding with the tryptophan 
binding pocket of MDM2 (125). The predicted binding mode also indicated that the 
chlorophenyl side-chain embedded into the p53 peptide tryptophan binding pocket of 
MDM2 protein had the lowest docking energy. This is also supported by the increase in 
binding potency produced with p53 peptide binding studies by the substitution of 
tryptophan by 6-chlorotryptophan. 
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Based on these two side-chain SAR analyses, we have generated a ‘See-Saw Theory’ 
for the binding mode (See Chapter 7). 
Table 3. 5 Side-chain –X modification comparison 
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3.3.1.4 Isoindolin-1-one compounds midofication on the main scaffold  
Finally is the isoindolin-1-one ring modification as summarised in Figure 3. 7. 
 
 
 
  
Figure 3. 7 Modification of the isoindolin-1-one ring based on the NU8260 scaffold 
Comparing the four compounds NU8393, NU8394, NU8395 and NU8412, with a methyl 
residue at the 4-, 5-, 6- or 7- position of the isoindolin-1-one ring, the IC50 results 
showed marked differences (Figure 3. 7). Comparing the potency of these compounds 
with the unsubstituted NU8260 basic scaffold compound, we can conclude that the 
addition of hydrophobic residues at the 4- and 6- position enhanced compound 
potency, but at the 5- and 7- position have lead to a marked loss of potency. 
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NU8393 
5.08 ± 0.65 µM (n=3) 
NU8395  
6.90 ± 2.74 µM (n=3) 1.46 ± 0.36 µM (n=3) 
NU8412  NU8394  
35.1 ± 6.8 µM (n=3) 502.0 ± 43.7 nM (n=3) 12.70 ± 1.40 µM (n=3) 797.7 ± 40.6 nM (n=3) 
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This conclusion was supported by compounds NU8396, NU8397 and NU8398, 
however, NU8413 and NU8414 with the –Br at the 5-/6- position do not follow the 
same pattern.  
On the other hand, the scaffold with two Cl residues on the ring leads to a marked loss 
of potency, which may not only be due to the binding affinity decreasing because of a 
poor fit to the MDM2 binding pocket, but also because of solubility decreasing. 
 
Figure 3. 8 Modification on isoindolin-1-one ring based on the NU8354 scaffold 
With the addition of the ‘(1-(methoxymethyl)cyclopropyl)methanol’ side-chain at the 
–R2 position, the compound potencies all increased markedly and became comparable 
to Nutlin-3 (Figure 3. 8).  
Furthermore, the most potent isoindolin-1-one compound within the group shown in 
Figure 3. 8, NU8046, was a racemic mixture with an IC50 of 143 nM. This encouraged us 
to anticipate that a pure active enantiomer might be comparable to or even more 
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potent than Nutlin-3. This also potentially provided a binding mode confirmation, 
when compared with the structure of NU8399, which, with a bulky tert-butyl 
substituent, had been predicted to be a negative control, but proved to be a quite 
potent compound (further discussion in the context of western blotting results in 
Section 4.2.3). 
3.3.2 Isoindolin-1-one compounds as MDMX/p53 interaction inhibitors 
The results of selected isoindolin-1-one compounds as MDMX/p53 binding inhibitors 
indicated that, almost none of them were able to disrupt the binding between MDMX 
and p53 effectively. However, detailed inhibition potency results gave us some more 
information, which might be encouraging (Figure 3. 9). 
 
Figure 3. 9 ELISA for isoindolin-1-one compounds as MDMX inhibitors 
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The results displayed in Figure 3. 9 indicated that potent MDM2 inhibitor 
isoindolin-1-one enantiomers (NU8406A, NCL-00017305_300A & 
NCL-00017306_301A) showed a greater, albeit weak, ability to inhibit MDMX/p53 
binding than the less potent MDM2 inhibitor isoindolin-1-one enantiomers, and some 
of the less potent compounds showed a negative effect; i.e. appeared to promote 
binding.  
Furthermore, the succinate ester NCL-00016149 showed greater than 50 percent 
inhibition potency at 100 µM concentration. These observations indicated that the 
binding pocket of MDMX differs markedly from that of MDM2 so that MDM2 inhibitors 
are not automatically MDMX inhibitors; however, they also have some similarity, and it 
is still possible to develop MDMX inhibitors based on the already obtained MDM2 
inhibitors as potential leads. One of the key question would be how different would 
they need to be and what kind of modification needs to be made to turn an MDM2 
inhibitor into an MDMX inhibitor or a joint MDM2 and MDMX inhibitor. 
For this reason, further research has been carried out by using different scaffold 
compounds and peptides, and this is discussed in detail in Chapter Five. 
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Chapter Four 
Isoindolin-1-one Compounds: Evaluation of Cellular 
Activity  
 
4.1 Introduction 
The previous chapter described the use of the cell-free ELISA to identify small 
molecular weight compounds that can interrupt the protein-protein binding 
interaction between p53 and MDM2, and to compare their potency with the positive 
control compounds Nutlin-3 and MI-63. However, this alone does not necessarily 
predict their behavior in intact mammalian cells, and questions such as: Will they be 
able to cross the cell membrane efficiently? Will the cells resist their effect by effluxing 
them out directly? Are there any off-target cellular effects, etc. need to be explored 
and answered by evaluation in cellular assays. 
With the progression of the research project, several isoindolin-1-one scaffold 
compounds with potency comparable to Nutlin-3 as MDM2/p53 inhibitors were 
identified by the ELISA screening method. The next step was to evaluate their cellular 
activity to ascertain whether they had effects on cells that were consistent with 
inhibition of MDM2-p53 binding.  
During the lead optimisation phase of development, the structures of these 
compounds were designed and synthesized step by step based on the SAR analysis 
(Figure 4. 1). The cellular responses of the compounds at each step were evaluated by 
western blotting to evaluate and compare their ability to induce p53 pathway protein 
expression. Compounds showing cellular responses as inducers of p53 activity were 
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taken forward to evaluate their growth inhibitiory and cytotoxic properties. The 
potency for growth inhibition was compared using the SRB assay to determine the 
concentration of compound required to inhibit growth by fifty percent (GI50). 
The key compound structures along the path of lead optimisation and associated IC50 
values are listed in Figure 4. 1. 
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Figure 4. 1 Progression of isoindolin-1-one scaffold compounds during lead optimisation as 
MDM2-p53 binding interaction inhibitors 
Stage 1 
Stage 2 
Stage 3 
NU8260    
MW 394.81 
2.4±0.2 M (N=4) 
NU8354    
MW 478.92 
269±12 nM (N=4) 
NU8406    
MW 513.37 
143±26 nM (N=4) 
NCL-00016149    
MW 613.44 
15.8±2.6 nM (N=4) 
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4.2 Western Blotting for Cellular Activity Evaluation and 
Comparison of Isoindolin-1-one Compounds 
4.2.1 Western Blot Result for Stage 1 Isoindolin-1-one Compounds 
All the selected stage 1 isoindolin-1-one compounds produced a dose-dependent 
increase in MDM2, p53 and p21, consistent with the release of p53 from MDM2 
binding and its transcriptional activation (Figure 4. 2-a, -b & -c). The corresponding 
quantitative analysis of the western blot band optical densities are shown in Figure 4. 3 
and comparison showed that the cellular activity of NU8354 and NU8361 was 
approximately two to three times less potent than Nutlin-3 for induction of MDM2 
protein expression as a marker of p53 activation. 
The most potent stage 1 isoindolin-1-one compound, NU8354, as determined by ELISA 
bioassay, was selected for further comparison with Nutlin-3 to ascertain whether they 
have similar effects on cells that were consistent with specific inhibition of MDM2-p53 
binding. For this purpose, three cell lines, SJSA-1, HCT116p53+/+ and HCT116p53-/- were 
selected for further cellular evaluation of the MDM2/p53 inhibitors. The cells were 
treated with 10 µM and 20 µM NU8354 for 6, 24 and 48 hours respectively, and the 
concentration of Nutlin-3 was 10 µM with the same time scale of treatment as 
NU8354. Cells were lysed after treatment for each time point and levels of MDM2, p53 
and p21WAF1 were investigated by western blotting (Figure 4. 4-a, b&c). 
The SJSA-1 cell line western blot result (Figure 4. 4-a) showed that all the tested stage 
1 isoindolin-1-one compounds were be able to induce p53 accumulation with a 
dose-dependent downstream target MDM2 and p21 activation in SJSA-1 cells; and 
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their cellular activities were similar to the Nutlin-3 effect. NU8354 was the most potent 
one also in western blotting assay. 
Both Nutlin-3 and NU8354 have the ability to inhibit the interaction between MDM2 
and p53 protein and activate p53-dependent transcription and consequent protein 
accumulation when compared with DMSO solvent control, as evidenced by the 
induction of increased levels of p53, MDM2 and p21WAF1 protein after 6 and 24 hours 
treatment. For both Nutlin-3 and NU8354, at the longer treatment time of 48 hours 
MDM2 and p21WAF1 protein levels tended to decrease compared with the 24 hour 
levels, although interestingly the p53 protein levels continued to increase. These 
results indicated that NU8354 can inhibit the MDM2-p53 protein-protein interaction 
with a similar mechanism to Nutlin-3, although with slightly lower potency than 
Nutlin-3.  
A comparison of the western blotting bioassay results between HCT116p53+/+ and 
HCT116p53-/- cell lines (Figure 4. 4-b and -c) showed that p53, MDM2 and p21 protein in 
both Nutlin-3 and NU8354 treated HCT116 p53+/+ tumour cells increased markedly 
compared to DMSO solvent control by 6 hours. In contrast, there were no p53 protein 
bands, as expected, and very faint MDM2 bands in the western blot result of 
HCT116p53-/- tumour cells, although the p21 protein bands were still detectable, but 
without marked variation. At longer time points, Nutlin-3 showed continued activity 
against HCT116p53+/+ tumour cells, but the cellular effect of NU8354 tended to 
decrease markedly from 6 h to 24 h and then 48 h, especially at the 20 µM 
concentration. Based on these observations, the stability of NU8354 has to be 
considered, although the exact reason has not been determined so far.  
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Figure 4.2-a 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2-b 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2-c 
 
Figure 4. 2 Western blotting evaluations of dose-dependent cellular effects of selected stage 
1 isoindolin-1-one compounds and Nutlin-3 using the SJSA-1 cell line 
Cells were treated with increasing concentrations of isoindolin-1-one compounds (1µM, 10 µM and 20 µM) and 
positive control Nutlin-3 (0.5 µM, 1 µM and 10 µM). Then cells were lysed after treatment with compounds for 4 
hours. Proteins involved in p53-dependent cell regulation including MDM2, p53 and p21
WAF1
 were detected by 
western blot analysis and either β-actin protein was evaluated as a loading control. 
 
Nutlin-3 NU8354 NU8361 NU8354 
DMSO  0.5  1  10   1   5   20   1   10  20  0.5  1   10 M 
MDM2 
p53 
p21 
Actin 
Actin 
Nutlin-3 NU8357 NU8358 NU8359 
DMSO  0.5  1  10   1  10   20  1   10  20   1  10   20 M  
MDM2 
p53 
p21 
Nutlin-3 NU8352 NU8353 NU8354 
DMSO 0.5  1   10   1  10   20  1   10  20  1   10  20 M  
MDM2 
p53 
p21 
Actin 
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Figure 4.3-a 
 
 
Figure 4.3-b 
 
 
 
Figure 4.3-c 
 
Figure 4. 3 Densitometry analyses of protein bands densities of MDM2, p53 and p21WAF1 for 
the western blotting results in Figure 4.2 
The densitometry analyses results confirmed the observation in Figure 2 with a quantitative comparison.  
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Figure 4.4-a (SJSA-1 Cell Line) 
      
 
Figure 4.4-b (HCT116 p53+/+ Cell Line)  
 
     
 
Figure 4.4-c (HCT116 p53-/- Cell Line) 
 
Figure 4. 4 Western blot analysis of p53, MDM2 and p21 WAF1 for three time points of 
treatment with NU8354 compared with Nutlin-3 in a) SJSA-1, b) HCT116p53+/+ & c) HCT116p53-/- 
cell lines 
Cells were treated with increasing concentrations of isoindolin-1-one compounds (1µM, 10 µM and 20 µM) and 
positive control Nutlin-3 (0.5 µM, 1 µM and 10 µM). Then cells were lysed after treatment with compounds for 4 
hours. Proteins involved in p53-dependent cell regulation including MDM2, p53 and p21
WAF1
 were detected by 
western blot analysis and either β-actin protein was evaluated as a loading control. 
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4.2.2  Western Blot Comparison of MDM2/p53 Inhibitors and X-ray 
Irradiation Time Course Cellular Effects 
To obtain a better understanding of the different mechanisms of activating the p53 
pathway, the effect of MDM2/p53 binding antagonists was compared with DNA 
damage induced by X-ray irradiation using SJSA-1 and NGP tumour cell lines (Figure 4. 
5 & Figure 4. 6).  
The images in Figure 4. 5 show the response of the SJSA-1 cell line with different 
treatments. Changes in MDM2, p53 and p21WAF1 protein levels were investigated, 
together with ser15-p53 phosphorylation. β-actin was probed for as a loading and 
transfer control.  
The DMSO control (Figure 4. 5-1) showed very stable expression of MDM2 protein and 
no marked p53 pathway protein induction in all the sample time points.  
Shortly after X-ray irradiation treatment (10 minutes), the ser-15 p53 band density 
increased and peaked at 1-2 hours, before decreasing back to near control 
unirradiated levels by 4 hours (Figure 4. 5-5).  
With Nutlin-3 and MI-63 treatment (Figure 4. 5-3 & 4), the ser-15 p53 signal appeared 
later than the increase in p53, and the increase were maintained continuously from 
the 2 hour treatment samples to 48 hour treatment samples.  
The effect of 5µM NU8354A (Figure 4. 6-2) was different from both of them. The 
expression of p53 was detected as early as 30 minutes after compound treatment, and 
achieved highest band density after 2 hour treatment, then continued to be detectably 
elevated for 48 hours; but the ser-15 p53 phosphorylation was detected from 30 mins 
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after compound treatment, and then continued to increase in the 2 hour time point 
sample, returning to only faintly detectable levels in all the remaining time point 
samples.  
On the other hand, the pattern of activation of the p53 pathway downstream targets, 
MDM2 and p21 was quite similar in SJSA-1 cell line samples with all three compound 
treatments (Figure 4. 5-2, 3 & 4). The MDM2 protein expression started to increase 
after 2 hours compound treatment, then remained over 24 hours of compound 
treatment, before slightly decreasing in the 48 hours time point samples. The 
accumulation of p21 protein started at the 4 hours time point samples and continued 
to increase untill the 24 hours time point, and then continued to increase in the 
NU8354A and Nutlin-3 treated 48 hour time point samples, but decreased in the MI-63 
treated 48 hours time point sample. With X-ray irradiation, both MDM2 and p21 
protein expression in the SJSA-1 cell line started to increase in the 2 hours time point 
sample, and then remained elevated for up to 48 hours (Figure 4. 5-5). 
In summary, based on the time course western blot comparison result using SJSA-1 
cancer cells, the NU8354A showed similar cellular effect as the published potent 
MDM2-p53 interaction antagonists Nutlin-3 and MI-63 induced cellular response 
(mainly relys on interruption of MDM2-p53 binding interaction), which is different 
from the X-ray irradiation reaction (mainly relys on p53 phosphorylation). The 
observation of multiple protein bands above and /or below p53 and p21 may need 
further experiment to confirm their existence and explore the mechanism in future.     
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Figure 4.5-1 DMSO Control 
 
Figure 4.5-2 NU8354A 5 μM Treatments 
 
Figure 4.5-3 Nutlin-3 5 μM Treatments 
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Figure 4.5-4 MI-63 5 μM Treatment 
 
Figure 4.5-5 X-ray Irradiation Treatments 
Figure 4. 5 Western blot time courses of SJSA-1 cellular effects comparing NU8354A with 
Nutlin-3, MI-63 and X-ray irradiation treatments. 
The time course effects of MDM2/p53 inhibitors Nutlin-3, MI-63 and the isoindolin-1-one compound ‘NU8354A’ 
were compared together with DMSO control and X-ray irradiation by using SJSA-1 cell line. Plated cells were treated 
with either 1% DMSO, test compounds at 5 µM, or 6.3 Gy X-ray radiation; cell lysates were then collected at each 
time point and analyzed by western blotting. MDM2, Ser-15 phosphorylated p53, p53, p21 protein expression were 
considered, and actin was probed as a loading and transfer control.   
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The cellular responses of the NGP cell line with various treatments are displayed in 
Figure 4. 6. Levels of proteins involved in p53-dependent cell regulation including 
MDM2, p53, p21WAF1, PUMA and cleaved caspase-3 were investigated by western 
blot analysis, and changes in MDMX, ser15-p53 and β-actin were also evaluated. 
The DMSO control result (Figure 4. 6-1) illustrated very stable expression of MDMX 
protein and no marked p53 pathway protein expression in all time point samples. The 
only protein expression variation that was detected was PUMA protein accumulation 
from 12 hours to 48 hours.  
Both Nutlin-3 and MI-63 treated NGP cell samples showed obvious p53 pathway 
activation (Figure 4. 6-3, 4). Noticeable accumulation of p53 started from after 2 hours 
compound treatment, and this increase was maintained over the 48 hours compound 
treatment; MDM2 accumulation started from 4 hours compound treatment and then 
was reduced in the 24 and 48 hour samples; p21 accumulated markedly from 8 hours 
drug treatment then was reduced after 48 hours drug treatment; cleaved caspase-3 
activation was evident after 24 and 48 hours treatment. Following the peak 
accumulation of MDM2, MDMX protein expression started to decrease at the 12 hours 
time point with the Nutlin-3 treatment, and much later but to a greater extent with 
the MI-63 treatment at the 24 hours time point, and could not be detected in 48 hour 
time point samples. Interestingly, the expression trends of PUMA in samples treated 
by both of the two drugs were quite similar, and the accumulation starting time points 
were the same as for p53 protein accumulation. 
The NGP cell responses with 5 µM NU8354A treatment were not very marked (Figure 
4. 6-2), which might because of the lower potency of the compound compare to 
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Nutlin-3 and MI-63. However, accumulation time points of p53, MDM2 and PUMA 
were the same with Nutlin-3 and MI-63 treated cell samples, although protein band 
densities were very low. Furthermore, decreased MDMX expression was also detected 
in the 48 hour time point sample. 
The X-ray irradiation effects were quite different (Figure 4. 6B-5). The MDMX 
expression started to decrease only 30 minutes after irradiation, and then continued 
until the end, although there was no marked MDM2 accumulation in all time point 
samples. Marked Ser-15 p53 phosphorylation was detected in 2 hours post-irradiation 
sample, decreased by 4 hours and almost vanished at subsequent time points. PUMA 
accumulation started to be detected by 2 hours, continued to increase until 48 hours, 
although there was no detectable accumulation of p53 protein. Accumulation of p21 
protein was detected at 8 and 24 hour time points, with a reduced level at the 
intervening 12 hour time point. No cleaved caspase-3 was detected in any of the X-ray 
irradiated samples. 
In summary, based on the time course western blot comparison result using NGP 
cancer cells, the NU8354A showed similar but weaker cellular effect than the 
published potent MDM2-p53 interaction antagonists Nutlin-3 and MI-63 induced 
cellular response, which is different from the X-ray irradiation reaction (mainly relys on 
p53 phosphorylation). Moreover, as one of the indicators of apoptosis pathway 
activation, cleaved caspase-3 showed better specificity than PUMA, since PUMA 
expression was not only detected in MDM2 antagonists and X-ray irradiation treated 
samples, but also in DMSO treated samples, although the initiating time is different.   
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Figure 4.6-1 DMSO Control 
 
Figure 4.6-2 NU8354A 5 μM Treatment 
 
Figure 4.6-3 Nutlin-3 5 μM Treatment 
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Figure 4.6-4 MI-63 5 μM Treatment 
 
 
Figure 4.6-5 X-ray Irradiation Treatment 
 
Figure 4. 6 Western blot time courses of NGP cellular effects comparing NU8354A with 
Nutlin-3, MI-63 and X-ray irradiation treatments. 
The time course effects of MDM2/p53 inhibitors Nutlin-3, MI-63 and the isoindolin-1-one compound ‘NU8354A’ 
were compared together with DMSO control and X-ray irradiation by using NGP cell line. Plated cells were treated 
with either 1% DMSO, test compounds at 5 µM, or 6.3 Gy X-ray radiation; cell lysates were then collected at each 
time point and analyzed by western blotting. MDM2, MDMX, Ser-15 phosphorylated p53, p53, PUMA, p21 and 
cleaved caspase 3 expression were considered, and actin was probed as a loading and transfer control.   
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4.2.3 Western Blot Analysis of the Cellular Effects of Potent Stage 2 and 3 
Isoindolin-1-one Compounds 
The three most potent stage 2 (Figure 4. 1) isoindolin-1-ones NU8399, NU8405 and 
NU8406 were selected for dose-dependent cellular activity evaluation by using SJSA-1, 
HCT116+/+ and HCT116-/- cell lines; with Nutlin-3 as positive control. Compound 
structures and western blotting results are displayed in Figure 4. 7, Figure 4. 8 & Figure 
4. 9. 
The western blotting results for both SJSA-1 and HCT116+/+ cell lines indicated that 
NU8399 induced less p53 accumulation and p53 downstream targets MDM2, p21 
activation than expected on the basis of its relative IC50 value in the cell-free ELISA. 
This means its cellular potency was not corresponding to the IC50 value. The result of 
HCT116-/- indicated that all these compounds have no cellular effects in p53 null cancer 
cells. 
 
 
 
 
 
Figure 4. 7 Structures, molecular weights and IC50 values of stage 2 isoindolin-1-one 
compounds selected for western blot analysis. 
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Cl
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 NU8406 MW 512.37  NU8405 MW 492.95  NU8399 MW 535.03 
152 ± 27 nM (n=3) 274 ± 35 nM (n=3) 143 ± 26 nM (n=3) 
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Figure 4. 8 Western blot result of selected stage 2 isoindolin-1-one compounds compared 
with Nutlin-3 using the SJSA-1 cell line 
   
 
 
 
                         HCT116+/+ 
 
 
 
                         HCT116-/- 
 
Figure 4. 9 Western blot result of selected stage 2 isoindolin-1-one compounds compared 
with Nutlin-3 using HCT116+/+ &-/- cell lines 
  
158 
 
The three most potent stage 3 isoindolin-1-one compounds were selected for dose 
dependent cellular activity evaluation using the SJSA-1 cell line with Nutlin-3 as a 
positive control. Compound structures and western blotting results are displayed in 
Figure 4. 10 & Figure 4. 11. 
In addition to p53, MDM2 and p21, the protein expression levels of PARP and p53 
ser-15 phosphorylation status were also considered. Both NCL-00016149 and 
NCL-00016659 showed quite similar dose-dependent cellular effects to those observed 
with the postive control Nutlin-3, although NCL-00016653 induced slightly less p53 and 
phosphorylated p53 ser-15 accumulation in the SJSA-1 cell line. 
          
 
 
 
Figure 4. 10 Structures, molecular weights and IC50 values of stage 3 isoindolin-1-one 
compounds selected for western blot analysis. 
 
 
NCL-00016149  MW 613.48  
15.8 ± 2.6 nM (n=3)  
NCL-00016653   MW 647.37 
119 ± 17 nM (n=3)  
NCL-00016659   MW 593.49  
97 ± 30 nM (n=3)  
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Figure 4. 11 Western blot showing the dose dependent effect of selected stage 3 
isoindolin-1-one compounds compared with Nutlin-3 using SJSA-1 cell line. 
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4.2.4 Potency Comparison of Isoindolin-1-one Enantiomers 
4.2.4.1 Background 
Because of the chiral carbon present in the isoindolin-1-one core structure, all of the 
isoindolin-1-one compounds synthesised are racemic mixtures. Furthermore, the 
shape of the MDM2 binding pocket strongly suggests that inhibition of p53 binding by 
isoindolin-1-ones is likely to be stereoselective, i.e. only one enantiomer was able to 
interrupt the MDM2/p53 binding effectively, and the other one not or only showed 
weak activity. This possibility would contribute to further structure design. To address 
this question, the resolving of pure enantiomers was required. 
NU8354 enantiomers were resolved successfully by using chiral HPLC (by Dr Karen 
Haggerty) (Figure 4. 12), and designated NU8354 A (the first eluting peak in chiral 
HPLC) and NU8354 B (the 2nd peak in chiral HPLC) for activity evaluation and 
comparison. 
 
Figure 4. 12 Resolution of enantiomers of NU8354 by using HPLC and a chiral column. 
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Then, following the successful design and synthesis of stage 2 compounds, 
enantiomers of the key compound NU8406 were also successfully resolved by using 
chiral HPLC (by Dr Karen Haggerty) (Figure 4. 13), and designated NU8406 A (the first 
peak in chiral HPLC) and NU8406 B (the 2nd peak in chiral HPLC) for activity evaluation 
and comparison using the same methods used for NU8354. 
 
Figure 4. 13 Resolution of enantiomers of NU8406 by using HPLC and a Prep-chiral column. 
Nutlin-3, NU8354, NU8354A, NU8354B, NU8406, NU8406A and NU8406B were 
evaluated for their relative activity as MDM2-p53 binding antagonists. The ELISA 
method was used for cell-free IC50 evaluation, and comparison and western blotting 
for intact cell activity as indicated by altered levels of proteins involved in 
p53-dependent cell regulation including MDM2, p53 and p21WAF1; α-tubulin expression 
was also investigated for loading and transfer control, and the SRB method was 
employed to determine cell culture growth inhibition (GI50) in response to antagonist 
treatment. The SJSA-1 osteosarcoma cell line was used for evaluation of cellular 
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response. Data analysis was carried out using PRISM software for IC50 determination, 
generating growth inhibition curves and enabling GI50 determination. 
4.2.4.2 NU8354 racemic mixture and NU8354 A & B enantiomers comparison 
The structures of racemic NU8354 and NU8354A & B are displayed below. The A and B 
nomenclature was initially designated (Figure 4. 14) without a knowledge of which of 
the two enantiomers they corresponded to. 
 
 
 
 
 
 
 
Figure 4. 14 NU8354 and Related Enantiomer Structures 
 
4.2.4.2.1 IC50 determination and comparison. 
As displayed in Figure 4. 15, with the successful separation of the two enantiomers, we 
obtained a more potent homochiral compound NU8354A with an IC50 = 164 nM 
compared to the racemic mixture NU8354 (IC50 = 269 nM). The other enantiomer 
NU8354B was much less active with the IC50 > 1 µM. 
NU8354 
(R)-3-(4-chlorophenyl)-3-((1-(hydroxymet
hyl)cyclopropyl)methoxy)-2-(4-nitrobenz
yl)isoindolin-1-one 
NU8354 (A & B) 
(S)-3-(4-chlorophenyl)-3-((1-(hydroxymet
hyl)cyclopropyl)methoxy)-2-(4-nitrobenz
yl)isoindolin-1-one 
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Figure 4. 15 IC50 Comparison of NU8354 Enantiomers. 
4.2.4.2.2 Western blot comparison of the cellular response to NU8354 
nnantiomers. 
As can be seen in Error! Reference source not found., both NU8354 and NU8354A 
treated SJSA-1 cells showed a marked dose-dependent accumulation of p53, MDM2 
and p21 proteins as observed with Nutlin-3 treated SJSA-1 cells; however, even 20 µM 
NU8354B did not induce an obvious increase in p53 and its downstream targets MDM2 
and p21, which reflected the cell-free (ELISA) potency difference between the two 
enantiomers. 
 
Figure 4. 16 Western Blot Analysis of the Cellular Response to NU8354 enantiomers. 
(SJSA-1 Cell Line) 
NU8354 A NU8354 B 
164 ± 18 nM (n=7) 1333 ± 120 nM (n=7) 
NU8354 
269 ± 12 nM 
(n=8) 
≈1:1.6 
≈1:8 
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4.2.4.2.3 SRB assay for cellular GI50 evaluation and comparison. 
In order to confirm the cellular response difference between the two NU8354 
enantiomers, their growth inhibitory effects on SJSA-1 cells were evaluated using the 
SRB method. The SJSA-1 cell line growth inhibition curves and GI50 values in response 
to NU8354A & B are presented in Figure 4. 17, which shows the marked difference in 
growth inhibition and 4-fold difference of GI50 values in response to the two 
enantiomers, with NU8354A being the more active form, consistent with the 
difference in IC50 observed in cell-free assays and p53 activation in intact cells. 
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Figure 4. 17 Comparison of the Growth Inhibitory Effect of NU8354 Enantiomers. 
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4.2.4.3 Comparison of NU8406 racemic mixture with NU8406 A & B 
The structures of NU8406 racemic mixture and NU8406A & B are displayed below. The 
A and B nomenclature was initially designated (Figure 4. 18) without determining 
which of the two enantiomers they corresponded to in absolute term. 
        
 
 
Figure 4. 18 NU8406 enantiomers structures 
 
4.2.4.3.1 IC50 determination and comparison. 
With the successful separation of the two enantiomers, a markedly more potent 
enantiomer, NU8406A (IC50 = 40 nM), was obtained, with almost a 4-fold higher 
potency compared with the racemic NU8406 (IC50 = 143 nM). The less potent 
enantiomer, NU8406B, was also obtained, which was 32-fold less active than 
NU8406A, with an IC50 value above 1 µM (Figure 4. 19). 
 
NU8406 
(R)-4-chloro-3-(4-chlorophenyl)-3-((1-(hy
droxymethyl)cyclopropyl)methoxy)-2-(4-
nitrobenzyl)isoindolin-1-one 
NU8406 (A & B) 
(S)-4-chloro-3-(4-chlorophenyl)-3-((1-(hy
droxymethyl)cyclopropyl)methoxy)-2-(4-
nitrobenzyl)isoindolin-1-one 
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Figure 4. 19 IC50 Comparison of NU8406 Enantiomers. 
 
4.2.4.3.2 Western blot comparison of the cellular response to NU8406 resolved 
enantiomers. 
The cellular effect of the NU8406 series of compounds can be seen in Figure 4. 20. 
Both NU8406 and NU8406A treated SJSA-1 cells showed a marked dose-dependent 
accumulation of p53, MDM2 and p21 proteins comparable to Nutlin-3 treated SJSA-1 
cells; however, even a 20 µM concentration of NU8406B did not induce an obvious 
increase of p53, although there was some dose-dependent accumulation of its 
downstream targets, MDM2 and p21, which to some extent reflected the potency 
difference between the two enantiomers, but also indicated that the less potent 
enantiomer can also show some activation of p53 at higher doses, possibly by a 
weaker interruption of the MDM2/p53 binding interaction or off-target effects. 
  
NU8406 A NU8406 B 
40 ± 5 nM (n=3) 1270 ± 10 nM (n=3) 
NU8406 
143 ± 26 nM (n=4) 
≈1:3.6 
≈1:32 
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Figure 4. 20 Western Blot Analysis of the Cellular Response to NU8406 enantiomers. 
(SJSA-1 Cell Line) 
 
 
4.2.4.3.3 SRB assay for cellular GI50 evaluation and comparison. 
In order to confirm whether the difference in p53 pathway response translates into a 
growth inhibitory difference between the two NU8406 enantiomers, and also to 
compare them with the NU8406 racemic mixture, SRB assays were carried out. The 
SJSA-1 cell line growth inhibition curves and GI50 values in response to the three 
compounds are presented in Figure 4. 21, which shows an 8-fold difference of GI50 
values in response to treatment with the two enantiomers. Moreover, the GI50 values 
of the three compounds correlated closely with the differences in their IC50 values. 
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Figure 4. 21 Comparison of the Growth Inhibitory Effect of NU8406 Enantiomers. 
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4.3 The Growth Inhibitory Activity (GI50) of Isoindolin-1-one 
Compounds compared with Nutlin-3 and MI-63 
4.3.1 Background 
With the improved activity of isoindolin-1-ones as the MDM2/p53 inhibitor drug 
development project progressed, we obtained the compounds NCL-00016149 and 
NU8406A with comparable IC50 values to those published for Nutlin-3 and MI-63. For 
accurate comparison, SRB assays were performed to compare MI-63 and Nutlin-3 side 
by side with our high potency isoindolin-1-one compounds. 
4.3.2 Materials and Methods 
Cell line: Osteosarcoma cancer cell SJSA-1, Neuroblastoma cancer cell NGP; 
Compounds: MI-63, Nutlin-3, NCL-00016149, NU8406, NU8406A and NU8406B; Drug 
concentration range: 0.5, 1, 2, 4, 8, 10, 15, 20 µM for MI-63, Nutlin-3, NU8406, 
NU8406A; 0.5, 1, 2, 4, 6, 8, 10, 20 µM for NCL-00016149; 1, 2, 5, 10, 20, 30, 40, 50 µM 
for NU8406B. The SRB assay with a re-designed plate arrangement was used to 
evaluate growth inhibitory effects and PRISM software was used to generate growth 
inhibition curves and determine GI50 values. 
4.3.3 Results 
The growth Inhibition Curves of the six compounds against SJSA-1and NGP cancer cell 
lines are displayed in Figure 4. 22; the IC50 values of the six compounds and the 
absolute GI50 values with the SJSA-1 and NGP cancer cell lines are listed in Table 4. 1. 
By using MI-63 values as standard values and dividing each value with their 
corresponding standard value, we have generated Table 4. 2 such that the relative 
differences in IC50 and GI50 values can be more easilly compared. 
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Based on the growth inhibition curves in Figure 4. 22 and GI50 values in Table 4. 1, 
NCL-00016149 showed comparable growth inhibitory effects to those published for 
the potent MDM2/p53 inhibitors, MI-63 and Nutlin-3.  
Alhough NCL-00016149 showed higher potency than NU8406 and NU8406A in the 
ELISA results, its cellular activity was lower than NU8406A in both of the two cell lines. 
Also, the two cell lines showed slightly different cellular response to NU8406 
enantiomers. 
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Growth Inhibition Activity Comparison Result_NGP Cell Line
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Figure 4. 22 SRB Assay Comparison of the Growth Inhibitory Effects of MDM2/p53 Inhibitors 
against (A) SJSA-1 and (B) NGP Cell Lines. 
 
Table 4. 1 IC50 and SJSA-1 and NGP Cell Line GI50 value Comparison of Potent MDM2/p53 
Interaction Inhibitors 
 
Table 4. 2 MDM2/p53 Inhibitors IC50 value and SJSA-1 and NGP Cell Line GI50 Standardised 
Value Comparison 
 
  
Compounds MI-63 Nutlin-3 NCL-00016149 NU8406 NU8406A NU8406B 
ELISA IC50 (nM) 9.0 ± 1.3 103.3 ± 
10.6 
18.9 ± 4.1 143.0 ± 
26.0 
42.8 ± 
2.6 
1270.0 ± 
10.0 
SJSA-1_GI50 (µM) 1.3 ± 0.2 1.6 ± 0.1 4.6 ± 0.4 3.8 ± 0.1 2.3 ± 0.1 20.1 ± 1.9 
NGP_GI50 (µM) 1.8 ± 0.1 5.2 ± 0.5 8.2 ± 0.7 10.7 ± 3.8 7.9 ± 1.9 17.7 ± 1.5 
Compounds MI-63 Nutlin-3 NCL-00016149 NU8406 NU8406A NU8406B 
ELISA IC50 std. 1 11.5 2.1 15.9 4.8 141.1 
SJSA-1_GI50 std. 1 1.2 3.5 2.9 1.8 15.5 
NGP_GI50 std. 1 2.9 4.6 5.9 4.4 9.8 
B 
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4.4 Apoptotic Effect of Isoindolin-1-one Compounds in SJSA-1 
Cells 
4.4.1 Background 
 In the last section, the growth inhibition effects and p53 pathway activation induced 
after 4 hours by NU8354 and NU8406 isoindolin-1-one enantiomers was presented, 
and demonstrated the difference between the cellular effect of the racemic mixture 
and that of the potent and less active separated enantiomers. This section describes 
experiments to measure the potential apoptotic effects consequent on p53 pathway 
activation, using western blot analysis of poly (ADP-ribose) polymerase (PARP) and 
caspase 3 protein cleavage, and a caspase 3 & 7 luminometer-based enzyme activity 
assay. 
The time course of apoptotic response to 5 µM NU8354A, Nutlin-3 and MI-63 
treatment was determined, and compared with the response to X-ray irradiation as a 
positive control. The response to the inactive enantiomer, NU8406B, was also included 
as a non-potent, but structurally closely related control. 
4.4.2 Results 
Microscope images of SJSA-1 cells treated with a range of compound concentrations 
for 48 hours were taken before collecting the cell lysates (Figure 4. 23). The images 
showed very marked cell density differences compare with the DMSO control when 
treated with high concentrations (Nutlin-3 10 µM, NU8354A 20 µM, NU8406A 10 and 
20 µM) of the compounds.  
With increasing compound concentration, there were fewer cells still attached to the 
bottom of sample wells and more cells floating in the medium. 
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      DMSO              Nutlin-3 1 µM          Nutlin-3 10 µM 
 
NU8354A 1 µM         NU8354A 10 µM         NU8354A 20 µM 
 
NU8406A 1 µM            NU8406A 10 µM       NU8406A 20 µM 
 
NU8406B 1 µM          NU8406B 10 µM         NU8406B 20 µM 
Figure 4. 23 SJSA-1 Cell Images with 48 hours Antagonist Treatment 
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Based on this observation, it would be interesting to check the whole protein 
concentration in the cell lysate samples that were collected by using the same amount 
of lysate buffer to confirm the cellular effects of the MDM2 antagonists quantitatively, 
which is like a simple version of SRB assay. The protein concentrations of all cell lysate 
samples were evaluated by using the BCA assay (see Section 2.3.4) and the results 
were generated using GraphPad Prism software and displayed in Figure 4. 24.  
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Figure 4. 24 BCA Assay Showed Marked Protein Concentration Variation of the Cell Lysate 
Samples in a Dose- and Potency-Dependent Manner 
The result showed that the protein concentration of cell lysate samples after 48 hours 
compounds treatment were markedly different, which reflected the dose and potency 
dependent cellular effects and correlated with the images displayed in Figure 4. 23 . As 
can be seen from Figure 4. 24 , both 20 µM NU8354A and NU8406A treated samples 
showed a lower protein concentration than 10 µM Nutlin-3 treated sample, which is 
very close to the 10 µM NU8406A treated sample. On the other hand, the inactive 
175 
 
enantiomer NU8406B has also shown a dose-dependent reduction in protein content, 
although the effect was much less than for other compounds. 
After equalising the protein concentration of each sample, a western blot analysis was 
carried out with the 48 hours drug treated SJSA-1 cell lysate samples, loading an equal 
amount of protein (Figure 4. 25).  
 
 
 
 
 
 
   
Figure 4. 25 Western blot result of SJSA-1 cells treated with MDM2 antagonists for 48 hours 
The results indicated that MDM2 antagonist treatment caused p53 stablization and 
accumulation, p53 ser-15 phosphorylation and then p53 downstream pathway 
activation indicated by an increase of MDM2 and p21 protein level. In addition, the 
induction of apoptosis markers was observed, with cleaved caspase-3 protein and the 
cleavage of PARP protein with the high concentration Nutlin-3 (10 µM), NU8354A (10 
& 20 µM) and NU8406A (10 & 20 µM) treatment. The western blot result also showed 
that high concentration NU8406B (20 µM) can also induce some p53 downstream 
target MDM2 and p21 accumulation, but with no evidence of apoptosis markers.  
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Interestingly, markedly decreased MDM2, p21 and PARP protein expression was 
observed in the 20 µM NU8406A treated sample, which correlated with the limited cell 
number after 48 hours drug treatment as displayed in Figure 4. 24; however, as the cell 
images in Figure 4. 23 displayed, with 10 µM Nutlin-3 and 20 µM NU8354A treatment, 
the attached cell numbers were also very low, but in their corresponding western blot 
result, the expression of MDM2 and p21 has no marked decrease, so the reduction in 
cell number is not by itself responsible for the reduced expression. 
To provide additional confirmatory evidence of an apoptotic effect, the Caspase-Glo 
3/7 enzymatic assay (see Section 2.5) was used, which can numerically evaluate the 
relative caspase-3/7 activity in cells treated by cytotoxic compounds as an indicator of 
apoptosis effect (Figure 4. 26). 
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Figure 4. 26 Caspase-Glo 3/7 assay for SJSA-1 cells treated with MDM2 antagonists for 48 
hours indicated the dose-dependent cellular effect of apoptosis induction. 
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As displayed in Figure 4. 26 , NU8354A started to induce caspase 3/7 activity from 5 
µM and showed a dose-dependent effect up to 20 µM concentration, then plateaued 
at 30 µM. As a more potent isoindolin-1-one compound based on IC50, NU8406A 
started to induce caspase 3/7 activation at 2 µM concentration, continued to show 
dose-dependent effect higher than the NU8354A induced caspase 3/7 activity with 
each concentration and plateaued at 20 µM concentration to approximately 22 fold 
higher than untreated cells, then dropped down to about 16 fold, which was even 
lower than the 30 µM NU8354A induced casease 3/7 activity. As a positive control, 
Nutlin-3 has also shown the ability to induce dose-dependent caspase 3/7 activation. 
Interestingly, 20 µM NU8406B has also slightly induced caspase 3/7 activation, which 
indicated that the sensitivity of this assay for Caspase 3 activity detection is higher 
than the western blot assay; above 11 fold increase of caspase 3/7 activity was 
obtained by enhancing the NU8406B concentration to 30 µM, which together with the 
western blot result, confimed that NU8406B can still induce caspase 3/7 activation by 
interrupting p53-MDM2 binding (or maybe due to some off-target effect at such high 
dose), although the caspase 3/7 activation effect is much weaker than for NU8406A. 
4.5 Conclusion and Discussion 
4.5.1 The Cellular Effects of the Lead Isoindolin-1-ones are Comparable to 
Nutlin-3 Treatment 
As a result of progressive lead optimisation, a series of isoindolin-1-one compounds 
was developed that had activity as inhibitors of MDM2-p53 binding with cell free ELISA 
IC50 values in the range from 15.8 nM (NCL-00016149) to 269 nM (NU8354), 
comparable to the IC50 measured for Nutlin-3 in the same assay. Once in this range, 
compounds (NU8354, NU8361 and NU8406, etc.) were chosen to test for activity as 
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disrupters of the MDM2-p53 binding interaction and activators of the p53 pathway in 
intact cells. The selected isoindolin-1-one compounds produced a dose-dependent 
increase of MDM2, p53 and p21 protein band densities, consistent with the release of 
p53 from MDM2 binding and p53-dependent transcriptional transactivation (Figure 4. 
2, Figure 4. 8 and Figure 4. 11). The semi-quantitative analysis of the band densities 
indicated that the cellular activity of NU8354 and NU8361 was approximately two- to 
three- times less potent than Nutlin-3. 
Most of the isoindolin-1-one compounds’ cellular activities were related to their 
potencies (IC50) evaluated by the cell-free ELISA. However, NU8399 showed an 
impaired cellular response that did not correlate with its IC50 value (Section 4.2.4). This 
observation indicated the possibility that compound physical characteristics, such as 
hydrophilicity, H-bonds, etc., may influence solubility, cellular uptake and stability in 
cell culture environment. 
Stage 3 compounds NCL-00016149, NCL-00016653 and NCL-00016659 also showed 
similar marked dose-dependent cellular effects, as seen with Nutlin-3, but were not as 
potent as Nutlin-3 in the cellular assays as might have been expected from their ELISA 
IC50 values. However, they were previously designed as prodrugs that contain ionizable 
side chains and these charged side chains may prevent them from readily passing 
through cell membranes. As a result, further research would have to be carried out to 
examine if they were hydrolyzed before entering the cells or not. 
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4.5.2 The Mechanism of p53 Pathway Activation by MDM2-p53 Binding 
Antagonists differs from that of X-ray irradiation 
The time course of cellular responses to NU8354, together with Nutlin-3 and MI-63 
treatment when compared with the effect of X-ray irradiation (Figure 4. 5 & Figure 4. 
6) indicated differing mechanisms of p53 pathway activation.  
With X-ray irradiation, the p53 protein levels increased half an hour after the detection 
of p53 ser-15 phosphorylation, which is caused by activation of the ATM pathway 
(186). In contrast, with the MDM2/p53 inhibitor treatments, the p53 protein 
accumulated about half an hour earlier than the increase of p53 ser-15 
phosphorylation. Also from Figure 4. 5 & Figure 4. 6, it can be seen that p53 
downstream target MDM2 expression was enhanced after 2 hours incubation with 
MDM2/p53 inhibitors or X-ray irradiation treatment, which indicated the p53/MDM2 
feedback loop effect was about 1-2 hours later than any activation of the p53 pathway 
by DNA damage dependent phosphorylation.  
These observations indicated that both MDM2/p53 inhibitor treatment and X-ray 
irradiation can activate the p53 downstream pathways when the cancer cells contain 
wild type p53; however, the detailed mechanisms of the two processes are different.  
By using MDM2/p53 inhibitors, we can block the hydrophobic binding pocket of the 
MDM2 protein to prevent binding of the transcriptional activation domain of wt-p53 to 
MDM2 and so break the auto-regulatory feedback loop, allowing the freed wt-p53 to 
activate its downstream pathway. This in turn can cause cell cycle arrest and/or 
apoptosis, and these cellular stresses cause the activation of other pathways and lead 
to p53 phosphorylation as a later event, rather than the initiating event associated 
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with response to DNA damage. It remains to be established whether the later onset 
p53 phosphorylation seen with MDM2-p53 antagonists is necessary to further drive 
activation of the p53 pathway and contribute to growth inhibition and apoptosis.  
4.5.3 Comparison of Isoindolin-1-one Enantiomers 
The ELISA IC50 values showed that enantiomer NU8354A was approximately 8-fold 
more potent than NU8354B and about 2-fold more potent than the racemic mixture, 
which means that enantiomer NU8354A has a better binding affinity with MDM2 
protein than NU8354B.  
Western blotting results using the SJSA-1 cell line confirmed that the potency 
difference between NU8354A and B extended to activity in intact cells. Furthermore, 
NU8354A showed very similar cellular effects to Nutlin-3. 
By applying the SRB assay using the SJSA-1 cell line, growth inhibition GI50 results for 
NU8354A and B were obtained, which showed a 4-fold difference between the 
NU8354A and B enantiomers. 
Noticeably, the difference of potencies between NU8354A and B was not as marked as 
between Nutlin-3a and b (77), which may not be because of the potency difference 
between NU8354 and Nutlin-3 racemic mixtures, but because the binding energies of 
the two enantiomers of NU8354 with the MDM2 protein were closer to each other 
than for Nutlin-3a compared with Nutlin-3b. By analyzing the synthetic route of 
Nutlin(187) series compounds, I observed that single enantiomer starting materials 
were used to limit the number of different enantiomers in the final products, which 
may also have caused the bigger difference between Nutlin-3 enantiomers than 
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between NU8354 enantiomers. Also for this reason, the resolution of Nutlin-3a and b 
was likely to have been much easier than NU8354A and B separation. 
The separation of NU8406A and B enabled us to confirm the relationship between 
isoindolin-1-one compound enantiomer structures and their IC50 values, cellular p53 
activation activities and GI50 values for growth inhibition.  
Since the NU8406 racemic mixture was more potent than the NU8354 racemic 
mixture, as expected the potent enantiomer NU8406A (IC50=40 ± 5 nM) also showed a 
markedly higher potency than NU8354A (IC50=164 ± 18 nM). Moreover, NU8406A was 
3.6 times more potent than the racemic NU8406 and 32 times more potent than 
NU8406B purified enantiomer. The possible reason could be because the introduction 
of a chloro group, not only enhanced the binding affinity of NU8406A with the MDM2 
protein, but also strengthened the stereo specific binding difference between 
NU8406A and B compared with the NU8354 enantiomers.  
Comparison of the SRB assay results of NU8354 enantiomers with NU8406 
enantiomers, demonstrates a clear relationship between compound potency (ELISA 
IC50 value) and their cellular activity. Since these data were obtained by using 
compounds with the same core structure and very similar final structures, they are 
more reliable for illustrating the relationship between the ELISA IC50 values with SRB 
assay GI50 values. 
4.5.4 The Cellular Activity Comparison of MDM2 Antagonists 
By using the SRB assay, the cellular growth inhibitory activity of potent 
isoindolin-1-one compounds NCL-00016149, NU8406A and NU8406 were evaluated 
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together with the published potent MDM2/p53 inhibitors Nutlin-3 and MI-63; NU406B 
was used as a low potency compound control.  
The comparisons of these compounds and their IC50 and GI50 values showed that MI-63 
was still the most potent inhibitor of the MDM2-p53 binding interaction, having the 
lowest IC50 (Table 4. 1) and gave the highest cellular potency of the compounds tested. 
Although the isoindolin-1-one compound NCL-00016149 was 5-fold more potent than 
Nutlin-3 in the ELISA evaluation, its GI50 values in both SJSA-1 and NGP cell lines were 
not only higher than MI-63 generated GI50 values, but also higher than Nutlin-3 
generated GI50 values. On the other hand, the pure enantiomer NU8406A generated 
GI50 values very similar to Nutlin-3 generated values, and even NU8406 had higher 
cellular potencies in the SJSA-1 cell line than NCL-00016149. This observation indicate 
that although derivatizing the (1-(hydroxymethyl)cyclopropane)methoxy side-chain 
with a 4-oxobutanoic acid group has enhanced the binding affinity between the 
isoindolin-1-one compound and the MDM2 protein, either the molecular weight or 
other properties of the compound may have counteracted its activity in the cellular 
assays. 
The western blot assay result for 48 hours treatment of SJSA-1 cell samples with the 
MDM2 antagonists and Caspase-Glo 3/7 assay results confirmed the ability of 
isoindolin-1-one compounds to induce apoptosis. Moreover, NU8406A showed 
comparable cellular effects in SJSA-1 cells to those observed with Nutlin-3.  
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Chapter Five 
Alternative Scaffold Compounds as MDM2/p53 and 
MDMX/p53 Interactions Inhibitors 
 
5.1 Introduction 
With the development of MDM2/p53 interaction antagonists by our research group, 
we were invited to join a European consortium that successfully won a European FP6 
Grant, with the title DePPICT (Designing Therapeutic Protein-Protein Inhibitors for 
Brain Cancer Treatment). This project was focused on α-helix binding groove 
interactions, using the MDM2/p53 interaction as a test-bed for developing design tools 
and thus novel templates. Since its target was brain cancer, blood-brain-barrier 
penetration was taken into consideration together with the drug-like parameters to 
guide design approaches. Since the focus of the project was on α-helix binding groove 
interactions and for the possibility to interrogate in more depth the role of p53 
interactions with MDM2/MDMX proteins via selective (MDM2 or MDMX) or pan-active 
(MDM2 and MDMX) inhibitors, parallel studies on MDMX and its inhibitors were also 
planned. 
One of our responsibilities within this project was the in vitro screening of in silico 
selected small molecular compounds from commercially available compound libraries 
and fragments using MDM2/p53 & MDMX/p53 interactions as test-beds, for 1) better 
understanding of the binding groove of MDM2/MDMX for the purpose of small 
molecular inhibitor design; 2) optimization of computer screening methods, especially 
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for MDM2/p53 and MDMX/p53 interaction antagonists; 3) Confirmation of hits and 
identification of core scaffolds for the purpose of further drug development. 
All together, more than 3800 compounds (4 batches) were screened by me and hit 
compounds were re-evaluated against both MDM2 and MDMX targets by using 
dose-dependent ELISA to generate IC50 values. Optimized binding modes were then 
predicted for hit compounds using automatic docking software combined with manual 
docking. For one hit compound with an IC50 ≤ 10 µM, cellular activity was tested for 
both MDM2 and MDMX inhibitory using the NGP cell line, which is a neuroblastoma 
cell line with MDM2 amplification, wild type p53 and relatively high MDMX expression.  
In addition, some in-house pyrrole scaffold compounds were evaluated using the ELISA 
method to test for activity against both MDM2 and MDMX targets.  
Furthermore, for the purpose of better understanding the difference between 
MDM2/p53 and MDMX/p53 binding, some specially designed peptide analogues of 
p53 were also evaluated and compared using the ELISA, for both MDM2 and MDMX 
inhibition activity. 
5.2 Materials and methods of ELISA for in vitro activity 
evaluation 
All the compounds selected by in silico screening by our colleagues in Siena Biotech 
and Crystax Ltd were available from commercial sources. 
Four batches of compound samples were received as 20 µL 10 mM concentration 
DMSO solutions in 96-well plates, with 63 samples per plate. Hit compounds were 
re-evaluated using the dose-dependent ELISA method and compounds with confirmed 
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activity were resupplied as 100 µL 10 mM DMSO solutions in small tubes after passing 
quality control analysis. 
IV-MDM2 and IV-MDMX protein samples were prepared with the detailed methods 
described in Chapter 2. Nutlin-3 was used as positive control for MDM2 inhibitor 
screening; IP3 peptide and NU8325 (an in-house pyrrole scaffold compound, IC50 = 
4.52±0.28 µM as an MDMX inhibitor, Figure 5. 7) were the positive controls for MDMX 
inhibitor screening. 
For MDM2/MDMX inhibitors screening, the ELISA method was carried out with the 
plate arrangement shown in Figure 5. 1, 63 compounds of the same concentration 
could be screened within one plate. The first three vertical lines of wells were solvent 
controls and three different concentrations of positive controls (Nutlin-3 50, 100, 200 
nM for MDM2 inhibitor screening, IP3 peptide or NU8325 0.1, 1, 10 µM for MDMX 
inhibitor screening) were placed in the top row 9 wells with 3 wells for each 
concentration.  
For dose-dependent IC50 evaluation, the ELISA assay were carried out with the plate 
arrangement shown in Figure 5. 2, 7 compounds could be tested within one plate. The 
first three vertical lines of wells were solvent controls and three different 
concentrations of positive controls (Nutlin-3 50, 100, 200 nM for MDM2 inhibitor 
screening, IP3 peptide or NU8325 0.1, 1, 10 µM for MDMX inhibitor screening) were 
placed in the top row 9 wells. Each concentration of every compound was plated out in 
triplicate at three different concentrations. 
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Figure 5. 1 Plate arrangements for MDM2/MDMX inhibitors screening purpose 
 
Figure 5. 2 Plate for MDM2/MDMX inhibitor dose-dependent activity evaluation 
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5.3 Results 
5.3.1 DePPICT compound screening 
An initial batch of 334 compounds were received from Siena Biotech for MDM2 and 
MDMX inhibitor screening. After screening using the ELISA method, hit compounds 
that showed high percentage inhibition values (> 50 %) were re-tested using the 
dose-dependent ELISA method, and then the cellular activity of the most potent 
compound was evaluated using the NGP cell line. 
5.3.1.1 MDM2 and MDMX Inhibitor Screening via ELISA Assay of the batch 1 
DePPICT compounds 
The screening results against the MDM2 target are displayed in Figure 5. 3. 
Compounds in different plates are grouped by different colour codes and every dot 
represents the percentage inhibition value for one compound. The medium value bars 
of compounds’ inhibition percentage values of each plate were short red lines. A 
dashed red line at the 50% inhibition value position was used to indicate the inhibition 
values above 50%. 
The result in Figure 5. 3a illustrates that with 10 µM final concentration, most of the 
compounds showed less than 50% inhibitory activities against MDM2/p53 interaction 
(between ±40%), and from all of the 334 compounds, only one compound in plate 
0029234 showed inhibitory activity above 50%.  
When the final concentration was increased to 50 µM (Figure 5. 3b), 6 compounds 
showed inhibitory activity above 50% and one of them in plate 0029234 exhibited the 
highest inhibition percentage, and was confirmed as the same one highlighted in 
Figure 5. 3a.  
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Figure 5. 3 a. Inhibitory activity against the MDM2/p53 interaction for the batch 1 
compounds screened at 10 µM final concentration (the most potent one is indicated by a red 
arrow together with its compound ID); b. Batch 1 compounds screened for inhibitory activity 
against the MDM2/p53 interaction with 50 µM final concentration (the most potent one is 
indicated by a red arrow together with its compound ID). 
SEN0040028 
SEN0040028 
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Interestingly, though most of the compounds showed increased inhibitory activity with 
an increase of concentration, there were nevertheless some compounds that showed 
even lower percentage inhibition when using 50 µM final concentrations compared 
with 10 µM final concentrations, especially in plate 0029235 and 0029236. 
The batch 1 compounds with above 30% inhibition values against the MDM2/p53 
interaction at 50 µM final concentrations are listed in Table 5. 1, with their plate 
location, compound ID and 10 µM final concentration inhibition percentage values 
against the MDM2/p53 interaction. 
Table 5. 1 Potent compounds in the batch 1 compounds screening results for inhibitory 
activity against MDM2/p53 interaction. 
Location Compound ID % inhibition (10 µM) % inhibition (50 µM) 
P1B4 SEN0000739 -11.4 33.6 
P1G12 SEN0031371 -0.1 33.1 
P2B7 SEN0031443 -11.8 31.4 
P2D7 SEN0031445 11.0 65.4 
P2F6 SEN0031436 2.5 37.6 
P3C6 SEN0031520 -4.5 84.0 
P3D10 SEN0031562 33.0 44.4 
P3G4 SEN0031505 22.9 76.6 
P3H4 SEN0031506 5.8 40.6 
P3H6 SEN0031526 10.6 33.5 
P3H7 SEN0031536 3.9 31.8 
P3H9 SEN0031558 17.6 46.3 
P4B8 SEN0040028 58.1 94.1 
P4C6 SEN0037768 -1.6 28.9 
P4E7 SEN0040024 -1.0 28.8 
P5D11 SEN0045653 6.3 33.7 
P5E11 SEN0045654 8.1 27.6 
P5F8 SEN0041719 -4.9 43.3 
P5F11 SEN0045655 16.2 72.3 
P5G10 SEN0045649 -8.5 38.0 
P5G11 SEN0045656 -3.5 37.4 
P5H10 SEN0045650 11.9 59.3 
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Compounds with inhibition percentage values higher than 50% at 50 µM are 
highlighted in yellow background, and the compound with the highest percentage 
inhibition value is highlighted by a orange background. The reason of negative 
percentage inhibition data will be discussed in section 5.4.4. 
Structures of the highlighted compounds in Table 5. 1 are shown in Figure 5. 4 and the 
most potent one (SEN0040028) is highlighted in blue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. 4 Structures of the batch 1 hit compounds with inhibitory activity against the 
MDM2/p53 interaction. 
 
              
 
SEN0031445                 SEN0031505   
 
          
 
SEN0031520                    SEN0040028 
 
           
 
SEN0045650                    SEN0045655 
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The result for the first batch of compounds from Siena Biotech screened against the 
MDMX/p53 interaction are displayed in Figure 5. 5.  
Figure 5. 5a shows that at a 10 µM final concentration, most of the compounds 
showed less than 50% inhibition against the MDMX/p53 interaction (between 40% and 
-60%), and only one compound in plate 0029234 showed inhibitory activity above 50% 
in all the screened 334 compounds. Importantly, this compound was confirmed to be 
the one highlighted in Figure 5. 3, which was also the most active against MDM2/p53 
interaction. Further discussion and binding mode prediction see section 5.4.2. 
When the final concentration was increased to 50 µM (Figure 5. 5b), 4 compounds 
showed inhibitory activity above 50% and one of them in plate 0029234 had the 
highest percentage inhibition, and was confirmed to be the same one highlighted in 
Figure 5. 5a. 
Interestingly, it seemed that the increase in compound concentration could only 
enhance the percentage inhibition values of some compounds, and there were still 
some compounds that showed even lower percentage inhibition values, especially in 
plate 0029234. 
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Figure 5. 5 Inhibitory activity against the MDMX/p53 interaction for the batch 1 compounds 
screened at 10 µM final concentration (the most potent one is indicated by a red arrow 
together with its compound ID); b. Batch 1 compounds screened for inhibitory activity 
against the MDMX/p53 interaction with 50 µM final concentration (the most potent one is 
indicated by a red arrow together with its compound ID). 
SEN0040028 
SEN0040028 
193 
 
The batch 1 compounds with inhibition percentage values against MDMX/p53 
interaction above 30% at 50 µM final concentrations are listed in Table 5. 2, with their 
plate location, compound ID and 10 µM final concentration percentage inhibition 
values against the MDMX/p53 interaction. 
Compounds with percentage inhibition values higher than 50% at 50 µM are 
highlighted in orange background and the compound with the highest percentage 
inhibition value is highlighted in red background. 
 
Table 5. 2 Potent compounds in the batch 1 compounds screening results for inhibitory 
activity against MDMX/p53 interaction. 
 
Location Compound ID % inhibition (10 µM) % inhibition (50 µM) 
P1B4 SEN0000739 -3.5  36.7  
P1D6 SEN0024849J -2.8  47.8  
P1D11 SEN0031364 -15.3  31.2  
P2B7 SEN0031443 19.0  31.7  
P2B8 SEN0031452 -10.7  37.5  
P2B10 SEN0031471 21.7  35.1  
P2B11 SEN0031479 26.8  36.9  
P2B12 SEN0031487 40.0  68.2  
P2C12 SEN0031488 22.5  56.1  
P2D7 SEN0031445 32.9  69.1  
P2D11 SEN0031481 9.6  42.0  
P2E11 SEN0031482 8.4  35.5  
P3F5 SEN0031513 31.9  35.6  
P3G4 SEN0031505 -0.7  40.1  
P4B8 SEN0040028 83.7  89.8  
P4B12 SEN0040432 32.0  33.8  
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Figure 5. 6 Hit compounds against MDMX/p53 interaction at 50 µM final concentration 
 
 
5.3.1.2  Dose-dependent-activity (DDA) evaluation for potent 1st batch DePPICT 
compounds 
One of the important purposes of screening the batch 1 compounds was to evaluate 
the reliability of the ELISA assay method, using the dose-dependent-activity ELISA to 
check the reproducibility of screening results was adopted as a standard validation 
procedure. 
The two compounds SEN0040028 and SEN0031562, which showed a dose-dependent 
percentage inhibition increase after the concentration increased from 10 to 50 µM, 
were selected for MDM2 target hit compound dose-dependent-activity evaluation via 
ELISA assay, using Nutlin-3 as a positive control. SEN0040028 was also tested as an 
MDMX target hit compound by using NU8325 as a positive control. The four 
compounds’ structures are displayed in Figure 5. 7. 
             
      SEN0031487                        SEN0031488 
 
                 
      SEN0031445                        SEN0040028 
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Figure 5. 7 Structures of compounds tested for dose dependent activity against MDM2/p53 
and/or MDMX/p53 binding interaction. 
Both SEN0031562 and SEN0040028 were evaluated for their dose-dependent-activity 
as MDM2/p53 interaction inhibitors. For each compound, three concentrations, 0.1, 1 
and 10 µM were tested. IC50 results of all compounds were calculated using Prism 
GraphpadTM software by point-to point and non-linear regression. 
As displayed in Figure 5. 8a, the 10 µM concentration percentage inhibition values for 
the two compounds were very close to the screening results. The IC50 value of 
SEN0040028 after calculation using Prism software, was 7.3 µM. 
The result in Figure 5. 8b shows that SEN0040028 inhibitory activity against 
MDMX/p53 interaction is also dose-dependent, with an IC50 = 8.6 µM.  
However, it was noticeable that the percentage inhibition value against MDMX/p53 
interaction at 10µM was much lower than the original value obtained on screening. 
This might relate to its limited solubility. The compound may not be able to disolve and 
distribute evenly in the DMSO with high concentration, as a result, the concentrations 
Nutlin-3 NU8325 
SEN0040028 SEN0031562 
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of diluted samples may variable from time to time, and these variable concentration 
may lead to inaccurate IC50 value.    
Because of this observation, it was decided to check the solubility of received 
compounds before ELISA evaluation in subsequent experiments. 
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Figure 5. 8 a) Dose-dependent-activity (DDA) of SEN0040028 and SEN0031562 as the 
MDM2/p53 interaction inhibitors (ELISA); b) dose-dependent-activity of NU8325 and 
SEN0040028 as the MDMX/p53 interaction inhibitors (ELISA). 
  
Nutlin-3 
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SEN0031562 SEN0040028 
7318.6±729.5 nM 
NU8325 
4.53±0.28 µM 
SEN0040028 
8.56 µM 
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5.3.1.3 Cellular Activity Evaluation for DePPICT Hit SEN0040028 
Nutlin-3 was selected as the positive control and the Michigan University compound 
MI-63 supplied by Siena Biotech was also included for comparison. 
Images of untreated NGP cells and cells treated using 1% DMSO, 1 µM or 10 µM 
Nutlin-3 or MI-63 and 5, 20 and 50 µM SEN0040028 for 24 hours are displayed in 
Figure 5. 9.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. 9 Images of NGP cells treated with various concentrations of Nutlin-3, MI-63 and 
SEN0040028 for 24 hours 
As can be seen from the result, after 24 hours, NGP cell cultures treated with 10 µM 
Nutlin-3 or MI-63 showed marked decrease in number and change in morphology; but 
NGP cell cultures treated with 20 or 50 µM SEN0040028 compound showed only slight 
loss of adherence ability and change in morphology that was very similar to 1 µM 
Cell Image Comparison 
Nutlin-3 10µM 40028 50 µM MI-63 10 µM 
NGP DMSO Control 
Nutlin-3 1 µM 
40028 5 µM 
40028 20 µM MI-63 1 µM 
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Nutlin-3 or MI-63 treated cells. In addition, some yellowish undissolved crystal-like 
compound clusters were observed under the microscope in 50 µM SEN0040028 
treated NGP cell culture media (Figure 5. 10), which indicated the limited solubility of 
this compound in an aqueous environment.  
 
 
Figure 5. 10 Undissolved compound clusters (surrounded with red circles) observed in 50 µM 
SEN0040028 treated NGP cell culture media.  
 
5.3.2 DePPICT compound screening as MDM2/MDMX inhibitors 
After initial confirmation of activity, the compounds were resupplied for full IC50 
evaluation. In addition, further batches of compounds and so called fragments were 
sent for 1st stage screening at a single 10 µM final concentration for standard 
compounds (from Siena Biotech) and 250 µM final concentration for fragment 
compounds (identified at Crystax Ltd by NMR based screening). After screening using 
the ELISA, hit compounds that showed percentage inhibition values close to and higher 
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than 50% were selected and initially confirmed by testing for dose-dependent activity 
with the ELISA. 
The further compound screening results against MDM2 and MDMX targets are 
displayed in Figure 5. 11 to Figure 5. 19. As can be seen from the whole screening 
results, we found that most of the compounds have shown inhibition percentage 
values below 50% inhibition potency. Altogether, there were only 7 compounds with 
percentage inhibition values above 50% out of more than 2500 compounds screened 
as MDM2 inhibitor candidates, and only 2 compounds from more than 1000 
compounds screened as MDMX inhibitor candidates at 10 µM final concentration; with 
the fragment compounds sent by Crystax Ltd. (Figure 5. 13), only 6 compounds showed 
greater than 50% inhibitory activity at 250 µM final concentration. 
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Figure 5. 11 Screening of plates 0034879-34887 for compounds with inhibitory activity 
against the MDM2/p53 interaction at 10 µM final concentration. 
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Figure 5. 12 Screening of plates 0035091-35099 for compounds with inhibitory activity 
against the MDM2/p53 interaction at 10 µM final concentration. 
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Figure 5. 13 Screening of plates 0035110-35113 for Crystax fragment compounds with 
inhibitory activity against the MDM2/p53 interaction at 250 µM final concentration. 
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Figure 5. 14 Screening of plates 0035114-35115, 35141-35142, 35476 and 35829 for 
compounds with inhibitory activity against the MDM2/p53 interaction at 10 µM final 
concentration. 
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Figure 5. 15 Screening of plates 0035440-35448 for compounds with inhibitory activity 
against the MDM2/p53 interaction at 10 µM final concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. 16 Screening of batch 4 plates for compounds with inhibitory activity against the 
MDM2/p53 interaction at 10 µM final concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. 17 Screening of batch 4 plates for compounds with inhibitory activity against the 
MDMX/p53 interaction at 10 µM final concentration. 
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Figure 5. 18 Screening of plates 0035449-35456 for compounds with inhibitory activity 
against the MDMX/p53 interaction at 10 µM final concentration. 
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Figure 5. 19 Screening of plates 0035468-35475 for compounds with inhibitory activity 
against the MDMX/p53 interaction at 10 µM final concentration. 
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5.3.3 Threshold value determination of DePPICT compounds 
Previously, we had set the threshold value for the definition of a hit to be above 50% 
inhibitory activity at 10 µM final concentration, such and hit compounds were then 
taken forward for confirmation and further evaluation using a dose-dependent ELISA. 
After the whole screening procedure, we combined inhibitory activity results of all 
10µM samples as MDM2 inhibitors together and obtained the curve shown in Figure 5. 
20, which supported the choice of threshold value that had been selected.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. 20 Frequency distribution of percentage inhibition values for DePPICT compounds 
screened for activity as MDM2/p53 interaction inhibitors. 
The blue curve represents the number of compounds distributing based on percentage inhibition values. The valley 
between two peak values, which is highlighted by using a red-dashed line, indicate the threshold value location that 
is close to 50% value position. 
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5.3.4 Pyrrole Compounds as MDM2/p53 and/or MDMX/p53 Inhibitors 
The Pyrrole scaffold compounds tested as MDM2/p53 and/or MDMX/p53 interaction 
inhibitors by the ELISA are listed in Table 5. 3.  
Each concentration of every compound was plated out in triplicate at three different 
concentrations and the experiments were repeated at least three times for 
confirmation. 
IC50 results of all compounds were calculated using Prism Graphpad
TM software by 
build-in point to point calculation programme. 
As the solubility of some pyrrole compounds was poor even in dimethyl sulphoxide 
(DMSO), we have used tetrahydrofuran (THF) as an alternative solvent, diluting to the 
required concentration with 2% THF in final DMSO solution, resulting in 0.01% THF in 
ELISA. However, an even higher concentration of THF was used for less soluble pyrrole 
compounds (Table 5. 3), with the solvent-only control also changed to give the same 
percentage of concentration THF in DMSO. 
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Table 5. 3 Inhibition Potency of Pyrrole Compounds as MDM2/p53 and MDMX/p53 
Interaction Antagonists 
 
Compounds 
Code 
Structure IC50 nM SE (nM) 
NU8291 
 
105
*
 20 
NU8323 
 
195 50 
994.9 
21.1 
MDMX 
NU8324 
 
168 62 
855.3 
40.1 
MDMX 
NU8325 
 
153 59 
4530 
280 
MDMX 
NU8327 
 
255
*
 44 
NU8356 
 
888
**
 44 
207 
 
NU8372 
 
613
***
  
NU8373 
 
300
*
 55 
NU8374 
 
255
*
 48 
NU8375 
 
341
*
 80 
NU8376 
 
113
*
 12 
* NU8377 
 
72.6
**
 2.2 
NU8379 
 
1290  
208 
 
NU8381 
 
736 61 
NU8382 
 
+ 
 
663 44 
NCL-00016067  
 
524.4 96.2 
963.2  
n=1 
MDMX 
NCL-00016068 
 
494.1 76.4 
1684.6  
n=1 
MDMX 
NCL-00016393 
 
740.2 105.1 
3428.3 
n=1 
MDMX 
NCL-00016394 
 
641.4 280.3 
3486.8 
n=1 
MDMX 
NCL-00016395 
 
642.8 151.9 
5322.4 
n=1 
MDMX 
209 
 
NCL-00016396 
 
583.9 228.9 
4916.0 
n=1 
MDMX 
NCL-00016746 
 
19930 626 
38.9%, 50 
µM 
n=1 
MDMX 
NCL-00016747 
 
1670  
10100  
n=1 
MDMX 
 
NB: 
IC50 values as MDM2 inhibitors are displayed using plain texts, and IC50 values as MDMX inhibitors are displayed 
using bold texts.  
Normally the compounds were tested using DMSO as the solvent, however some pyrrole compounds could not be 
dissolved in DMSO, as a result THF was used to dissolve them and * was used to indicate these compounds. 
 
*
 Means the final concentration is 0.2% THF in DMSO solvent, 
**
means 0.4% THF in DMSO and 
***
means 0.8-1% THF 
in DMSO. 
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5.3.5 Comparison of Peptide Inhibitors against both MDM2 and MDMX 
Targets 
The research breakthrough of potent peptide inhibitors (Figure 5. 21) for MDM2/p53 
interaction started almost at the same time as the report of discovering and 
developing potent MDM2/p53 small molecular inhibitors, and quite a lot of these 
peptides have been reported together with the publication of the MDM2/inhibitor 
co-crystal structures (12, 125).  
 
Figure 5. 21 Potent peptide inhibitors for MDM2-p53 interaction and crystal structure 
analysis of p53 related peptide bound to the MDM2 protein(12, 125) 
 
A recently published co-crystal structure of MDMX binding with p53 peptide (168) 
allowed the comparison of the MDM2 and MDMX binding pockets side by side. 
As an initial approach, the MDM2 (1YCR) (116) and MDMX (3DAB) (168) crystal 
structures were superimposed using PyMOL software, to compare the difference 
between their p53 binding grooves. The most marked differences was highlighted 
(Figure 5. 22). Firstly, the red arrow shows that the MDMX side chains make the Leu26 
binding pocket of MDMX to be smaller than that of MDM2; Secondly, in the red circle 
surrounded area, MDMX side chains make the Trp23 binding pocket of MDMX 
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shallower than that of MDM2; Finally, the red twin-arrow points out that the Phe19 
binding pocket of MDMX is wider than that of MDM2, which may be because of the 
whole p53 transactivation domain being pushed backward, when binding with MDMX 
because of the smaller Leu26 binding pocket, then the Phe19 side-chain of p53 makes 
this pocket open wider. This observation suggests that the p53 peptide binding groove 
of MDM2/MDMX might be flexible and the shape may adapt according to the nature 
of the ligand which binds to the pocket, although the flexibility may be very limited.  
 
 
 
 
 
 
 
 
 
Figure 5. 22 Binding groove comparison of MDM2 1YCR and MDMX 3DAB structure 
The cartoons above showed the comparison of MDM2 and MDMX protein 3D structure. A. Surface image of MDM2 
protein colour coded as cyaneine; B. Surface image of MDMX protein colour coded as green; C. Superimposed 
MDM2 and MDMX cartoon as 3D ribbon structures; D. Superimposed MDM2 and MDMX surface image with key 
differences highlighted by red circle and arrows. The figures were generated using PyMOL (DeLano, 2002). 
Then to compare the MDM2/p53 and MDMX/53 binding grooves in detail and with 
some quantitative results, the surface representations of human MDMX (3DAB & 
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3DAC) and two human MDM2 (1YCR & 1T4F) protein structures are displayed in Figure 
5. 23.  
Marked differences in the shape of the p53 binding pocket are clearly visible in the 
light green colour filled area in the first row of images. Amino acid side chains of 
MDM2/MDMX proteins that are responsible for forming the binding groove are 
displayed in the second row of images; amino acid side chains of MDM2/MDMX 
proteins that surrounding the highlighted binding grooves are also listed in the third 
row.  
In the list, the same side chains at the same location are coded in bold black, the 
different side chains at the same location are coded in bold red, the amino acid only 
present in the MDM2 protein crystal structures is coded in bold green (Phe86), and 
one amino acid side-chain (Ile103) present only in the MDM2 (1YCR) crystal structure is 
in indicated in normal Font. 
Moreover, the volume, surface area and depth of each pocket were calculated by 
using Molegro Virtual Docker software, as displayed in Figure 5. 23.  
Clearly from this comparison, the binding pocket of MDMX is smaller and shallower 
than the MDM2 binding pocket when they bind to the p53 peptide. This result 
indicates that a smaller compound candidate may be more suitable for MDMX 
inhibitor screen and/or design. Their differences between the surrounding side chains 
may lead themselves to be exploited to design selective inhibitors of MDMX. 
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PDB Code 3DAB(MDMX) 3DAC (MDMX) 1YCR (MDM2) 1T4F (MDM2) 
Cavity 
highlighted 
with Protein 
Surface 
Image 
    
Protein Side 
Chains 
Surrounding 
the 
Highlighted 
Cavity 
    
List of 
protein Side 
Chains 
Surrounding 
the 
Highlighted 
Cavity 
Met53, Leu56, Gly57, Ile60, 
Met61, Tyr66, Gln71, Val74, 
Phe90, Val92, Pro95, Leu98, 
Tyr99. 
Met50, Leu53, Gly54, Ile57, 
Met58, Tyr63, Gln68, Val71, 
Phe87, Pro92, Leu95, Tyr96. 
Leu54, Leu57, Gly58, 
Gln59, Ile61, Met62, 
Tyr67, Gln72, Val75, 
Phe86, Phe91, Val93, 
His96, Ile99, Tyr100, 
Ile103. 
Leu54, Leu57, Gly58, Ile61, 
Met62, Tyr67, Gln72, Val75, 
Phe86, Phe91, Val93, His96, 
Ile99, Tyr100. 
Cavity 
Volume (A3) 
68.904 71.064 126.576 115.128 
Cavity 
Surface (A2) 
295.92 343.44 516.96 453.60 
Cavity 
Depth (A) 
0.233 0.207 0.244 0.254 
 
Figure 5. 23 MDM2 and MDMX binding pockets comparison by using 3DAB, 3DAC, 1YCR and 1T4F protein database structures.
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Based on this comparison, it was hypothesised that suitable modification of the 
structure of MDM2 peptide inhibitors might make them more potent against MDMX, 
which could inform the development of small molecule inhibitors of MDMX/p53 
interaction and provide a better understanding of the hydrophobic binding pocket 
differences between MDM2 and MDMX protein when they bind with the p53 
transactivation domain. Based on the research reports shown in Figure 5. 21, three 
p53 peptide analogues were synthesised (by Dr Nicola O’Reilly, ICRF Peptide Synthesis 
Laboratory), as listed in Table 5. 4, with the differences between them highlighted by 
using different colours. In particular, the APv2 peptide was made without the chlorine 
modification of the tryptophan residue in the β-AP peptide on the hypothesis that the 
former would better fit the more shallow MDMX tryptophan binding pocket. 
Table 5. 4 Modified peptides made for binding affinity evaluation with MDM2/MDMX 
 
Name Sequence 
IP3 peptide Ac-Phe19-Met-Asp-Tyr-Trp23-Glu-Gly-Leu26-NH2 
β-AP peptide Ac-Phe19-Met-Aib-Pmp-6-Cl-Trp23-Glu-Ac3c-Leu
26-NH2 
APv2 peptide Ac-Phe19-Met-Aib-Pmp-Trp23-Glu-Ac3c-Leu
26-NH2 
By using the ELISA, binding inhibition curves and IC50 values were obtained for all the 
three peptides as MDM2 and MDMX inhibitors (Figure 5. 24). 
Interestingly, as can be seen from Figure 5. 24, the IP3 peptide showed the weakest 
binding affinity with both MDM2 and MDMX proteins among all the three p53 
peptide analogues; β-AP peptide showed the strongest binding affinity with MDM2, 
which was about 8-fold stronger than APv2 and 1000-fold stronger than the IP3 
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peptide; however, its binding affinity with MDMX protein was 2.5 folds weaker than 
the APv2 peptide, though still 9 times stronger than the IP3 peptide. It is also worth 
pointing out that by modifying the p53 peptide analogue side chains, although we can 
still enhance their binding affinity with the MDMX protein, but the enhancement 
ratios are much lower than the modification confers on their binding affinity with the 
MDM2 protein. 
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Figure 5. 24 Comparisons of the binding affinity of three p53 peptide analogues with MDM2 
and MDMX by using ELISA method. 
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p53 Analogues MDM2 Ratio MDMX Ratio 
IP3 peptide 390.1 nM 951.5 1548 nM 9.0 
β-AP peptide 0.41 nM 1 172.7 nM 1 
APv2 peptide 3.41 nM 8.3 62.9 nM 0.4 
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 Manual docking of the two p53 peptide analogues β-AP peptide and APv2 peptide 
with both MDM2 (from 1YCR) and MDMX (from 3DAC) proteins crystal structure 
binding pockets are represented in Figure 5. 25.  
 
 
 
 
 
 
 
 
 
 
Figure 5. 25 Comparisons of peptides binding with MDM2 and MDMX by manual docking. 
The chloro group at the 6-position of the tryptophan side-chain of β-AP peptide, 
which was colour coded as light green and displayed in a space occupying mode, 
could fill the remaining space in the tryptophan binding pocket of MDM2 and 
enhance their binding affinity; however, since the MDMX protein binding groove was 
smaller and shallower as illustrated in Figure 5. 23, the chlorine atom would either 
stick out of the tryptophan binding pocket of the MDMX protein; or force the 
   
β-AP peptide Binding with MDM2        APv2 peptide Binding with MDM2 
 
   
β-AP peptide Binding with MDMX         APv2 peptide Binding with MDMX 
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tryptophan binding pocket to change shape to accommodate it, which would 
consume more energy; or force the whole peptide move away from the binding 
groove, which would decrease the binding affinity between the peptide with MDMX 
protein.  
Both of the two mechanisms will cause the binding affinity of β-AP peptide with 
MDMX to be lower than APv2 peptide binding with MDMX.  
Together with the observation made in Chapter 3 about the isoindolin-1-one scaffold 
compound side chains modification, I have referred to this phenomenon in terms of a 
‘See-Saw Theory’ that we will be discussed in detail in Chapter 7. 
5.4 Conclusion and Discussion 
5.4.1 The DePPICT project as a successful attempt to use virtual screening 
technology 
Our colleagues in Siena Biotech and Crystax Ltd. have analyzed millions of 
commercially available compounds by using Glide or GOLD virtual docking software 
and narrowed the total number down to no more than 4,000 compounds for us to 
screen by the ELISA method. 
This has generated a number of hit compound leads that showed dose-dependent 
activity as MDM2/p53 and/or MDMX/p53 binding interaction inhibitors. Moreover, 
seven scaffold series were selected, within which there was evidence of 
structure-activity relationships and further SAR exploration was started to be carried 
out by using synthetic chemistry technology. 
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As a result, I believe with the continued progress of this project, which has identified 
novel core structures of some potent candidate compound series and started to 
develop a systematic SAR analysis, we may be able to obtain new series of potent 
MDM2 and/or MDMX inhibitors in the near future. 
The aim of this project was not only to obtain potent MDM2/MDMX inhibitors, but 
also to learn from the combination of technologies such as in silico screen and binding 
mode prediction, biochemistry, cellular biology, synthetic chemistry, crystallography, 
animal model design, which have been carried out within the DePPICT project. 
Everyone who had the opportunity to be involved will have gained enormous 
knowledge from the international collaboration.   
5.4.2 DePPICT compound SEN0040028 binding mode prediction 
One interesting hit compound SEN0040028 was identified from the screened batch 
one compounds with above 50% inhibition activity for both MDM2/p53 and 
MDMX/p53 interaction at the concentration lower than 10 µM. As a result, the 
computer-predicted binding mode of this compound with MDM2 and MDMX was 
investigated to gain insight into the binding groove difference between these two 
proteins and to obtain some ideas about the potential further development of this 
class of MDMX/p53 antagonist. 
The energy-minimized 3D structure of SEN0040028 was produced by using Chemdraw 
3D and by using PyMOL software (DeLano, 2002). A 3D docking structure was built, 
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and a potential binding mode of the compound with both MDM2 (1YCR) and MDMX 
(3DAB) via manual docking was generated (Figure 5. 26).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5. 26 Comparisons of predicted binding mode of SEN0040028 binding with MDM2 
and MDMX by manual docking. 
 
As can be seen in Figure 5. 26, SEN0040028 can fit into both the MDM2 and MDMX 
grooves. In the predicted binding mode, one of its furan rings can occupy the Leu26 
binding pocket and the other stretches into the Trp23 binding pocket, with the 
4-fluorophenyl side-chain covering the Phe19 binding pocket; furthermore, the 
 
 
SEN0040028 binding with 
MDM2 Protein 
SEN0040028 binding with 
MDMX Protein 
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imidazo[2,1-c][1,2,4]triazine scaffold in the middle may also contribute to the binding 
with some H-bond donor effects.  
As a compound with a molecular weight of only 346.31, the 7.3 µM IC50 values against 
MDM2 and 8.6 µM against MDMX is very encouraging.  
5.4.3 Cellular evaluation of SEN0040028 and potential drug design 
direction 
After passing the quality control analysis, the cellular activity of SEN0040028 was 
tested. However, no cellular activity in NGP cells was detected by using this 
compound at quite high concentrations (up to 50 µM), although both Nutlin-3 and 
MI-63 positive controls have shown marked cellular effects. Moreover, yellowish 
crystal-like compound clusters were observed in tissue culture medium contain 50 
µM SEN0040028, which indicated that the compound was precipitating in culture 
medium due to poor aqueous solubility. 
However, a possible way to overcome this limitation is to connect a hydrophilic 
side-chain on the imidazo[2,1-c][1,2,4]triazine scaffold, which may result in some 
higher potency MDM2/MDMX antagonists with better solubility in tissue culture 
medium, as has been shown in the development of the isoindolin-1-one scaffold 
MDM2/p53 antagonists (Chapter 3 and 4). 
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5.4.4 The possible reason for marked negative percentage inhibition values 
in the binding assay 
Within the screening results, we have observed frequent marked negative percentage 
inhibition values, and some of them became even more negative when the compound 
concentration was increased.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. 27 Example of DePPICT compounds screening results showing lower than -50% 
MDMX inhibition values and their related compounds structures. 
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For example, in Figure 5. 27, one compound SEN0064901 showed above 85% 
inhibition potency, however, another compound (SEN0066733) within the same plate 
showed -68% inhibition value, and there were another two compounds (SEN0071091 
and SEN0071104A) which also showed <-50% inhibition values. These three 
compounds shared the properties when compared to the potent one (SEN0064901): 
much lower molecular weight (~300), smaller scaffold and more lipophilic. 
Nevertheless, they might not be mischosen compounds through the virtual screening 
procedure, but may represent compounds that have a high binding affinity with 
MDMX proteins. As we have seen from their structure, the only problem with these 
compounds is that they are all very small lipophilic molecules, as a result, they may be 
able to form a ‘bridge’ between the MDMX/MDM2 binding groove and p53 peptide, 
which could contribute to their binding. 
This hypothesis may open up a potential drug design direction to turn these negative 
potency compounds into high potency antagonists, i.e. based on their computer 
generated binding mode, one could add a hydrophilic side-chain opposite to their 
binding side. Such a side chain, would solve the water solubility problem and 
potentially be able to break the ‘bridge’ effect. In addition, this side-chain might act 
as Leu22 does in the p53 peptide and contribute to an enhancement of the binding 
affinity. 
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5.4.5 Pyrrole scaffold compounds as a potent MDM2 and MDMX inhibitor 
lead compounds 
As has been shown in section 5.2.4, the pyrrole scaffold compounds were interesting 
due to their high potency as MDM2 inhibitors and acceptable activity against MDMX. 
However, the solubility of this series of compounds was very poor, which is a 
hindrance for them to become a drug candidate. As a result, further development 
should be focused on solving the solubility problem and also building up a reliable 
structure-activity relationship map. On the other hand, an attempt to generate a 
co-crystal structure of pyrrole scaffold compounds with either MDM2 or MDMX 
protein, or predict their binding mode by using virtual docking might be worth trying. 
All information obtained by these approaches together with the research based on an 
optimized peptide, will contribute to not only the further development of these 
compounds, but also a better understanding of the MDM2/MDMX binding groove 
‘appetite’.  
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Chapter Six 
Generation and Characterization of MDM2/p53 Inhibitor 
Resistant Cell Lines 
 
6.1 Introduction 
So far, several potent and selective small-molecular MDM2 antagonists have been 
identified, e.g. Nutlin-3 (77) and MI-63 (13, 133). Studies with these compounds have 
strengthened the concept that selective, non-genotoxic p53 activation might 
represent an alternative to current cytotoxic chemotherapy (68, 188-189). 
The entry of these agents into clinical trials (189) raises the question of drug 
resistance effects that may lead to relapse. 
This chapter describes our research into the potential for drug resistance against 
p53-MDM2 binding antagonists in order to understand any underlying mechanisms 
that would inform potential therapeutic strategies to circumvent this. We have 
established a series of clonal variants resistant to Nutlin-3 and MI-63 from NGP 
neuroblastoma and SJSA-1 osteosarcoma parental cell lines, which contain wild type 
p53 with the transcriptional activity suppressed by amplified and over-expressed 
MDM2. The drug resistance phenotypes of these clones were evaluated by SRB 
growth inhibition assay, western blotting for activation of p53 and downstream 
mediators of p53 dependent growth inhibition and cytotoxicity, as well as cell cycle 
and caspase-3/7 activation analysis. DNA sequence analysis was used for p53 
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mutation detection and a FISH assay was also conducted to explore possible 
resistance mechanisms involving allelic loss of the p53 gene. 
6.2 Overview of resistant cell line selection and 
characterization 
The NGP human neuroblastoma and SJSA-1 osteosarcoma cell lines were used for 
selection of cell clones resistant to MDM2-p53 antagonists. They both contain wild 
type p53 genes with the p53 transcriptional transactivation activity suppressed by 
over-expressed MDM2 as a result of gene amplification. In addition, the NGP cells 
also express MDMX, which contributes to the negative regulation of p53. 
Based on the potencies of Nutlin-3 and MI-63 evaluated in the ELISA and their GI50 
value for growth inhibition of NGP and SJSA-1parental cell lines, various drug 
concentrations were applied to select for resistant cell clones. NGP and SJSA-1 cell 
lines were exposed to increasing concentrations of Nutlin-3 (3- 40 µM) and MI-63 (1-6 
µM), respectively. Single cell clones were isolated with cloning cylinders and the 
colonies expanded by growth in fresh culture medium containing the original 
selective concentrations of MDM2 antagonists, which was refreshed weekly. Stage 
one resistant cell clones were obtained after 60 days drug treatment by using 
relatively low concentrations (for SJSA-1, 1 µM MI-63 or 3 µM Nutlin-3; for NGP, 3 µM 
MI-63 or 5 µM Nutlin-3) (Figure 6. 1).  
The derived resistant clones were named by starting with the parental cell line’s 
initial, followed by the initial of the antagonist used for generating the cell clone and 
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then the drug concentration, then the ‘R’ designation to indicate a ‘Resistant clone’, 
and ending with the clone number. For example, S_M1R1, means resistant clone 1, 
generated from the SJSA-1 cell line by using 1 µM MI-63; N_N5R1, means resistant 
clone 1 generated from the NGP cell line by using 5 µM Nutlin-3. Altogether, there 
were 3 SJSA-1 resistant cell clones obtained from MI-63 treatment, 5 SJSA-1 resistant 
cell clones obtained from Nutlin-3 treatment; for NGP Resistant clones, there were 4 
clones obtained from MI-63 treatment and only one clone from Nutlin-3 treatment.  
The images in Figure 6. 1 show that some cells survived and were growing in the 
continued presence of Nutlin-3 or MI-63. After analysing the first set of selected 
clones by SRB assay, western blotting and DNA sequencing, treatment was increased 
by using higher drug concentrations based on the GI50 evaluation results. Based on 
DNA sequencing results, which in SJSA-1 resistant cell clones showed heterozygous 
point mutation in the two MI-63 induced resistant cell clones and the Nutlin-3 
induced resistant cell clone S_N3R2, and homozygous point mutation in S_N3R1, and 
all NGP resistant cell clones showed heterozygous point mutation; S_M1R1 and 
S_N3R1 were chosen for further selection of SJSA-1 resistant clones, and N_M3R2, 
N_M3R4 and N_N5R1 were chosen for further selection of NGP resistant clones. After 
another 30 days drug treatment, two SJSA-1 resistant cell clones were obtained from 
MI-63 treatment and four from Nutlin-3 treatment; two NGP resistant cell clones 
obtained from MI-63 treatment and two from Nutlin-3 treatment. 
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Figure 6. 1 Selection of SJSA-1 and NGP resistant cell clones. 
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6.3 Characterization Stage I selected resistant cell lines  
6.3.1 Resistant potency evaluation 
To compare the sensitivity of the selected resistant clones to the parental cell lines 
and investigate cross resistance between Nutlin-3 and MI-63 selection, the GI50 values 
for Nutlin-3 and MI-63 induced cell growth inhibition were determined by 
Sulphorhodamine B (SRB) assay, as described previously (Section 2.4). Briefly, 
adherent exponentially growing cells were seeded into 96-well plates at 2×103 
cells/well for SJSA-1 parental and resistant cell clones and 5×103 cells/well for NGP 
parental and resistant cell clones. After 24 hours incubation at 37°C, the medium was 
replaced with fresh medium containing MDM2 antagonists at appropriate ranges of 
drug concentrations in 1% DMSO. After a drug exposure period of 72 hours 
(equivalent to three cell population doubling times), the cells were fixed by adding 
trichloroacetic acid (TCA) to a final concentration of 10% into each well, left in 4°C for 
24 hours, washed with water, air dried, and then stained with SRB solution. The 
absorbance per well was measured, the percentage cell density curves were 
generated for comparison and fifty percent cell growth inhibition values (GI50) 
determination after calculation. By using parental cell line GI50s, we have also 
calculated the GI50 ratios of resistant cell clones to that of their parental lines as a 
measure of fold-resistance. 
Figure 6. 2 and Figure 6. 3 show the differences in the cellular growth inhibition 
response between the parental and resistant cell clones, and the stage I resistant cell 
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clones established by using either MI-63 or Nutlin-3 for both the SJSA-1 (tested by Dr 
Xiaohong Lu) and NGP cell lines. The cross-resistance effects are also shown.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. 2 SJSA-1 parental and stage I resistant cell clone GI50 Comparison. 
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Figure 6. 3 NGP parental and stage I resistant cell clone GI50 Comparison. 
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The potency differences between the two antagonists was reflected not only by the 
SJSA-1 and NGP parental cell lines, but also by their resistant cell clones.  
The GI50 results and the fold-changes in them between parental and resistant cell 
clones for both of the two cell lines are shown in Table 6. 1. In all cases, the selected 
clones showed increase in GI50. Interestingly, the Nutlin-3 generated SJSA-1 resistant 
cell clone S_N3R1 showed a greater level of resistance to MI-63 and Nutlin-3 than all 
the MI-63 generated SJSA-1 resistant cell clones. However, the Nutlin-3 generated 
NGP resistant cell clone N_N5R1 showed slightly weaker resistance than the two 
MI-63 generated NGP resistant cell clones. 
Table 6. 1 GI50 comparison of stage I resistant clones with their parental cell lines 
Cell Clones MI-63_GI50 
Folds 
change 
Nutlin-3_GI50 
Folds 
change 
SJSA-1 0.70 ± 0.05 µM (n=3) 1 2.1 ± 0.2 µM (n=3) 1 
S_M1R1 1.68 ± 0.09 µM (n=3) 2.4 4.0 ± 0.1 µM (n=3)         1.9 
S_M1R2 1.64 ± 0.15 µM (n=3) 2.34 3.4 ± 0.4 µM (n=3)         1.6 
S_M1R3 1.86 ± 0.11 µM (n=3) 2.66 4.4 ± 0.4 µM (n=3)         2.1 
S_N3R1 3.8 ± 1.4 µM (n=4) 5.43 6.9 ± 0.9 µM (n=4)         3.3 
S_N3R2 1.9 ± 0.3 µM (n=4) 2.71 3.9 ± 0.3 µM (n=4)         1.9 
     
NGP 1.58 ± 0.21 µM (n=3) 1 2.20 ± 0.39 µM (n=3) 1 
N_M3R1 6.65 ± 1.01 µM (n=3)         4.21 10.69 ± 1.29 µM (n=3) 4.86 
N_M3R4 5.86 ± 0.98 µM (n=3)         3.71 9.62 ± 1.23 µM (n=3) 4.37 
N_N5R1 5.47 ± 0.51 µM (n=3)         3.46 9.01 ± 0.44 µM (n=3) 4.09 
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6.3.2 Measurement of p53, MDM2 and p21WAF1 expression. 
To investigate whether the resistance of selected SJSA-1 clones was reflected in the 
induction of p53 and its downstream targets MDM2 and p21WAF1 protein, SJSA-1 
resistant cell clones S_M1R1 and S_N3R1 were selected to compare with the SJSA-1 
parental cell line. After MDM2 antagonist treatment, the expression of these proteins 
was determined using total cell extracts prepared from untreated control or cells 
treated with DMSO, 5 µM MI-63 or Nutlin-3 for 6 hours and α-tubulin in each sample 
was also evaluated as a loading and tansfer control (Figure 6. 4). 
 
 
 
 
 
 
 
Figure 6. 4 Western blot showing p53 pathway activation by Nutlin-3 and MI-63 for the 
SJSA-1 parental cell line and reduced activation in stage I resistant cell clones. 
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The western blotting results for the SJSA-1 parental cell line and stage I resistant 
clones (Figure 6. 4) indicated that both MI-63 and Nutlin-3 can disrupt the interaction 
between MDM2 and p53 protein and release the p53 transactivation domain from 
MDM2 binding in both the SJSA-1 parental cell line and its resistant cell clones, 
resulting in p53 accumulation and transcriptional transactivation of MDM2 and p21, 
when compared to untreated or DMSO only treated cell samples. However, the band 
densities of MDM2 and p21 proteins in resistant clones were lower than parental 
clones indicating an attenuated p53 activation, especially in the Nutlin-3 generated 
resistant cell clone S_N3R1, which reflected the SRB result in Figure 6. 2 and Table 6. 
1. The cross resistance effect is also evident in the western blot result.  
To investigate whether the resistance effect in NGP resistant clones was also reflected 
in the induction of p53 and its downstream target MDM2 and p21WAF1 protein, NGP 
resistant cell clones N_M3R1, N_M3R4 and S_N5R1 were chosen to compare with the 
NGP parental cell line. After MDM2 antagonist treatment, the expression of these 
proteins together with MDMX protein were determined using total cell extracts 
prepared from untreated control or cells treated with DMSO, 5 µM MI-63 or Nutlin-3 
for 4 hours β-actin in each sample was also evaluated as loading control (Figure 6. 5). 
The western blotting results for the NGP series cell clones (Figure 6. 5) also indicated 
that both MI-63 and Nutlin-3 can disrupt the interaction between MDM2 and p53 
protein and release p53 transactivation domain from MDM2 binding in both NGP 
parental cell line and its resistant cell clones, and there were no marked difference in 
p53 levels between parental and resistant clones after two antagonists treatment. 
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However, attenuated MDM2 and especially p21 expression were observed in 
resistant clones after treatment with the two antagonists.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. 5 Western blot comparing p53 activation by Nutlin-3 and MI-63 in the NGP 
parental cell and stage I resistant cell clones. 
On the other hand, interestingly, the MDMX expression was quite stable in both 
parental and resistant NGP cell clones, with or without the treatment of the MDM2 
antagonists.  
Furthermore, cross resistant effects were evident in all three cell clones established 
by using different antagonists, which was consistent with the SRB assay results.  
6.3.3 DNA Sequencing of p53 in Stage I Resistant Cell Clones 
Since both the growth inhibition and western blotting analysis experiments showed 
marked resistance effects and attenuation of p53 pathway activation in the cell clones 
developed from both SJSA-1and NGP cell lines, the functional inactivation of p53 by 
mutation was investigated.  
 
 
236 
 
To determine the p53 status of the resistant cell clones, total DNA was extracted from 
each cell clone for the analysis. PCR products of Exons 4 to 9 that encode the DNA 
binding domain of p53 were sequenced. We analyzed the sequencing results of all 
PCR products produced by using primers (gifts from Dr Claire Hutton and Dr Jennifer 
Jackson) for the coding strand first and compared them with both p53 full sequence 
and relative to PCR products of the parental cell line DNA samples, when sequence 
differences were detected, they were confirmed by analyzing sequences from the 
opposite strand using the antisense primers. 
In all SJSA-1 resistant cell clones only one missense point mutation was detected, 
which was present within all SJSA-1 resistant cell clones established by using both of 
the two antagonists. The mutation was at codon 285, changing GAG to AAG, which 
corresponds to an amino acid change from Glutamic acid to Lysine (Figure 6. 6, Figure 
6. 7 & Figure 6. 8). This amino acid lies withinin the codon 280-286 region which 
forms an alpha-helix that docks with the major groove of DNA (Figure 1. 3 in Section 
1.1.1.2). Interestingly, the sequencing trace images showed that in resistant cell 
clones S_M1R1, S_M1R2 and S_N3R2, the point mutation peaks were the same height 
as the non-mutant peaks; however, both the SN and ASN primer PCR products of 
S_N3R1 showed almost pure mutation peaks, suggesting a homozygous mutation. 
This observation showed an interesting relationship to the GI50 evaluation results 
shown in Table 6. 1, in which the S_N3R1resistant cell clone showed higher resistance 
compared with all the other SJSA-1 resistant cell clones. 
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In all three tested NGP resistant cell clones (N_M3R1, N_M3R4 and N_N5R1) one 
missense point mutation was detected (Figure 6. 9 & Figure 6. 10). This point 
mutation was detected at codon 152 in Exon 5, changing CCG to ACG, which 
corresponds to an amino acid change from proline to threonine. The sequencing trace 
images showed that in all analyzed NGP resistant cell clones, the point mutation 
peaks were nearly the same height as the non-mutant peaks. This observation was 
also consistent with the GI50 evaluation results showed in Table 6. 1, in which all 
selected cell clones showed similar levels of resistance. 
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Figure 6. 6 SJSA-1 parental and resistant cell clones DNA sequencing alignment results of 
Exon 8 SN primers PCR products showed similar 14522 genomic DNA position point 
mutation.  
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Figure 6. 7 SJSA-1 parental and resistant cell clones DNA sequencing alignment results of 
Exon 8 ASN primers PCR products confirming the 14522 p53 genomic DNA point mutation. 
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Figure 6. 8 SJSA-1 parental and resistant cell clones DNA sequencing traces of Exon 8 PCR 
products confirming the 14522 point mutation corresponding to codon 285, changing GAG 
to AAG. 
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Figure 6. 9 NGP parental and resistant cell clones DNA sequencing results 
(A) DNA sequencing results for Exon 5 SN primers indicated the p53 genomic DNA position 13133 point mutation, 
(B) DNA sequencing for Exon 5 ASN primers confirmed the p53 genomic DNA position 13133 point mutation. 
C
el
l C
lo
n
es
 
Sequencing results of PCR Products produced from sense primers 
N
G
P
 
 
N
_M
3
R
1
 
 
N
_M
3
R
4
 
 
N
_N
5
R
1
 
 
 
C
e
ll 
C
lo
n
e
s 
Sequencing of PCR Products produced from anti-sense primers 
N
G
P
 
 
N
_M
3
R
1
 
 
N
_M
3
R
4
 
 
N
_N
5
R
1
 
 
 
A 
B 
242 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. 10 NGP parental and resistant cell clones DNA sequencing traces of Exon 5 PCR 
products confirmed the 13133 point mutation corresponding to codon 152, changing CCG to 
ACG. 
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6.4 Further developed resistant cell clones: characterization 
and analysis of potential mechanism  
After analyzing the DNA sequencing results of stage I resistance clones, further 
selection under higher concentrations of inhibitors was carried out to test whether 
resistance levels could be increased. Based on DNA sequencing results, S_M1R1 and 
S_N3R1 were chosen for further selection of SJSA-1 resistant clones, and N_M3R1, 
N_M3R4 and N_N5R1 were chosen for further selection of NGP resistant clones. After 
a further 30 days of drug treatment at the higher concentration, two SJSA-1 resistant 
cell clones were obtained from MI-63 treatment and four from Nutlin-3 treatment; 
two NGP resistant cell clones were obtained from MI-63 treatment and two from 
Nutlin-3 treatment. I have mainly focused on investigating the SJSA-1 series of cell 
clones (Figure 6. 1). 
6.4.1 Growth curve comparison 
After the further development of the resistance clones, the cell population doubling 
times were evaluated. After 5 passages of the resistant clones in fresh medium 
without drugs, the growth curves of SJSA-1 parental and resistant clones were 
determined using the SRB assay.  
Briefly, adherent exponentially growing cells were seeded into 96-well plates at a 
range of initial cell densities from 24,000 to 12 cells/well (with half cell density than 
the previous row for 12 rows) for SJSA-1 parental and resistant cell clones (S_M6R1 
and N_N40R1). After every 24 hours within a period of 9 days, the cells were fixed by 
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adding trichloroacetic acid (TCA) to a final concentration of 10 % into each well, left in 
4°C for above 24 hours, washed with water, air dried, and then stained with SRB 
solution. The absorbance per well was measured, the cell density curves were 
generated (Figure 6. 11) for comparison.  
The doubling times (dT) were calculated from the seeding densities at 6000, 3000 and 
1500 cells/well, over the time period when the cells were growing exponentially 
(approximately 70 % confluent) using the equation:  
dTCell line_X=ln2/kCell line_X, 
where k is the growth rate constant, and the mean values and standard errors for the 
doubling time of each cell line were calculated based on the three selected seeding 
densities.  
The results indicated that both SJSA-1 parental and resistant cell population doubling 
times were quite similar (dTSJSA-1=32.5±1.6 h, dTS_M6R1=35.7±2.0 h and 
dTS_N40R1=33.5±2.5 h) within appropriate cell densities. 
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Figure 6. 11 Growth curves of SJSA-1 parental cell line and resistant cell clones 
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6.4.2 Resistance evaluation for stage II resistant cell clones 
Because of the observation that the gaps of drug concentrations for parental cell lines 
treatment might be too big (Figure 6. 2 & Figure 6. 3), when I was designing the SRB 
assay for the further developed resistant clones, I included a narrower range of 
concentrations around their GI50 values to obtain more accurate GI50 values for 
parental cell lines.  
The GI50 results and the ratios between parental and resistant cell clones for both of 
the two cell lines in Table 6. 2 showed marked increase in resistance for the SJSA-1 
stage II resistant clones, and higher resistance levels for the NGP resistant clones, 
which will be discussed in detail later. 
Figure 6. 12 and Figure 6. 13 show the marked differences of the cellular response 
between the parental and the stage II resistant cell clones established by using either 
MI-63 or Nutlin-3. Both of the SJSA-1 and NGP resistant cell lines showed cross 
resistance effects to Nutlin-3 and the other MDM2 inhibitor MI-63. Moreover, the 
potency differences between the two antagonists reflected not only by the SJSA-1 
and NGP parental cell lines, but also reflected in the responses of their resistant cell 
clones.  
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Table 6. 2 Comparison of stage II resistant cell clones with their parental cell lines showing 
marked increases in GI50 
Cell Clones MI-63_GI50 
Folds 
change 
Nutlin-3_GI50 
Folds 
change 
SJSA-1 0.70 ± 0.05 M (n=3) 1 2.1 ± 0.2 M (n=3) 1 
SJSA-1* 0.36 M 
 
1.14 M 
 
S_M6R1 16.04 M 22.9 43.23 M 20.1 
S_N40R1 16.74 M 23.9 49.62 M 23.6 
     
NGP 1.58 ± 0.21 M (n=3) 1 2.20 ± 0.39 M (n=3) 1 
NGP* 0.75 M 
 
0.74 M 
 
N_M5R1 12.07 M 7.6 31.07 M 14.1 
N_M5R2 10.54 M 6.7 22.33 M 10.2 
N_N20R1 9.75 M 6.2 25.85 M 11.8 
The ‘*’ labelled rows were shown the GI50 of the parental cell lines tested by using a narrower concentration range. 
For the consistent results comparison, the original GI50 values were used to calculate the fold increase in 
resistance.   
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Figure 6. 12 SJSA-1 parental and resistant cell clone GI50 Comparison. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. 13 NGP parental and resistant cell clone GI50 Comparison. 
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6.4.3 Western blotting assay for protein expression determination 
To investigate whether the increased cell resistance was related to changes of p53 
and its downstream target MDM2 and p21WAF1 protein after MDM2 antagonist 
treatment, the expression of these proteins was determined using total cell extracts 
prepared from control or cells treated with DMSO, 5 µM MI-63 or 20 µM Nutlin-3 for 
6 hours and α-tubulin in each sample was also evaluated as a loading and transfer 
control. The appearance of cleaved PARP and phosphorylated ser15 p53 were also 
evaluated (Figure 6. 14). 
The western blotting results of the SJSA-1 parental cell line and further developed 
stage II resistant clones (Figure 6. 14) confirmed that both MI-63 and Nutlin-3 can 
disrupt the interaction between MDM2 and p53 protein and release the p53 
transactivation domain from MDM2 binding in both SJSA-1 parental cell line and its 
resistant cell clones, causing p53 accumulation compared to untreated or DMSO only 
treated cell samples. However, in contrast to the response of the SJSA-1 parental cell 
line in which the release of p53 was seen to activate its downstream targets, the 
MDM2 and p21 protein bands of the two stage II resistant clones showed no marked 
change or increase after treatment with Nutlin-3 or MI-63.  
The western blotting results also showed that after 6 hours drug treatment, the 
detection of cleaved PARP and phosphorylated ser-15 p53 were marked only in the 
SJSA-1 parental cell line, but not in the resistant clones treated by either Nutlin-3 or 
MI-63. 
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As an alternative measure of the functional integrity of p53 in the resistant clones, 
the time course effect of DNA damage induced by X-ray irradiation was then 
investigated. Adherent exponentially growing SJSA-1 parental cells and resistant cell 
clone S_M6R1 were seeded into 6-well plates at a density 4×104 cells/well. After 24 
hours incubation at 37 °C, the cell samples were exposed to 6.3 Gy of X-rays from a 
310 kV source (D3300 X-ray system, Gilmay Medical Ltd, Chertsey UK). Then following 
a period of incubation at 37 °C, cell lysate samples were collected at 0.5, 1, 2, 4 and 
24 hours post-irradiation and analysed by western blotting (Figure 6. 15). The Ser-15 
phosphorylated p53 and p21 protein levels were evaluated. As can be seen from the 
western blotting result, the Ser-15 phosphorylated p53 accumulated in parental cell 
lysate samples collected at 0.5, 1 and 2 hours time points after x-ray treatment and 
then decreased in 4 and 24 hours time points samples; also in these samples, the p21 
protein expression increase was detectable from the 2 hour samples and then 
continued to increase with time and showed the highest levels of increase in the 4 
and 24 hours samples. In the resistant cell clone S_M6R1 samples, the Ser-15 
phosphorylated p53 accumulation was also detectable from the 0.5 hour time-point 
although the bands intensities were lower than in parental cell samples; and were 
seen to decrease only after 24 hours. Interestingly, although we have not observed 
p21 expression in SJSA-1 resistant cell clones treated by using high concentration 
MI-63 and Nutlin-3, we have nevertheless detected it in S_M6R1 4 and 24 hours after 
X-ray irradiation. 
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Expression of multidrug resistance proteins, P-glycoprotein (P-gp) and MDR1, were 
also examined as potential mechanisms of resistance to the MDM2-p53 antagonists, 
Nutlin-3 and MI-63. In these experiments, the cell lysates of the Madin-Darby canine 
kidney strain II cell line transfected with a human MDR1 gene (MDCK II-MDR1) was 
used as a positive control for the P-gp expression, and the the lysates of the human 
lung adenocarcinoma cell line A549-cDDP, that not only expresses the MDR1 gene but 
also has high level expression of the multidrug-resistance associated protein (MRP) 
gene was used as multidrug-resistance protein 1 (MRP1) expression positive control. 
The western blotting results in Figure 6. 16 demonstrated that both SJSA-1 parental 
cell clone and the two resistant cell clones S_M6R1 and S_N40R1 have undetectable 
expression of P-gp and MRP1 multidrug resistant proteins in either parental cell lysate 
samples or MDM2-p53 antagonists resistant cell line sample lysates, whether 
untreated or treated with Nutlin-3 or MI-63.   
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Figure 6. 14 Western blot results showing p53 pathway activation in the SJSA-1 parental cell 
line by Nutlin-3 and MI-63, but not in the stage II resistant cell lines, with cross resistance 
effects. 
 
 
 
 
 
 
 
 
Figure 6. 15 Western blot results of the time course response of the SJSA-1 parental cell line 
and resistant clone S_M6R1 induced by 6.3 Gy X-ray irradiation. 
 
 
 
Figure 6. 16 Western blot results showing lack of increased p-glycoprotein and/or MRP1 
overexpression in the SJSA-1 resistant cell clones tolerant to p53-MDM2 antagonists, 
compared to the parental SJSA-1 cells.  
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6.4.4 Cell cycle studies 
The lack of p21 induction in the SJSA-1 resistant cell clones with 6 hours MDM2-p53 
antagonists treatment, suggest there might be an associated resistance to G1 cell 
cycle arrest. To confirm this, cell cycle analysis by fluorescence activated cell sorting 
(FACS) was carried out, both in response to MDM2-p53 antagonists and to X-ray 
irradiation. The parental SJSA-1 cells showed S phase shrinkage that indicated G1 and 
G2/M phase arrest in response to both Nutlin-3 and MI-63, as well as in response to 
X-ray irradiation, which is mainly G2 phase arrest. In the contrary, for both of the two 
resistant cell clones, there was no obvious cell cycle change observed after 
MDM2-p53 antagonists treatment compared with the untreated samples; however, 
similar cell cycle arrest at the G1 and G2/M phase was observed with both the 
parental cell line and the two resistant cell clones after x-ray irradiation (Figure 6. 17 
and Figure 6. 18). Another interesting observation was that even without drug 
treatment, both of the two resistant cell clones showed a much lower percentage of S 
phase cells, and different G1 and G2/M phases percentages compared with the 
parental cell line, even though there was no noticeable difference in the overall 
population growth rates in the experiment described in section 6.4.1.  
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Figure 6. 17 Histogram of cell cycle distribution for the SJSA-1 parental cell line and the two resistant cell clones S_M6R1 and S_N40R1 after 24 hours 
treatment with Nutlin-3 or MI-63 and 24 hours post-treatment with 6.3 Gy of X-rays, compared with untreated controls. 
Sub confluent cells were treated with 1% DMSO, 5 µM Nutlin-3 or MI-63 for 24 h, or with 6.3 Gy of X-ray irradiation then incubated at 37°C for 24 h, harvested, then rinsed with PBS and fixed 
with freezing cold (-20°C) ethanol : PBS (7:3,v/v)for >2h. The fixed cells were rehydrated and stained in PI/RNase staining buffer at 37°C for 30 minutes and analysed for DNA content on a 
FACScan flow cytometer (BD, San Jose, CA). 10,000 cells in total were counted for each sample analysis. Cell cycle distribution and histograms were generated with WinMDI 2.8 software.
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Figure 6. 18 Bar chart of cell cycle distribution for the SJSA-1 parental cell line and the two resistant cell clones S_M6R1 and S_N40R1 after 24 hours 
treatment with Nutlin-3 or MI-63 and 24 hours post-treatment with 6.3 Gy of X-rays, compared with untreated controls. 
Bar chart of cell cycle phase population ratios were generated with Excel software. 
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6.4.5 Caspase-Glo® 3/7 Assay for apoptosis analysis 
To assess the consequence of the p53 mutations on any apoptotic response to the 
MDM@-p53 antagonists, caspase 3 and 7 activities were analysed using a 
Caspase-Glo® 3/7 Assay Kit. Briefly, adherent exponentially growing cells were seeded 
into 96-well plates at 2×103 cells/well for SJSA-1 parental and resistant cell clones and 
5×103 cells/well for NGP parental and resistant cell clones. After 24 hours incubation 
at 37°C, the medium was replaced with fresh medium containing 1 % DMSO or MDM2 
antagonists Nutlin-3 or MI-63 at appropriate ranges of drug concentrations in 1 % 
DMSO so that the plate was containing blank, negative control and treated cells in 
culture medium. After a drug exposure period of 48 hours, the plate was taken out 
from the incubator and equilibrated to room temperature, then an equal volume of 
Caspase-Glo® 3/7reagents was added into each well. The plate was covered with a lid 
and gently shaken at 300 rpm for 30 seconds to mix the content. The plate was 
incubated at room temperature for 1.5 hours, then the contents of wells were 
transferred into a white-walled 96-well plate and the luminescence of each sample 
measured in a micro plate Luminometer (Berthold Technologies, Hertfordshire, UK). 
Then luminescence data obtained were analyzed and line charts were generated 
(Figure 6. 19 A & B) with Graphpad Prism 5 software.  
The SJSA-1 parental cells respond with a dose dependent increase of caspase-3/7 
activity, which showed saturation at the higher dose levels (Figure 6. 19). 
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In contrast, no noticable caspase-3 and 7 activities were observed in wither of the 
two SJSA-1 resistant cell clones when treated with the concentrations ranges for 
MI-63 from 0.5 to 5 µM or for Nutlin-3 from 1 to 10 µM. The strong induction of 
caspase-3/7 activity in the parental cells treated with only 0.5 µM MI-63, which 
showed a similar effect to that caused by 2 µM Nutlin-3, reflected the GI50 evaluation 
and western blotting results. 
Another interesting phenomenon worth pointing out is that the untreated SJSA-1 
parental cells also expressed a higher baseline caspase 3/7 activity than the two 
resistant clones, even though the seeding densities were the same, which indicated 
the expression of caspase 3/7 induced by active p53 pathway in SJSA-1 parental cell 
clone, even without any treatment, in which was reduced in the resistant cell clones.  
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Figure 6. 19 Caspase 3/7 enzymatic activity in resistant cell clones treated by various 
concentrations of MI-63 (A) or Nutlin-3 (B) for 48 hours showed little induction compared to 
the response in SJSA-1 parental cell lines, which increased markedly.  
A 
B 
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6.4.6 DNA Sequencing of p53 
To determine the p53 status of the further developed stage II resistant cell clones, 
total DNA was extracted from each cell clone for the analysis. PCR products of Exon 4 
to 9 that represent p53 DNA binding domain were sequenced for mutation detection. 
As previously, the sequencing results of all PCR products produced were analysed by 
using SN primers first, and then the mutations were confirmed by analyzing the ASN 
primers generated PCR products. 
In all the SJSA-1 stage II resistant cell clones there was still only one missense point 
mutation at codon 285 detected within all SJSA-1 (Figure 6. 20). The chromatogram 
shows a homozygous codon 285 mutation confirmed with both SN and ASN 
sequencing primers. 
 
 
                  
Figure 6. 20 Resistant SJSA-1 cell clone S_M6R1 DNA sequencing result showing the point 
missense mutation in the p53 DNA binding domain. The same point mutation was found in 
SJSA-1 resistant clones obtained from Nutlin-3 treatment.  
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6.4.7 Comparison of p53 Specific PCR Amplification of DNA from Resistant 
Cell Clones and parental SJSA-1 Cell line 
Since the same mutation was detected in resistant clones independently derived from 
the same parental cell line, this suggested that the mutation was already present in a 
small subpopulation of the parental SJSA-1 cell line, below the level of detection by 
direct sequencing of the whole population. To confirm the detected mutation and 
test for its presence in the parental SJSA-1 cell population, a mutation specific PCR 
was designed. Using specifically designed primers 5’-GGA GAG ACC GGC GCA CAA-3’ 
and 5’-TCC ACT TGA TAA GAG GTC CC-3’ and PCR procedure TD63 (see Appendix II) 
and the method mentioned previously (Section 2.7.3). Then 30 µL of each reaction 
product SJSA-1 parental and resistant cell clones was compared with PCR products 
using normal primers on a 1.8 % agarose gel contain ethidium bromide and images 
were taken under UV light transillumination, using a Bio-Rad imaging system (Figure 
6. 21).  
The result confirmed the existence of the detected point mutation in all the SJSA-1 
resistant cell clones; the low level of detectable normal sequence PCR product from 
the resistant cell clones indicated the predominance of mutated p53 in the resistant 
cell clone populations. 
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Figure 6. 21 PCR products comparison using wild-type and mutation specific p53 sequence 
primers to amplify DNA from SJSA-1 resistant clones and the parental cell line. NGP 
parental cell line DNA is included as a additional wild-type p53 positive control.  
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6.4.8 Low level p53 Mutation Detection in SJSA-1 parental cell line DNA 
extracts 
To investigate the possibility of the codon 285 (GAG to AAG) p53 point mutant 
detected in the resistant clones was already present in the parental cell line at a low 
level undetectable by direct sequencing, further mutation specific PCR amplification 
was carried out on the SJSA-1 and NGP parental cell lines DNAs and the reaction 
products compared with PCR products using normal primers on 1.8% agarose gel 
contain ethidium bromide (Figure 6. 22).  
 
Figure 6. 22 p53 mutation specific and normal PCR products compared for SJSA-1 resistant 
clones and SJSA-1 and NGP parental cell line DNAs. 
The PCR products produced by using p53 specific primers or normal primers are labelled with ‘+’ on top 
of each cell clone name with the primer label at the left of each row. 1 Kb DNA ladder are added at 
both side of the gel, and controls of PCR reagents contain either normal primers or mutant specific 
primers and without adding any DNA sample are loaded onto the gel to inspect contamination. The red 
box highlighted all target PCR product bands location area.   
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The faint band seen in track 3 that shows the PCR product from SJSA-1 parental cell 
line DNA amplified with mutation specific PCR primers, confirmed the existence of the 
point mutation in the SJSA-1 parental cell line, although the mutant sub-population 
was at too low a level to be detectable by direct sequencing of the whole population 
DNA. The absence of detectable mutation specific PCR products within the control 
without any DNA sample and NGP parental cell line track DNA strengthened the 
reliability of the mutation specific PCR technique for point mutation confirmation. 
To seek further evidence of resistant cells pre-existing in the parental cell line 
population, high concentrations of MDM2-p53 binding antagonists (MI-63 5 µM, 
Nutlin-3 5 and 20 µM) were used to treat the SJSA-1 parental cells directly. After 15 
days treatment, low numbers of individual-morphologically intact cells were observed 
in the 5 µM Nutlin-3 treated cell samples, but not in 5 µM MI-63 or 20 µM Nutlin-3 
treated cell samples (Figure 6. 23), which might because of either the selection of 
resistant cells or cells experiencing senescence, therefore, further experiment maybe 
required for the confirmation of the status of these cells in future.  
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Figure 6. 23 Direct evidence of resistant cells in the parental SJSA-1 population undergoing 
single step selection with 5 µM Nutlin-3  
SJSA-1 parental cells treated with different concentrations of MDM2-p53 antagonists for 15 days showing the 
marked effects of these compounds_and also the presence of sparse numbers of surviving cells in the 5 µM 
Nutlin-3 treated cell samples (red arrow), but not in the 5 µM MI-63 or 20 µM Nutlin-3 treated cell samples. 
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6.4.9 SJSA-1 parental and resistant cell clones comparison using 
fluorescence in situ hybridization (FISH) to test for allelic loss of the 
p53 gene 
All the above discribed DNA sequencing and mutation specific experiments based on 
the stage II further developed resistant cell clones, indicated that they are relatively 
pure cell clones showing the same homozygous mutation, and PCR results illustrated 
that both of the S-M6R1 and the S_N40R1 cell clones have the same point mutation. 
However, at the intermediate, stage I selection (Figure 6. 6, Figure 6. 7 & Figure 6. 8) 
the DNA sequencing indicated an apparent heterozygous population. Two alternative 
explanations are possible for the progression of stage I apparent heterozygous 
mutations to the stage II detection of apparent homozygous mutations. The first 
possibility is that the whole stage I population contains a heterozygous mutation, with 
one normal allele and one mutant allele, with subsequent loss of the second allele 
when progressing to the stage II selected clones. The alternative possibility is that the 
stage I selected population is actually an approximately equal mixture of cells with 
two normal p53 alleles and cells with a homozygous mutation, with only a mutant 
allele present in them. To distinguish between these possibilities, FISH studies were 
performed (at Sir James Spence Institute, Royal Victoria Infirmary, Newcastle upon 
Tyne) to detect the p53 gene locus copy number in the stage I and stage II selected 
populations, as well as parental cells.  
By comparing the experiments results listed above, we have observed some small 
differences between the S_M6R1 with S_N40R1 cell clones. Firstly, the GI50 values for 
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them against either Nutlin-3 or MI-63 were slightly different, with S_N40R1 
(GI50_Nutlin-3=16.74 µM, GI50_MI-63=49.62 µM) showing slightly higher resistance than 
S_M6R1 (GI50_Nutlin-3=16.04 µM, GI50_MI-63=43.23 µM). Secondly, in western blotting 
results, S_N40R1 showed less p53 and MDM2 protein expession than S_M6R1 with 
either 20 µM Nutlin-3 or 5 µM MI-63 treatment. Thirdly, in cell cycle analysis, S_M6R1 
showed noticeable differences when compared with S_N40R1 when treated with 
either MDM2/p53 antagonists or X-ray irradiation; also with the S_M6R1 cell clone 
cell cycle analysis results, a marked tetraploid cell population was observed (Figure 6. 
17), which may be consistent with 17p allelic loss (190) in this cell clone. 
The images in Figure 6. 24 show examples of the detection of the p53 alleles on 
chromosome 17 in the SJSA-1 parental cell line and resistant cell clones S_M6R1 and 
S_N40R1. The number of p53 allele chromosome 17 centromeric probe signals per 
cell were recorded for a total of above 100 (Table 6. 3). 
 
 
SJSA-1 Parental          SJSA-1 S_M6R1        SJSA-1 S_N40R1   
 
Figure 6. 24 FISH images illustrating the different p53 status (red) and chromosome 17 copy 
number (green) alteration in resistant cell clones S_M6R1 and S_N40R1 compared to SJSA-1 
parental cell line. 
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Table 6. 3 FISH assay colour coded signal counting results showing marked differences 
between the three SJSA-1 cell clones 
Cell Line 
Signals 
SJSA-1 parental SJSA-1 S_M6R1 SJSA-1 S_N40R1 
Number Percentage Number Percentage Number Percentage 
2G2R 99 94.29 102 76.69 6 6.0 
2G1R 5 4.76 17 12.78 68 68.00 
1G1R 1 0.95 2 1.50 3 3.00 
4G1R   2 1.50 1 1.00 
3G3R   9 6.77   
4G2R   1 0.75   
3G1R     6 6.00 
2G0R     14 14.00 
1G0R     1 1.00 
3GR0     1 1.00 
Total 105 100.00 133 100.00 100 100.00 
 
NB: In the first column of this table, the codes contain ‘G’ and ‘R’. ‘G’ is corresponding to green signal in FISH 
image that indicate the copy number of chromosome 17, and ‘R’ is corresponding to red signal in FISH image that 
indicate p53 status. 
The SJSA-1 parental cell line FISH results showed less than 5% p53 deletion and 1% 
chromosome 17 numerical variation; however, above 16% of S_M6R1 and 94% 
S_N40R1 cells have lost at least one p53 allele; Moreover, about 7% S_M6R1 cells 
contain 3 copies of chromosome 17 with 3 p53 alleles, and about 2% S_M6R1 and 8% 
S_N40R1 cells contain 3 or 4 chromosome 17 copies but only 1 or no p53 allele.     
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6.5 Conclusion and Discussion 
As with other therapeutic agents, treatment with MDM2-p53 binding antagonists is 
likely to be subject to the development of drug resistance mechanisms.  
A panel of clones selected for resistance to Nutlin-3 and MI-63 showed impaired 
activation of growth inhibitory and apoptotic pathways downstream of p53 in 
response to treatment with these agents compared to parental cells.  
DNA sequencing and p53 pathway analysis were consistent with a p53 mutation 
resistance mechanism. 
The western blotting result for multidrug resistance proteins P-gp and MRP1 
expression examination indicated that the resistance effect of the two SJSA-1 selected 
clones was not related to the increased expression of multidrug resistant proteins. 
This result may correlated to the report from Michaelis et al. that Nutlin-3 can reverse 
the P-glycoprotein/MRP1-mediated multidrug resistance by incuding inhibition of 
P-gp and MRP-1 mediated efflux (191).  
The western blotting and cell cycle analysis results of the comparison of SJSA-1 
parental and resistant cell clones treated with X-ray irradiation pointed out a possible 
alternative therapeutic strategy. In western blotting results (Figure 6. 15), p21 protein 
was detected in the 4 and 24 hours post-X-irradiation treated S_M6R1 cell lysate 
samples, which suggesting the X-ray irradiation causes p53-independent induction of 
p21. In the cell cycle analysis results (Figure 6. 17), X-ray irradiation-induced cell cycle 
arrest at the G2/M phase was observed not only with the SJSA-1 parental cell line but 
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also the two resistant cell clones, which suggesting the X-ray irradiation causes 
p53-independent induction of cell cycle arrest. Interestingly, several research groups 
have reported that the combination of Nutlin-3 and radiotherapy (RT) showed higher 
efficacy than using RT alone in several cancer cell lines, e.g. lung cancer (192), 
prostate cancer (193) and laryngeal squamous cell carcinoma (LSCC) (194), etc. As a 
result, the alternative therapeutic strategy could be the treatment that not rely on 
p53 pathway activation. 
By comparing the results of stage I and stage II SJSA-1 resistant clones, a relationship 
between the ratio of mutated peak and normal peak in the DNA sequencing 
chromatograms and the resistance of those clones was apparent. A FISH assay 
indicated that this resistance might be related not only to the presence of a p53 
mutation but also to the progression of further resistance by subsequent selection for 
loss of the normal p53 allele. The intermediate level of resistance shown by the stage 
I selected population with predominatly heterozygous mutations was further 
increased in the stage II population, in association with predominant loss of the 
wild-type p53 allele, consistent with the appearance as a homozygous mutation in the 
sequencing chromatograms. This suggests that mutation of one allele produces an 
intermediate level of resistance and loss of the second allele results in a higher level 
of resistance. 
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Chapter Seven 
Further Discussion and Future Work 
 
7.1 Further Discussion 
7.1.1 Summary of Achievements 
The IC50 evaluation of the isoindolin-1-one scaffold compounds using the ELISA 
method enabled the construction of a quantitative structure-activity relationship 
(QSAR) map that has contributed to the step by step compound side-chain 
modification that has improved potency. Furthermore, based on the QSAR analysis 
together with the NMR data generated by our collaborators in Oxford University 
(Professor Martin Noble, Dr Jane Endicott and Dr Jan Gruber) I was able to propose 
the possible binding mode of some key isoindolin-1-one compounds, which has 
contributed to a better understanding of the interaction of the small molecule 
compounds with the MDM2 protein, and will facilitate further lead compound 
structure design and development. 
After three years of memorable team work, the isoindolin-1-one scaffold MDM2-p53 
binding interaction antagonists project has entered a very encouraging phase, in 
which the lead compound potency (racemic mixture) has come to below 20 nM, with 
cellular activity comparable to Nutlin-3 and pre-clinical in vivo studies will soon 
commence. Moreover, with the successful resolution of several potent 
isoindolin-1-one racemic mixtures, pure enantiomers have been obtained, which have 
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shown marked in vitro potency differences and a corresponding variation in cellular 
activity. These observations have helped to provide a better understanding of the 
binding between isoindolin-1-one enantiomers with the p53 binding groove of MDM2 
and enabled us to compare them with Nutlin-3 and MI-63, which in turn has lead to a 
refinement of the binding mode model and further structure optimization. 
The testing of isoindolin-1-one scaffold compounds as MDMX-p53 binding interaction 
antagonists was carried out to examine the possibility of finding lead isoindolin-1-one 
scaffold compounds to develop as MDMX-p53 antagonists. This would be attractive 
because of the already large accumulation of experience on this compound series, 
with detailed SAR analysis and compound synthesis routes. 
My involvement and contributions to the DePPICT project has enabled me to get a 
better understanding of the lead compound mining procedure, leading to the 
selection of active compound series. This experience, together with the research on 
pyrrole scaffold compounds and potent peptide inhibitors of the MDM2/MDMX-p53 
binding interaction, will be helpful for further structure optimization of the various 
core scaffold lead compound series. This includes the use of in silico molecular 
modelling to inform ‘scaffold hopping’ in order to take active compounds forward 
into new series with a potentially more favourable pharmacophore. 
With the anticipated possibility for drug resistance against MDM2-p53 binding 
antagonists, Nutlin-3 and MI-63 resistant cell clones were selected from parental 
SJSA-1 osteosarcoma and NGP neuroblastoma cell lines. Dysfunctional p53 point 
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mutation was confirmed to be the major resistance mechanism. A FISH assay 
indicated a sequential mechanism of resistance involving mutation of one p53 allele 
and loss of the normal p53 allele. These observation may benefit patients that will 
treated with MDM2-p53 binding interaction antagonists, indicating that the 
monitoring of p53 status at both presentation and relapse should be used to guide 
treatment. 
7.1.2 “See-saw Theory” generation based on the development of 
MDM2/p53 and MDMX/p53 antagonists 
First of all, it is important to define the ‘See-saw Theory’. In this theory, we assume 
the shape of the target protein’s binding groove is not very flexible, since the 
flexibility of every amino acid side-chain corresponds to breaking the balance of the 
interaction between amino acid residues and energy consumption and even protein 
function. As illustrated by the cartoon in Figure 7. 1, the shape and character of the 
binding site of the compound candidate should be able to fit the binding groove of 
the target protein. As a result, we can design or develop compounds to fit this binding 
groove, or carry out in silico screening by using some virtual docking software as we 
have already done within the DePPICT project. 
For interrupting the MDM2/p53 or MDMX/p53 binding, the principle is to design or 
find compound scaffolds to mimic the three key amino acid side chains, Leu26, Trp23 
and Phe19, on the p53 transactivation domain that fits into the MDM2(X) binding 
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groove and to do so with a higher binding affinity than p53, so that they can 
competitively bind with MDM2(X) and release active p53 (Figure 7. 1).  
With the SAR analysis of isoindolin-1-one compounds as antagonists of the 
MDM2/p53 binding interaction, we have observed that when we replaced the 
chlorine atom on side-chain -X with other halogen atoms, methyl group or hydrogen, 
the compound potency decreased markedly (Table 3. 5 in Chapter Three). A similar 
observation was made in our research, and research published on p53 peptide 
analogues as MDM2 (MDMX)/p53 binding interaction inhibitors. These observations 
indicated that a ‘See-saw Theory’ may be important in this kind of drug design and 
development. 
 
 
 
 
 
 
 
 
Figure 7. 1 ‘See-Saw Theory’ based on MDM2/p53 and MDMX/p53 antagonist design 
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Based on this theory, if the compound contains more binding points then interaction 
with the binding groove will induce a higher binding affinity with the target protein; 
on the other hand, if a target protein has a binding groove that contains more binding 
pockets or deeper binding clefts, then it will be more suitable to be a drug 
development target, i.e. the more points of interaction there are, the greater is the 
likelihood of designing a specific inhibitor. That is the reason why we have to mimic 
three key side chains of p53 peptide and see Trp23 as the most important one, rather 
than focus on only Leu26 and Phe19 and design compounds to just cover the binding 
site of MDM2, like a lid. This has lead me to conclude that MDM2 is more like a drug 
target than MDMX, since it has a deeper binding groove than MDMX, although both 
of them can bind with the p53 transactivation domain to inhibit its transcriptional 
function.  
7.1.3 “Parachute Analogy” generation based on MDM2/p53 antagonists 
development 
Based on the observation of the binding mode generated by using virtual docking 
software and SAR analysis results we obtained from isoindolin-1-one compounds 
development, together with the published MDM2/p53 binding interactions with small 
molecular inhibitors and p53 peptide analogues, we have generated a ‘Parachute 
Analogy’ to illustrate the effect of the R2 side-chain on isoindolin-1-one scaffold 
inhibitors. 
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As displayed in Figure 7. 2, the hydrophilic R2 side-chain on isoindolin-1-one 
compound acts like a parachute.  
 
 
 
 
 
 
 
 
Figure 7. 2 Side-chain –R2 of idoindolin-1-one compound NU8354 act as a parachute 
Because of its hydrophilicity, it would always be forced towards solution phase and 
help to force the lipophilic side chains towards the hydrophobic binding groove of 
MDM2, which could enhance the possibility of the right isoindolin-1-one side chains 
to land into the most favorite binding pocket that the three key amino acid residues 
of p53 normally occupy. On the other hand, also because of its hydrophilicity, it could 
prevent p53 key amino acid residues from binding onto it. For this reason, the 
compound gained higher potency after the addition of hydrophilic side chains. 
Based on this ‘Parachute Analogy’, it will be a balance between the hydrophilicity of 
the side-chain with the lipophilicity of the whole compound. As a result, when we try 
 
 
 
      
 
  Parachute image          3D structure of NU8354 
Hydrophilic 
part act as a 
parachute 
Hydrophobic 
part contribute 
to binding to 
MDM2 
Atmospheric resistance 
Gravity of the earth 
Solution phase 
Hydrophobic binding groove 
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to modify compound structure to gain potency, we have to consider this balance, 
which may correspond to logP value. 
As I have mentioned in Chapter 3, the –R2 side-chain may also contribute to the 
binding with MDM2 protein just like the Leu22 side-chain of p53 peptide does. 
Therefore, the side-chain length and shape variation can also influence the whole 
binding affinity of the isoindolin-1-one compound with MDM2 protein (As displayed 
in the SAR figure in Section 3.3.2). 
As a result, according to ‘Parachute Analogy’, the key factors such as size, shape and 
the balance of hydrophilicity and lipophilicity of the –R2 side-chain have to be 
considered for the development of isoindolin-1-one scaffold MDM2/p53 interaction 
inhibitors, even when the modification is introduced on other side chains.  
7.1.4 “Bridge Effect Theory” based on screening data analysis of the 
DePPICT compounds and suggestions for future in silico screens 
In the DePPICT project, we have observed that several compounds produced 
noticeable negative inhibitory percentage values, which raised the question: why did 
they produce such negative results even though they passed virtual screening with 
acceptable binding energy values?  
Further detailed analysis revealed that they were all low molecular weight (～300) 
compounds with relatively high lipophilicity, and their post-binding modes may turn 
them into a bridge between MDM2 and p53 peptide analogues (b-IP3 peptide). This 
may be able to enhance the binding affinity of MDM2 with b-IP3 peptide, just like 
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produced another ‘MDMX’ like binding groove, which lead to marked negative result, 
as I have discussed in Chapter 5 and named the ‘Bridge Effect Theory’.  
This hypothesis raised another question: how can we prevent the bridge effect? 
Actually, if we can successfully prevent this effect, we may be able to develop some 
quite potent MDM2/p53 inhibitors at the same time based on DePPICT screening 
results. And the answer is, add a hydrophilic side-chain at the back of the binding side 
of the compound in the post-binding docking mode generated via virtual docking 
software. 
However, it seems to be not that simple, and maybe quite inefficient, since it will take 
time to work out the synthetic route to add the side chain, if the compounds are not 
available commercially. Then, is there any way to increase the efficiency? The answer 
is ‘Yes’. Based on the binding mode, we can do another ‘screen’, by synthetic 
chemists, to identify the candidates that can be easily produced, synthesise them and 
evaluate their potency by ELISA assay together with the original commercially 
available compounds.  
7.1.5 “Predictable vs. unpredictable”, the lesson learnt from MDM2/p53 
antagonists resistant mechanism research 
In most people’s mind, cancer is a monster. Although most solid tumours may be very 
aggressive and can cause big problem, but we can generally find first-line treatment 
strategy; the unpredictable relapse tend to be another big problem. 
So what can we learn from the resistant cell clones research?  
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First of all, we have to bear in mind that relapse is often associated with resistance to 
treatment and poor outcome. As a result, we have to maintain vigilance with those 
patients that experience a successful treatment response rather than getting excited 
too early. What we have done here is to make the possible mechanism and 
consequence more predictable, which may benefit patients in future. In this particular 
context, the potential for p53 mutation as the most likely resistance mechanism in 
cases of relapse from treatment with MDM2-p53 antagonists should be anticipated 
and guide appropriate strategies for further treatment. 
Secondly, combinational treatment strategy may be applied from the beginning of 
cancer patient treatment, or if the resistant effect starts to be detected, some other 
pathways may have to be considered as early as possible rather than increase the 
dosage of the original drug to gain some more effects. 
Finally, cancer patient therapeutic strategy has to become a personalized treatment 
plan, so that we can obtain more accurate information to optimize the treatment and 
also accumulate more information for future therapeutic strategy design. 
7.2 Future Work 
7.2.1 Possible plan for MDM2/p53 antagonists design and development 
For the isoindolin-1-one scaffold MDM2/p53 antagonist development, the 
modification and SAR analysis of side-chain –R2 may need to be considered, 
especially with the fact that the ‘pro-drug’ NCL-00016149 induced much higher 
potency than parental compound NU8406 in ELISA evaluation. Some better 
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hydrophilic ‘parachute’ side-chains in the –R2 position may be designed with the 
collaboration between chemists and biologists.  
On the other hand, cellular evaluation results we have obtained so far have told us a 
relatively more complicated story.  
The western blotting and SRB assay results of stage 1 series compounds and NU8354, 
NU8406 enantiomers comparison have given us an idea that in cancer cells which 
contain wild type p53 the cellular response to drug treatment correlated with 
compound potency; however, the cellular behavior of stage 2 compound NU8399 told 
us that we should not assume this will always be the case and make this conclusion 
too early. There may be more factors that need to be considered, such as the balance 
between lipophilicity with hydrophilicity; then the cellular behaviour of stage 3 series 
compounds suggest that molecular weight might be another key factor we have to 
consider. As a result, more cellular assays, especially quantitative techniques such as 
SRB assay, Caspase Glo-3/7 assay, Clonogenic assay, etc. may need to be carried out 
in future, which may contribute to the overall SAR analysis together with the cell-free 
ELISA results. 
7.2.2 Possible plan for MDMX/p53 antagonists design and development 
For the MDMX/p53 antagonists design and development, different research 
strategies may need to be carried out. The first route is based on the already obtained 
MDM2/p53 antagonists, with the modification and SAR analysis together with 
detailed comparison of MDM2/MDMX binding groove. The other route is like the 
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research we have done in the DePPICT project, to screen or design new scaffolds 
based on the structure of the MDMX binding groove, and use the experience we have 
obtained from MDM2/p53 antagonist development. The key thing will be the design 
of persuasive cellular experiments to evaluate the cellular effects of compounds and 
confirm it is caused by the inhibition of the MDMX/p53 interaction. 
7.2.3 Further research on MDM2/p53 antagonists resistant cell clones  
One noticeable observation in the GI50 evaluation results is that the potency 
differences between MI-63 and Nutlin-3 were reflected not only in both SJSA-1 and 
NGP parental cell lines, but also in their resistant clones established by using these 
two drugs. Furthermore, the further developed resistant clones of both of the two 
cell lines established by using the two antagonists showed similar cross resistance 
effects. This observation may point out the existence of some other resistant 
mechanisms as cofactors of the p53 mutation, which may need some further 
experiments to reveal. 
Since the GI50 values of the further developed resistant clones were much higher than 
their parental cell lines, and the variations were even bigger than that between 
HCT116 p53 +/+ and -/- cell lines, some further experiment may also need to be carried 
out to check if other mechanisms contribute to the overall resistance or not, although 
the observation that Nutlin-3 treated HCT116 p53+/+ cells only experience cell cycle 
arrest but not apoptosis (143), could be an explanation for this phenomenon. One of 
the possible experiments for that purpose will be to introduce wild type p53 back into 
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the resistant cell clones and see if they can regain their sensitivity against MI-63 and 
Nutlin-3. 
On the other hand, finding efficient strategies to kill resistant cell clones can be 
another research direction, which will obviously benefit patients experiencing clinical 
trials using MDM2/p53 antagonists and prevent unnecessary sacrifice of life.  
Finally, I want to use a famous quote from an ancient Chinese poet Qu Yuan’s poem 
‘Li Shao’ to finish my thesis: 
Though the journey towards the truth is very long, but I have urged on to seek after 
my dream!  
路漫漫其修远兮，吾将上下而求索。 
——屈原《离骚》 
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Appendix I 
Potent Isoindolin-1-one compounds and MDM2 protein 
binding mode prediction 
Background 
The IC50 evaluation and investigation of cellular effects for the isoindolin-1-one 
scaffold compounds not only confirmed the inhibitory effect of these compounds on 
the p53/MDM2 interaction, but also enabled us to examine the correlation between 
compound structures and their activities. However, further structure design and 
development based on the isoindolin-1-one scaffold was encumbered with some 
technical handicaps. Firstly, all the synthesized isoindolin-1-one compounds were 
racemic mixtures because of their chiral carbons. Although we have already 
successfully separated some of them, we have not confirmed their solid 
stereo-structures without their crystal structure analysis data; secondly, so far we still 
have not obtained the co-crystal structure of an isoindolin-1-one compound binding 
with MDM2. As a result, it is important for us to predict their binding mode for a 
better understanding of structure activity relationship of isoindolin-1-one 
compounds, which benefit further structure design and drug development. 
As a result, both docking software and manual docking were applied for binding 
mode prediction. 
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Results 
1. MDM2 protein structures selection and docking software training 
By reviewing all the literature corresponding to MDM2/p53 related co-crystal 
structure analysis, we have selected 1YCR (MDM2 BOUND TO THE TRANSACTIVATION 
DOMAIN OF P53), 1RV1 (CRYSTAL STRUCTURE OF HUMAN MDM2 WITH AN 
IMIDAZOLINE INHIBITOR), 1T4F (MDM2 in complex with an optimized p53 peptide) 
and 2GV2 (MDM2 in complex with an 8-mer p53 peptide analogue) for docking mode 
prediction. Then by applying Molegro Virtual Docker software, we have isolated 
MDM2 protein, p53 peptide, Nutlin-2 optimized p53 peptide, and 8-mer p53 peptide 
for MDM2 protein work space generating and docking software learning purpose. 
The published co-crystal structures of 1YCR, 1RV1, 1T4F and 2GV2 with each 
correlated MDM2 protein binding pockets were displayed in Appendix I Figure 1 and 
Appendix I Figure 2. The MDM2 proteins were shown as electrostatic solid protein 
surfaces, p53 relative peptides or Nutlin-2 compounds were shown as thin sticks with 
colour coded elements (CPK).  
The images in Appendix I Figure 1 display the interaction of ligands with MDM2 
proteins. Interestingly, a cofactor [SO4
2-] was used in the generating of 1T4F co-crystal 
structure, and in the 1RV1 interaction structure image, we can find another Nutlin-2 
binding with the MDM2 protein in another position close to the positive charged area 
near the cofactor functional area of MDM2 in 1RV1, which might indicate that this 
Nutlin-2 act as an cofactor for crystalisation; furthermore, the extended p53 peptide 
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side-chain in 1YCR also formed some H-bond interaction with the positive charged 
area of MDM2 protein. However, this kind of cofactor effect had not been displayed 
in 2GV2 co-crystal structure.  
On the other hand, the images of 1RV1, 1T4F and 2GV2 co-crystal structures had 
also displayed the interaction between ligands and water molecules, which may 
contribute to positioning side chains of ligands into the MDM2 binding pockets and 
enhancing the binding potency. 
The four images in Appendix I Figure 2 illustrate the shape and depth of the MDM2 
protein hydrophobic clefts formed by binding with p53 related peptides or the same 
position binding with Nutlin-2. These images indicate that the difference of shape and 
atom characters of ligand can influence the hydrophobic binding pocket of the MDM2 
protein. As a result, we have to evaluate and select the most suitable workspace for 
virtual docking analysis of the isoindolin-1-one scaffold compounds. 
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Appendix I Figure 1. Reproduction images of published co-crystal structure of 1YCR, 1RV1, 1T4F and 2GV2.  
  1YCR:            1RV1:   
  1T4F:         2GV2:  
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Appendix I Figure 2. Reproduced hydrophobic binding pocket images of MDM2 protein in 1YCR, 1RV1, 1T4F and 2GV2. 
1YCR:       1RV1:  
1T4F:       2GV2:  
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2. MDM2 and isoindolin-1-one compounds binding mode prediction and 
comparison 
By using the three MDM2/p53 related co-crystal structure data, we have created 
three MDM2 protein workspaces and tried to generate MDM2 binding mode models 
for a progressive series of isoindolin-1-one compounds (NU8260, NU8354, NU8399, 
NU8406 and NCL-00016149) using Molegro Virtual Docker software (Nutlin-2 was 
used as positive control for prediction accuracy validation). Then highest ranked 
docking result of each MDM2 protein workspace was picked out and images were 
taken for further SAR analysis. Key compound binding modes with every workspace 
and docking score results were illustrated in Appendix I Table 1.  
The virtual docking results in Appendix I Table 1 indicate that different workspaces 
can produce different top scored binding modes for each compound and the water 
solvent molecules can also affect the binding mode. As a result, we have to consider 
the docking score together with ELISA IC50 value of each compound to determine the 
most suitable workspace, and water solution effect to be considered. 
By comparing the scatter charts for correlation of the docking scores with the IC50 
values of isoindolin-1-one scaffold key compounds (Appendix I Figure 3) together with 
the reproduced Nutlin-2 binding modes (Appendix I Table 1), it was noted that the 
docking results generated by using the 1T4F and the 2GV2 workspace including the 
effect of water molecules produced the more reliable and most favourable binding 
modes for every compound. Furthermore, some other isoindolin-1-one docking mode 
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predictions with MDM2 produced by using other workspaces were also produced by 
using 2GV2 workspace containing solution effect with higher docking energy, which 
indicated a less favourable binding possibility. As a result, the 2GV2 structure 
workspace including solvent effect was applied for further binding mode predictions. 
By using the 2GV2 structure incorporating the effect of water molecules, I then 
generated and compared the binding mode and energy of the key isoindolin-1-one 
compounds enantiomers (Appendix I Table 2) for further SAR analysis. It is noted that 
the docking scores have indicated the same side-chain positions for all the pure 
enantiomers, i.e. all potent enantiomers have shown the same side-chain orientation 
(S), whereas all the less potent enantiomers have the opposite orientation (R), 
although the binding mode for NU8399 enantiomers are apparently different from 
the NU8354 and NU8406 enantiomers.   
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Appendix I Table 1. Virtual docking predicted binding modes and scores of the 
published MDM2 crystal structures of 1YCR, 1RV1, 1T4F and 2GV2 binding with 
Nutlin-2 and isoindolin-1-one scaffold key compounds. 
Workspace 
Name 
Compounds 
Code 
Binding Mode 
MolDock 
Score 
1YCR Nutlin-2 
 
-139.654 
1YCR NU8260 
 
-104.358 
1YCR NU8354 
 
-130.448 
1YCR NU8399 
 
-126.237 
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1YCR NU8406 
 
-133.184 
1YCR NCL-00016149 
 
-146.711 
1RV1+H2O Nutlin-2 
 
-140.733 
1RV1+H2O NU8260 
 
-110.197 
1RV1+H2O NU8354 
 
-130.977 
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1RV1+H2O NU8399 
 
-127.134 
1RV1+H2O NU8406 
 
-121.363 
1RV1+H2O NCL-00016149 
 
-137.408 
1RV1-H2O Nutlin-2 
 
-160.626 
1RV1-H2O NU8260 
 
-108.594 
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1RV1-H2O NU8354 
 
-127.019 
1RV1-H2O NU8399 
 
-120.545 
1RV1-H2O NU8406 
 
-134.294 
1RV1-H2O NCL-00016149 
 
-144.844 
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1T4F+H2O Nutlin-2 
 
-124.839 
1T4F+H2O NU8260 
 
-108.139 
1T4F+H2O NU8354 
 
-108.192 
1T4F+H2O NU8399 
 
-116.788 
1T4F+H2O NU8406 
 
-126.327 
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1T4F+H2O NCL-00016149 
 
-143.341 
1T4F-H2O Nutlin-2 
 
-132.752 
1T4F-H2O NU8260 
 
-100.166 
1T4F-H2O NU8354 
 
-111.486 
1T4F-H2O NU8399 
 
-125.646 
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1T4F-H2O NU8406 
 
-116.801 
1T4F-H2O NCL-00016149 
 
-132.029 
2GV2+H2O Nutlin-2 
 
-159.499 
2GV2+H2O NU8260 
 
-113.140 
2GV2+H2O NU8354 
 
-126.983 
311 
 
2GV2+H2O NU8399 
 
-141.080 
2GV2+H2O NU8406 
 
-144.067 
2GV2+H2O NCL-00016149 
 
-148.766 
2GV2-H2O Nutlin-2 
 
-142.392 
2GV2-H2O NU8260 
 
-104.355 
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2GV2-H2O NU8354 
 
-127.028 
2GV2-H2O NU8399 
 
-133.780 
2GV2-H2O NU8406 
 
-128.333 
2GV2-H2O NCL-00016149 
 
-132.323 
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y = 6.6762x + 963.78
R² = 0.9072
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Appendix I Figure 3. Scatter Charts show the correlation of the Docking Scores with 
the IC50 Values of isoindolin-1-one scaffold key compounds. 
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Appendix I Table 2. Virtual docking predicted binding modes and scores of isoindolin-1-one enantiomers binding with the 2GV2 MDM2 
structure. 
Compound Code NU8354A NU8354B 
Compound Structure 
  
MolDock Score -126.983 -111.752 
Binding Mode 
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Compound Code NU8399A NU8399B 
Compound Structure 
  
MolDock Score -142.407 -122.177 
Binding Mode 
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Compound Code NU8406A NU8406B 
Compound Structure 
  
MolDock Score -144.067 -113.921 
Binding Mode 
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Appendix II 
 
Western Blotting Reagents and Equipment 
1. Electrophoresis buffer (5 litres made with dH2O) 
151.5 g Tris 
720.5 g Glycine 
50.0 g SDS 
 
2. Blotting buffer (10 litres with dH2O) 
30.3 g Tris 
141.4 g Glycine 
2 L Methanol 
 
3. SDS loading buffer (10 ml) 
2 ml Glycerol 
2 ml 10% SDS 
2.5 ml 4 x stacking gel buffer 
3 ml dH2O 
0.5 ml -mercaptoethanol (50 ml/ml) 
0.25 mg Bromophenol blue (0.5 %) 
 Aliquot into 1 ml volume eppendorfs and store at -20 ˚C 
 
4. TBS-Tween (10 x  5 litres made with dH2O) 
300 g Tris 
450 g NaCl 
25 ml Tween 20 
  Adjust pH to 7.5 
 
5. SDS (ionic) lysis buffer (20 ml made with dH2O) 
2.5 ml 0.5 M Tris-EDTA pH 6.8 
0.4 g SDS 
2 ml glycerol 
Before loading onto the gel, add 5 % 1:1 -mercaptoethanol and bromophenol blue. 
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6. Transfer Buffer 
25 mM Tris (Sigma) 
192 ml glycerol (Sigma) 
20 % v/v Methanol (BDH analytical grade) 
 
7. Equipments for electrophoresis 
Novex XL tank (Invitorgen) 
gel cassette holder 
Power pack 
 
8. Equipments for Western blot 
Biorad mini trans-blot holder tank  
Transfer tank 
Power pack 
2 pieces of filter paper (the same size as the gel, Whatman 3MM Chr) 
2 glass fibre pads for each gel 
1 mini gel holder cassette 
 
 
 
Cell Culture Reagents 
1. Carnoy’s fixative 
1:3 ratio of glacial acetic acid (Sigma) and Ethanol (BDH analytical grade) 
 
2. Phosphate Buffered Saline (PBS) 
500 ml dH2O 
1 tablet phosphate buffer salt 
  Solution was sterilized by autoclaving. 
 
3. 0.25 % trypsin-0.02 % EDTA solution 
0.02 % EDTA (Sigma) : 0.2 g in 1000 ml PBS 
0.25 % trypsin (Sigma, proteomics grade)   
dilute stock 2.5 % stock trypsin 1:10 with 0.02 % EDTA solution 
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Sulphurhodamine B (SRB) colourimetric assay Reagents 
1. 50 % w/v Trichloroacetic acid (TCA) 
1:1 ratio (w/v) of Trichloroacetic acid (Sigma) and double distilled water 
2. 0.4 % w/v SRB solution (500 ml solution) 
2 mg Sulphurhodamine B (Sigma) 
495 ml dH2O 
5 ml Acetic acid (Sigma) 
 
3. 1 % v/v Acetic acid (5 litres solution) 
50 ml Acetic acid (Sigma) 
4.95 litres dH2O 
 
4. 10 mM Tris-base (pH 10.5) 
605.7 mg Tris-base (Sigma) 
500 ml ddH2O 
 
 
 
Polymerase chain reaction assay Reagents 
1. 0.5 × Tris Borate EDTA (TBE) 
45.5 mM Tris (Sigma) 
45.5 mM Boric Acid (BDH) 
1 mM EDTA (Sigma) 
 
2. Loading buffer 
25 mg bromophenol blue (Sigma) 
4 g sucrose 
Add dH2O to 10 ml 
Store at 4 °C to avoid mould growing in the sucrose. 
 
3. 10 mg/ml Ethidium Bromide (EtBr) 
10 mg EtBr tablet (Sigma, for molecular biology, 10mg/tablet) 
Add dH2O to 10 ml, the shield from light. 
 
 
 
322 
 
Polymerase chain reaction assay procedure for sequence amplification 
 
For Mutation Specific Primers: Touchdown 63 protocol 
 
 Hotstart 14 cycles 26 cycles End 
Temperature (°C) 94 94 70 72 94 63 72 72 4 
Time (minutes) 10 20 sec 1* 1 20 sec 1 1 5 ∞ 
 
 *- This temperature is optimized based on the primer manufacturer recommend 
temperature and decreased by 0.5 °C each cycle.  
Because of the touchdown PCR protocol was used, the detailed sequence amplification 
procedure was named ‘TD’ plus the stabilized cycle annealing temperature. 
 
For Exons 4, 5, 6 and 9: Touchdown 55 standard protocol 
 
 Hotstart 14 cycles 26 cycles End 
Temperature (°C) 94 94 62 72 94 55 72 72 4 
Time (minutes) 10 20 sec 1* 1 20 sec 1 1 5 ∞ 
*-decreases by 0.5 °C each cycle 
 
For Exons 7 and 8: Touchdown 60 standard protocol 
 
 Hotstart 14 cycles 26 cycles End 
Temperature (°C) 94 94 67 72 94 60 72 72 4 
Time (minutes) 10 20 sec 1* 1 20 sec 1 1 5 ∞ 
*-decreases by 0.5 °C each cycle 
 
 
